Regulation of the ubiquitin RING E3 ligase Parkin by Chaugule, V.K.
1 
Regulation of the Ubiquitin RING E3 Ligase Parkin 
 
 
Viduth Kiran Chaugule 
 
 
University College London 
and 
Cancer Research UK London Research Institute 
PhD Supervisor: Dr. Helen Walden 
 
 
A thesis submitted for the degree of 
Doctor of Philosophy 
University College London 
September  2010 
 
 2 
Declaration 
 
I Viduth Kiran Chaugule confirm that the work presented in this thesis is my 
own.  Where information has been derived from other sources, I confirm that 
this has been indicated in the thesis. 
 3 
Abstract 
 
Regulation of the Ubiquitin RING E3 ligase Parkin 
 
Post-translational modification of proteins by ubiquitin is a central regulatory 
process in all eukaryotic cells. Substrate selection and type of modification are 
events catalyzed by the E3 ligase, a component of the ubiquitin pathway. 
Several ubiquitin E3 ligases are implicated in cancer and other disease states, 
underlying the need for mechanistic insight of these enzymes.  
 
Parkinson’s disease is a neurodegenerative disorder characterised by the loss 
of dopaminergic neurons from the substantia nigra, the presence of Lewy 
Bodies, and pathogenic aggregates rich in ubiquitin. Autosomal Recessive 
Juvenile Parkinsonism (AR-JP), which is one of the most common familial forms 
of the disease, is directly linked to mutations in the Parkin gene (PARK2). 
Parkin is a RING E3 and catalyses a range of ubiquitination events (mono, multi 
mono, K48- and K63- linked poly) in concert with several E2s on a variety of 
substrates, including itself. Furthermore, Parkin is capable of binding the 26S 
proteasome and mediates selective degradation of target substrates. 
 
The data presented will demonstrate that the Ubiquitin-like domain (UblD) of 
Parkin functions to inhibit its auto-ubiquitination via a novel mechanism. 
Pathogenic Parkin mutations disrupt this inhibition and result in a constitutively 
active molecule. The inhibition is mediated by an intra-molecular interaction 
between UblD and the C-terminus of Parkin, and Lysine 48 on UblD participates 
in this interaction. The study also uncovered unique UblD/Ubiquitin Binding 
Regions (UBRs) on the C-terminus of Parkin that play a novel role in its RING 
E3 ligase activity. The observations provide critical mechanistic insights into the 
myriad functions of Parkin and the underlying basis of Parkinson’s disease. 
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Chapter 1. Introduction 
 
Ubiquitination is a protein-based post-translation modification (PTM) event that 
regulates nearly every cellular pathway; cell cycle, DNA repair, transcription, 
signal transduction, immune response, protein localisation, protein quality 
control and proteasomal degradation (Pickart, 2001). The modification involves 
covalent attachment of ubiquitin (Ub) onto a substrate protein. PTMs can also 
occur through Ubiquitin-like proteins (Ubls) like; Small Ubiquitin-like Modifier 
(SUMO, called sumoylation), Neural precursor cell expressed, developmentally 
down-regulated protein 8 (NEDD8, called neddylation) and interferon-stimulated 
15kDa protein (ISG15, called ISGylation) among others. Each of the modifiers 
has their own cohort of proteins to facilitate the PTM event and the following 
sections introduce those involved in ubiquitination.  
 
1.1 Machinery of Ubiquitination 
 
Ubiquitination occurs through a series of biochemical transactions between 
three classes of enzymes: E1 or activating enzyme, E2 or the conjugating 
enzyme and E3 or the ligating enzyme (Pickart, 2001). In humans, the 76-
residue ubiquitin (~8.5kDa) is translated either as a polyprotein of tandem 
ubiquitin repeats (Ubiquitin B (UBB) and Ubiquitin C (UBC)) or a single ubiquitin 
with an unrelated tail extension (Ubiquitin A-52-residue ribosomal protein 
(UBA52) and Ribosomal Protein S27A (RPS27A)) (Baker and Board, 1991, 
Lund et al., 1985, Wiborg et al., 1985). The precursor protein, upon proteolytic 
processing by a ubiquitin C-terminal hydrolase, yields ubiquitin monomers that 
enter the ubiquitin pathway (Ozkaynak et al., 1984).  
 
Activation of ubiquitin transpires over two steps; an energy dependent formation 
of the ubiquitin adenylate intermediate, which is transferred onto E1’s catalytic 
cysteine to form a C-terminal ubiquitin thioester conjugate (Haas et al., 1982). A 
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loaded E1 thus carries both adenylate and thioester ubiquitin states (Figure 1). 
Subsequent ubiquitin conjugation of the E2 involves a transthioesterification 
reaction between the catalytic cysteines of E1 and E2 (E1~ubiquitin  
E2~ubiquitin). Nucleophilic attack on the E2~ubiquitin thioester conjugate by the 
target lysine (-amino group) or free amino terminus of the substrate protein 
results in formation of an isopeptide or peptide bond respectively (i.e. 
ubiquitination). 
 
The E3 ligase complex predominantly orchestrates substrate ubiquitination 
event(s) however the E2 enzymes can catalyse certain events (Nagy and Dikic, 
2010, Ciechanover and Ben-Saadon, 2004, Hoeller et al., 2007). E3 ligases are 
classified based on their catalytic domains; Homologous to the E6-AP Carboxyl 
Terminus (HECT) domain E3 ligases (Scheffner et al., 1995) or Really 
Interesting New Gene (RING) domain E3 ligases (reviewed in (Joazeiro and 
Weissman, 2000)). HECT E3s bear a conserved active site cysteine that 
accepts ubiquitin from the E2~ubiquitin conjugate before ligating the substrate 
Figure 1: Ubiquitination machinery. A schematic of the ubiquitin (Ub) pathway (left) and the members involved at 
each step; activation (E1), conjugation (E2) and ligation (E3). Ubiquitin activation is catalyzed by the E1 in an energy 
intensive process (Adenosine triphosphate (ATP)). A ‘loaded’ E1 constitutes the ubiquitin adenylate intermediate 
(E1AMPubiquitin) and the ubiquitin thioester conjugate (E1~ubiquitin) at the active adenylation site and catalytic 
cysteine site respectively.  The ubiquitin thioester conjugate is then passed onto the catalytic cysteine site on the E2 
(E1~ubiquitin  E2~ubiquitin) and finally ligated (isopeptide linkage) onto a target lysine of a substrate (substrate-
ubiquitin), an event orchestrated by E3 ligases. The flowchart on the right illustrates numerical hierarchy in the ubiquitin 
pathway with a high degree of orthogonal cross-talk observed towards the functional end of the pathway (E2-E3-
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with ubiquitin (E2~ubiquitin  E3~ubiquitin  Substrate-ubiquitin). RING E3s 
bring together substrate and E2~ubiquitin facilitating direct transfer of the 
ubiquitin moiety (E2~ubiquitin  Substrate-ubiquitin).  
 
A significant number of E2s have been reported, enabling the wide repertoire of 
ubiquitin based signals. However, the E3s represent an even larger family of 
enzymes as they and are responsible for the critical facets of ubiquitination; 
substrate recognition, recruitment of specific E2s and facilitating the 
ubiquitination event (Deshaies and Joazeiro, 2009, Ye and Rape, 2009). The 
ubiquitin~E2s conjugation, for all known ubiquitin E2s can established by the 
E1s, however each E3 recruits one or a few E2s to ligate ubiquitin signals to a 
set of substrates. Substrates are known to have either a sole E3 or many E3s 
facilitating ubiquitination. The machinery for ubiquitination thus follows a 
numerical hierarchy with significant degree of orthogonal crosstalk (Figure 2). 
Deubiquitinating enzymes (DUBs: enzymes to remove ubiquitin of substrates 
and disband polyubiquitin structures) and E4s (chain elongating E3 enzymes) 
are other players that play contrasting roles in the ubiquitin pathway and their 
cellular functions have been reviewed elsewhere (Hoppe, 2005, Komander et 
al., 2009a). The following sections set out to introduce E1s, ubiquitin signals 
and associated receptors, the enzymatic properties of E2s, E3 ligases. 
 
1.2 E1s: activators of ubiquitin signals  
 
Pioneering structure-function studies have revealed the mechanistic details of 
the Ubiquitin E1 (Lake et al., 2001, Lee and Schindelin, 2008), SUMO E1 (Lois 
and Lima, 2005, Olsen et al., 2010) and the NEDD8 E1 (Huang et al., 2005, 
Walden et al., 2003a, Walden et al., 2003b). Briefly, the E1 comprises of three 
structural elements; the adenylation domain (binds ATP and ubiquitin), catalytic 
cysteine domain and the ubiquitin-fold domain (UFD, E2 selection). In the E1s 
for SUMO and NEDD8, the adenylation domains are shared between 
heterodimers (SUMO Activating Enzyme 1 (SAE1) – Ubiquitin Activating 
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enzyme 2 (UBA2) for SUMO and NEDD8 Activating Enzyme 1 (NAE1) – UBA3 
for NEDD8), while the catalytic cysteine domain and UFD are borne on one 
protein (UBA2 for SUMO and UBA3 for NEDD8 respectively). In contrast, the 
E1s for ubiquitin, UBA1 and the recently discovered UBA6 (Jin et al., 2007), are 
monomeric proteins and bear the three structural elements interspersed on a 
polypeptide chain (Figure 2) (Schulman and Harper, 2009). 
 
The adenylation domain bears structural homology with the molybdopterin 
biosynthetic enzyme B (MoeB) and thiamine biosynthesis protein F (ThiF), both 
bacterial enzymes involved in the biosynthesis of molybdenum cofactor and 
thiamin respectively. These E1-like enzymes activate the bacterial proteins 
molybdopterin converting factor subunit 1 (MoaD) and ThiS respectively, both of 
which bear the Ubl fold, via a mechanism analogous to eukaryotic E1s (Lake et 
al., 2001, Lehmann et al., 2006, Leimkuhler et al., 2001, Taylor et al., 1998).  
 
Recognition and activation of ubiquitin, E2 selection and subsequent ubiquitin 
charging (E2~ubiquitin) can be listed as the fundamental properties for the 
ubiquitin E1. In the Saccharomyces cerevisiae Uba1 structure, a long flexible 
linker (called ‘crossover loop’) that connects the active adenylation domain with 
Figure 2: E1 domains. Cartoons depict the structural elements of E1s; adenylation domain (light and dark pink), 
catalytic cysteine domain (blue) and ubiquitin-fold domain (red), for ubiquitin (UBA1 and UBA6), the Small Ubiquitin-like 
Modifier (SUMO - SAE1/UBA2) and the Neural precursor cell expressed, developmentally down-regulated protein 8 
(NEDD8 - NAE1/UBA3) aligned with the adenylation domains of bacterial E1-like enzymes molybdopterin biosynthetic 
enzyme B (MoeB)/thiamine biosynthesis protein F (ThiF). UBA is Ubiquitin Activating Enzyme, SAE and NAE is SUMO 
and NEDD8 Activating Enzyme respectively.  Black lines indicate sequence insertions within the conserved domains. 
Figure adapted from (Schulman and Harper, 2009).  
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the catalytic cysteine domain interacts with residue Arg72 on the C-terminal tail 
of ubiquitin. This residue acts as the crucial determinant of Ubl discrimination by 
their E1s (Ala and Glu/Gln are present in the corresponding positions of Ubls 
NEDD8 and the SUMO family respectively) (Lee and Schindelin, 2008, Whitby 
et al., 1998). In addition, a conserved four-stranded  sheet within the active 
adenylation domain recognizes the canonical hydrophobic patch of ubiquitin 
(described in section 1.3). While the UFD confers E2 recognition properties, 
further structural and biochemical studies are required for deeper understanding 
of the multiple productive E2 interactions enabled by the ubiquitin E1 (Lee and 
Schindelin, 2008).  
 
1.3 Ubiquitin: patches and signals  
 
Structurally, ubiquitin (Ub) and ubiquitin-like (Ubl) proteins share the -grasp 
ubiquitin superfold (accession number IPR000626) despite low sequence 
conservation. The ‘ubiquitons’ share a compact globular structure consisting of 
a five-stranded -sheet, a short 310 helix, a 3.5-turn -helix and a flexible tail on 
the C-terminus (Figure 3) (Mayer et al., 1998, Vijay-Kumar et al., 1987, Vijay-
Kumar et al., 1985). 
Figure 3: Ubiquitin – Structure, patches and acceptors. Structural features of the  grasp fold in ubiquitin (left) (PDB 
1UBQ) alongside a surface representation of the functional patches (hydrophobic (Ile44, blue) patch, acidic (Asp58, 
pink) patch and the carboxy terminal tail (Arg72-Gly76)) supported by the fold (middle). Ubiquitin ligation occurs through 
its carboxy terminus, however modification on ubiquitin occurs at any of the seven lysines as well on the amino 
terminus (right). Structure figures were generated using PyMOL (Schrodinger, 2010). 
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Functionally important surfaces and regions on the protein include the solvent 
exposed hydrophobic patch (Leu8, Ile44, Val70 with an extended region 
surrounding Phe4), an acidic patch (residues surrounding Asp58) and the 
flexible tail (Leu73, Arg74, Gly75 and Gly76) (Figure 3) (Sloper-Mould et al., 
2001, Raiborg et al., 2006).  
 
While ubiquitination entails the ligation of ubiquitin C-terminus onto the target 
lysine/amino terminus, a chain can be initiated from any of the internal seven 
lysines within ubiquitin (Lys (x) -linked chains where x can be 6, 11, 27, 29, 33, 
48 or 63) or the amino terminus (linear ubiquitin chains). However, non-
canonical ubiquitination (on Cys, Ser and Thr acceptors) by viral E3 ligases 
using cellular E2s have been reported (Cadwell and Coscoy, 2005, Wang et al., 
2007, Wang et al., 2009). Consequently, ubiquitin offers a versatile surface for 
facilitating interactions and in addition is capable of supporting distinct 
polyubiquitin based signals. Polyubiquitination can be either homotypic (lysine 
specific and linear linkages) or heterotypic (mixed and branched linkages) and 
play decisive roles in several cellular pathways (Figure 4A and recently 
reviewed here (Komander, 2009)). 
  
Monoubiquitination and multi monoubiquitination regulate several cellular 
pathways including receptor trafficking, DNA repair and transcription regulation 
(Polo et al., 2003, Ulrich and Walden, 2010). Lys48- linked polyubiquitination is 
the canonical signal for proteasomal degradation of substrates (Chau et al., 
1989), however examples of mono- and Lys11-, Lys63-linked poly- 
ubiquitinated substrates degraded by the 26S proteasome have also been 
presented (reviewed in (Finley, 2009)). Cellular functions of Lys63-linked 
polyubiquitin chain are well established in signalling pathways and DNA 
damage response pathways, however recent reports have revealed roles for 
monoubiquitinated and Lys63-linked polyubiquitinated signals in autophagy 
(reviewed in (Chin et al., 2010, Kirkin et al., 2009)). Structural features of linear 
(PDB 2W9N) (Komander et al., 2009b), Lys48- (PDB 1AAR) (Cook et al., 1992) 
and Lys63- (PDB 2ZNV) (Sato et al., 2008) linked diubiquitin chains and more 
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recently, Lys11- (PDB 2XEW) (Bremm et al., 2010) and Lys6- (PDB 2XK5) 
linked diubiquitin chains have been characterized.  
Structural insights into ubiquitin chain conformations have been vital in 
understanding the diverse physiological responses they generate. Extended 
chain conformations are observed in linear and Lys63- linked chains and similar 
Figure 4: Diversity of Ubiquitin Signals. A. Classification of ubiquitin signals can be based on number 
(mono/multimono/poly), structure (extended/closed) and composition (homotypic/heterotypic). Ubiquitin chains adopt 
extended (Lys29/33/63- or linear linkages) or closed conformations (Lys6/11/27/48- linkages) depending on the linkage 
type. Homotypic ubiquitination refers to polyubiquitination of a single linkage type. In contrast heterotypic refers to either 
mixed polyubiquitination where two or more linkages occur (yellow and green) or branched polyubiquitination where two 
or more ubiquitins are linked to different lysines of a single ubiquitin (reds to yellow). B. Surface representations of 
ubiquitin (PDB 1UBQ, left), Lys63 linked di-ubiquitin (PDB 2JF5, middle) and Lys48 linked di-ubiquitin (PDB 1AAR, 
right) illustrating the functional patches as well as the extended (Lys63 di-Ub) or closed (Lys48 di-Ub) conformations 
adopted by ubiquitin chains. Proximal and distal ubiquitin moieties in di-ubiquitin structures are coloured yellow and 
green respectively. Residues Lys48 and Lys63 that support isopeptide linkages with C-terminus of subsequent ubiquitin 
moieties are coloured cyan (‘proximal’ Lys48 and Lys63 on the left, distal Lys63 in middle and distal Lys48 on the right). 
Structure figures were generated using PyMOL (Schrodinger, 2010). 
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conformations expected in Lys29- and Lys 33- linked structures (Figure 4B) 
(Fushman and Walker, 2010). 
 
1.4 Ubiquitin: patches and receptors  
 
The hydrophobic patch, regardless of the signal type, is the noncovalent 
recognition patch for majority of signal receptors or Ubiquitin Binding Domains 
(UBDs) contained in several proteins (reviewed in (Dikic et al., 2009) and 
(Hurley et al., 2006)). Thus, substrates bear the ubiquitin signal (mono, multiple 
mono or polyubiquitination) that is discriminated by various UBD-bearing 
proteins facilitating downstream transduction of the signals. UBDs themselves 
are generally small (<100 residues, except the ubiquitin conjugation fold (UBC 
fold)) and nearly two-dozen have been structurally characterised showing some 
fold diversity (-helical, zinc fingers (ZnF), plekstrin homology (PH) domains, 
UBC and other domains).  
 
In recent years, a surge of structural and biophysical studies has provided the 
molecular details required to appreciate the multivalent signal-receptor 
(ubiquitin-UBD) interaction. For example, members of ubiquitin associated 
(UBA) -helical UBDs include the UBA2 of human homolog of yeast Rad23a 
(hHR23A) having a selective preference for Lys48 linked polyubiquitin chains, 
while the UBA of Ubiquilin-1 shows little or no selective criterion in their ubiquitin 
(mono/chain) binding (Varadan et al., 2005, Zhang et al., 2008). UBDs 
generally display low binding affinities (100-500 μM) for the monoubiquitin 
moiety however, affinity can be enhanced through cooperation and avidity 
mechanisms that have bearing on their downstream events (Sims et al., 2009). 
Examples of avidity include the double-sided ubiquitin interaction motif (UIM) of 
Hepatocyte growth factor–Regulated tyrosine kinase Substrate (HRS) (PDB 
2D3G) (Hirano et al., 2006, Ren and Hurley, 2010) that play a role in the 
degradation of internalized receptors in the Endosomal Sorting Complexes 
Required for Transport (ESCRT) pathway. Tandem UIMs of Receptor 
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Associated Protein 80 (RAP80) (PDB 3A1Q) (Sato et al., 2009, Sims and 
Cohen, 2009) binding the extended structure of Lys63-linked ubiquitin chains to 
initiate DNA repair pathway (Figure 5). UBD cooperation in trans is observed 
between the proteasomal subunits Regulatory Particle Non-ATPase (RPN) 10 
(UIM) and 13 (PH domain) (PDB 2KDE and 2KDF) in selecting Lys48-linked 
chains to initiate substrate degradation (Zhang et al., 2009).  
 
The Ub/Ubl - UBD interactions have also been observed to influence substrate 
ubiquitination as described in the case of ‘coupled monoubiquitination’ (Haglund 
and Stenmark, 2006). In this event, the interactions between substrate UBD 
and the E3 ligase (ubiquitinated or Ubl bearing) lead to ubiquitination of the 
substrate a different site. Subsequently, intramolecular interaction between 
UBD and ligated ubiquitin could occlude binding of Ub/Ubl bearing E3 or 
conceal acceptor sites on the ligated Ub, thereby inhibiting successive 
ubiquitination. The phenomenon has been observed with monoubiquitination of 
Figure 5: Avidity in Ubiquitin-Ubiquitin Binding Domain (UBD) interactions. Ubiquitin bound structures of double-
sided ubiquitin interacting motif (UIM, on left) present in Hepatocyte growth factor–Regulated tyrosine kinase Substrate 
protein (HRS, PDB 2D3G) and tandem UIM (on right) present in Receptor Associated Protein 80 (RAP80, PDB 3A1Q) 
illustrate how UBDs enhance binding affinities of non-covalent interactions with ubiquitin. The double-sided HRS UIM 
presents two interaction surfaces on opposite sides of the helical UBD, each of which binds the hydrophobic patch of 
ubiquitin. The resulting combined affinity is 2.5-3 fold greater than the individual affinity (Hirano et al., 2006). The 
extended helical UBD of RAP80 presents two tandem UIMs that exhibit greater affinity and preference for the extended 
conformation of Lys63-linked ubiquitin chains over monoubiquitin and Lys48-linked (closed conformation) ubiquitin 
chains (Sato et al., 2009). Structure figures were generated using PyMOL (Schrodinger, 2010). 
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Epidermal growth factor receptor substrate 15 (EPS15) by E3 ligases, Parkin 
and Neural precursor cell expressed developmentally down-regulated protein 4 
(NEDD4) (Fallon et al., 2006, Woelk et al., 2006). UIMs on EPS15 interact with 
Parkin’s Ubiquitin like Domain (UblD) as well as monoubiquitinated NEDD4 
contributing to coupled monoubiquitination (Figure 6).  
 
 
Interestingly, coupled monoubiquitination can also occur in the absence of an 
E3, with substrate UBDs binding the ubiquitin charged/loaded E2s and the latter 
catalysing ubiquitin ligation on the substrate (Hoeller et al., 2006). In addition, 
UBDs on E2s facilitate polyubiquitin chain building mechanisms, discussed in 
section 1.5. Taken together, ubiquitin provides a fertile landscape for generating 
a variety of post-translational modifications and multivalent ubiquitin-UBD 
interactions enable downstream transmission of these signals.  
 
Figure 6: Mechanisms of Ubiquitin Binding Domain (UBD) based ubiquitination. Coupled monoubiquitination is a 
result of interactions between certain Ubiquitin (Ub)/Ubiquitin-like (Ubl) moieties and UBDs present on the carboxy 
terminus of Epidermal growth factor receptor substrate 15 (EPS15). Interactions between EPS15 Ubiquitin Interacting 
Motifs (UIMs, a class of helical UBDs) and ubiquitinated HECT E3 ligase Neural precursor cell expressed 
developmentally down-regulated protein 4 (NEDD4, top left) or the integral Ubiquitin-like Domain (UblD) of RING E3 
ligase Parkin (top centre) leads to coupled monoubiquitination of EPS15. Alternatively, the UIM can interact with the 
ubiquitin moiety of UBE2D2/UbcH5B~ubiquitin thioester conjugate (top right), resulting in an E3-independant cis 
monoubiquitination event. Subsequently, intramolecular interactions between UBD and ligated ubiquitin (double headed 
red arrow, bottom) could inhibit repeat events (bottom centre). Figure adapted from (Haglund and Stenmark, 2006). 
(HECT is Homologous to the E6-AP Carboxyl Terminus and RING is Really Interesting New Gene.) 
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1.5 E2s: signal-conjugating enzymes  
 
Over three-dozen ubiquitin conjugating enzymes/ubiquitin E2s have been 
identified in humans all sharing a core ubiquitin conjugation (UBC) fold. The 
topology of the core domain consists of an N-terminal helix, followed by a four-
stranded -meander (anti-parallel -sheet), tethered with a ‘flap-like’ structure 
comprised of two extended elements 
in a -hairpin fold, and finally one to 
two -helices at the C-terminus. The 
catalytic cysteine is located in a 
shallow groove on the ‘flap-like’ 
structure and functionally supported 
by a conserved ‘chain of interacting 
residues’ (CIR - asparagine and 
histidine and an aromatic residue). 
Other conserved residues include 
the hydrophobic pairing of a Pro-
Trp/Met that helps tether the ‘flap-
like’ structure to the -meander 
(Figure 7) (Burroughs et al., 2008).  
 
A bioinformatics-driven nomenclature for the various mammalian E2s using the 
UBE2Xn syntax (X and n denote a letter and number respectively) has been 
suggested recently (Ye and Rape, 2009). Further structural sub-categorization 
is based on extensions around the core domain; Class I consists of just the core 
domain, N and C terminal extensions make up Classes II and III respectively, 
while Class IV E2s have extensions on both ends (Hofmann and Pickart, 2001, 
Winn et al., 2004). Proteins that contain the UBC fold but lack the catalytic 
cysteine are known as E2 variants and have critical roles in chain formations 
(UBE2V1, 2 and 3 (UEV1, 2 and 3)). A selective list of the mammalian E2s, 
specialized chain products and other associated features have been compiled 
in Table 1. 
Figure 7: E2 Topology. Conserved structural features of 
the ubiquitin conjugation (UBC) fold include the -meander, 
‘chain of interacting residues’ (CIR) and a ‘flap-like’ 
element bearing the catalytic cysteine and interactions with 
ubiquitin tail. Adapted from (Burroughs et al., 2008)  
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Principal binding patches on E2s are those establishing E1-E2 and E2-E3 
interactions. Restructuring of the ubiquitin E1 during ubiquitin activation reveals 
the UFD region for E2 interaction via conserved residues in N-terminal helix 
(Lee and Schindelin, 2008, Huang et al., 2007, Lois and Lima, 2005). The 
ubiquitin tail packs between the extended elements that bear the catalytic 
cysteine and asparagine when conjugated to the E2 (Figure 7) (Eddins et al., 
2006, Hamilton et al., 2001, Reverter and Lima, 2005, Yunus and Lima, 2006). 
The CIR (Figure 7) has been suggested to affect deprotonation of the target 
lysine (or free amino group) as a result facilitating a nucleophilic attack on the 
thioester (E2~ubiquitin). Concomitantly, CIR’s Asn could stabilise the 
oxyanionic intermediate during isopeptide linkage (Wu et al., 2003, Yunus and 
Gene Other names Class Salient roles Function 
UBE2D2 UbcH5B, E2-17K2 I  
UBE2C UBCX, UbcH10 II Lys11-linked  Cell cycle regulation 
UBE2S E2-EPF5, E2-24K III Lys11-linked Cell cycle regulation 
UBE2R1 Cdc34, Ubc3, E2-32K III Lys48-linked Cell cycle regulation 
UBE2K Ubc1, HIP-2, E2-25K III Lys48-linked Protein quality control 
UBE2T HSPC150 III Monoubiquitination DNA repair 
UBE2Z Use1, HOYS7 IV Functions with Uba6 (E1) 
UBE2G2 Ubc7 I Lys48-linked, non-lysine sites 
UBE2J2 NCUBE2, Ubc6 III 
Lysine and non-lysine sites, 
transmembrane domain 
Endoplasmic Reticulum 
(ER) quality control 
UBE2N Ubc13, BLU I 
Lys63-linked as heterodimer with 
UBE2V1/V2 
UBE2V1 UEV-1 II 
UBE2V2 MMS2, UEV2 I 
E2 variant, Lys63-linked as 
heterodimer with UBE2N 
NFB signaling, 
DNA repair, 
Aggresome formation, 
Macroautophagy 
UBE2L3 UbcH7, E2-F1 I  Protein quality control 
UBE2L6 UbcH8, RIG-B I Ubiquitin and ISG15 conjugation Interferon signaling 
UBE2I Ubc9 I SUMO conjugation Cell cycle regulation 
UBE2F NCE2 I NEDD8 conjugation Regulation of SCF 
Table 1: Diversity of Mammalian E2s. Select list of Mammalian E2s and their associated properties. Adapted from 
(Ye and Rape, 2009). E2s known to function with Parkin are highlighted (brown). 
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Lima, 2006). Conversely, molecular dynamics simulations propose the 
trajectory of the attacking amino group, rather than a general base (Asp), helps 
lower the pKa, thus favouring its deprotonation and nucleophilic attack on the 
thioester bond (Hau et al., 2006). The mechanistic details of these events await 
further biochemical and structural studies.  
 
The N-terminal helix along with two other loops (L1 – loop connecting strands 
45 of the -meander, L2 – the exit loop from the ‘flap-like’ structure leading to 
the first of the C-terminal helices) make up the generic E3 interaction surface. A 
combination of X-ray crystallography, Nuclear Magnetic Resonance (NMR) 
spectroscopy and interaction mutagenesis experiments have revealed the 
details and variations of the E2-E3 interface ((Christensen and Klevit, 2009, van 
Wijk and Timmers, 2010) and reviewed recently in (Ye and Rape, 2009, 
Deshaies and Joazeiro, 2009)). Despite the distal nature of the E2-E3 interface, 
E3 binding enhances the rate of ubiquitin offloading/discharge with conserved 
internal residues are suggested to take part in allosteric transmission 
mechanics (Figure 8) (Eletr and Kuhlman, 2007, Huang et al., 2009, Ozkan et 
al., 2005). The E2-RING interface of UBE2L3 (UbcH7) – Casitas B-lineage 
lymphoma proto-oncogene (c-Cbl) (Zheng et al., 2000), UBE2N (Ubc13) – 
Tumor Necrosis Factor (TNF) receptor-associated factor 6 (TRAF6) (Yin et al., 
2009) and UBE2D2 (UbcH5B) – Inhibitor of Apoptosis protein 2 (cIAP2)  (Mace 
et al., 2008) are depicted in Figure 8.  
 
Examples of sequence elements that co-operate with RING domains in 
allosteric activation of the E2~ubiquitin thioester have also been presented in 
context of UBE2G2/Ubc7, an E2 associated with the endoplasmic reticulum 
(ER). The Ubc7p binding region (U7BR) and G2 Binding Region (G2BR) are cis 
sequence elements to RING domains of ER anchored Conjugation to ER 
degradation protein-1 (Cue1p) and Autocrine Motility Factor Receptor 
(AMFR/gp78) E3 ligases respectively. These elements bind UBE2G2 in tandem 
with the RING domains at a site distinct from the ‘canonical’ E2-E3 interface 
and have been observed to enhance UBE2G2 activation as well as E3 
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mediated substrate ubiquitination (Bazirgan and Hampton, 2008, Biederer et al., 
1997, Chen et al., 2006, Das et al., 2009).  
 
 
As the regions on the UBC fold that support E1 and E3 interactions are partially 
overlapping (helix1 being the shared interface), E1-E2 and E2-E3 binding 
events have been observed to be mutually exclusive (Eletr et al., 2005). 
Furthermore, the transient nature of E2-E3 interactions allow for E2 uncoupling, 
Figure 8: E2 enzyme dynamics. Structural efforts of RING-E2 interactions have revealed three regions on the E2 
critical for the interface; helix (H) 1, loops (L) 1 and 2 (loop numbers do not correspond to E2 topology). Multiple 
sequence alignments (top, generated using ClustalW (Chenna et al., 2003)) depict RING binding regions of select E2s 
with their interacting residues indicated above with coloured dots; purple, orange and red dots for UBE2L3/UbcH7 - c-
Cbl, UBE2N/Ubc13 - TRAF6 and UBE2D2/UbcH5B - cIAP2 interactions respectively. c-Cbl is Casitas B-lineage 
lymphoma proto-oncogene protein, TRAF6 is Tumor Necrosis Factor (TNF) receptor-associated factor 6, cIAP2 is 
Inhibitor of Apoptosis protein 2 and RING is Really Interesting New Gene domain. Also aligned are corresponding 
regions of two other E2s (UBE2L6/UbcH8 and UBE2G2/Ubc7) that function with Parkin. Conserved residues (blue and 
red sticks) and CIR (green sticks) and the location of RING binding helix 1, loop 1 and 2 are indicated on the 
UBE2L3/UbcH7 structure (PDB 1FBV, left). Also shown on UBE2L3/UbcH7 structure (PDB 1FBV, middle) are residues 
that interact with c-Cbl RING and those predicted to be involved in RING mediated allosteric activation of E2 (dark olive 
and brown sticks respectively) (Ozkan et al., 2005, Zheng et al., 2000). E3 binding residues and the CIR are depicted as 
sticks (dark olive and green respectively) on UBE2N/Ubc13 (PDB 2GMI), which is covalently linked to ubiquitin via an 
ester linkage (Ser87 — Gly76, right). Catalytic cysteine (Cys86) of UBE2L3/UbcH7 (left and middle) and the cysteine to 
serine mutant (Ser87) used to generate the UBE2N/Ubc13 — ubiquitin ester conjugate are shown as red sticks. 
Structures were generated using PyMOL (Schrodinger, 2010). 
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ubiquitin recharging of the E2 (via E1) and subsequent E2 
reattachment/switching as a strategy to sustain substrate polyubiquitination 
(Rodrigo-Brenni and Morgan, 2007, Christensen et al., 2007, Windheim et al., 
2008, Parker and Ulrich, 2009, Andersen et al., 2005). E2 switching (where an 
E3 uses two distinct E2s to ubiquitinate a single substrate) enhances the 
processivity of ubiquitination; defined as the number of ubiquitin moieties ligated 
on the substrate during a single enzymatic encounter with the E3. In certain 
scenarios, substrate polyubiquitination can be delineated as a concert with two 
distinct acts; ubiquitin chain initiation followed by elongation, with different E2s 
operating in each act.  
 
The pliable UBE2D (UbcH5) family have been reported as the chain initiating 
partners to the linkage specific E2s. Conversely, numerous E2s have been 
observed to specialise in linkage specific chain synthesis; UBE2N/UBE2V1/2 
(Ubc13/UEV1) for Lys63-linked (Eddins et al., 2006, McKenna et al., 2003, Hau 
et al., 2006), Lys11-linked by UBE2S (E2-24K) and UBE2C (UbcH10) 
(Williamson et al., 2009, Jin et al., 2008, Wu et al., 2010), Lys48-linked chains 
by UBE2K (Ubc1/E2-25K) (Haldeman et al., 1997), UBE2G2 (Ubc7) (Li et al., 
2007, Ravid and Hochstrasser, 2007) and UBE2R1 (Cdc34) (Gazdoiu et al., 
2007, Petroski and Deshaies, 2005b). Mechanisms of linkage specific chain 
formation are suggested to involve non-covalent UBC-ubiquitin interactions best 
demonstrated through structural studies on the heterodimeric 
UBE2N/UBE2V1/2 (Ubc13/UEV1/2) complexes (Eddins et al., 2006, Hau et al., 
2006). Non-covalent ubiquitin interactions and E2 self-association are crucial for 
chain processivity by UBE2D (UbcH5B), an E2 that lacks intrinsic ability to form 
linkage specific polyubiquitin chains (Brzovic et al., 2006, Christensen et al., 
2007).  
 
An alternative strategy employed to enhance processivity is observed with 
UBE2G2 (Ubc7), which can preassemble Lys48 linked chains and transfer them 
en masse onto the substrate (Li et al., 2007, Ravid and Hochstrasser, 2007). 
Interestingly, presence of certain E3s have been observed to enhance the 
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preassembly of Lys63- and Lys48- linked polyubiquitin chains in vitro (Petroski 
et al., 2007, Li et al., 2007).  
 
Other models for linkage specific ubiquitin chain formation have been described 
in the context of HECT E3 ligases (refer (Hochstrasser, 2006) for an elegant 
discussion). An ‘indexation model’ has been proposed to explain mechanisms 
involved in tetra-ubiquitin chain synthesis by WW domain-containing protein 1 
(WWP1) HECT E3 ligase (Verdecia et al., 2003) and Lys48 linked di-ubiquitin 
chain synthesis (in vitro) by Human papillomavirus E6-associated protein (E6-
AP) HECT E3 ligase (Wang and Pickart, 2005). In this model, the catalytic 
cysteine located on the flexible lobe C-terminal lobe (C-lobe) bears the HECT 
E3~ubiquitin thioester conjugate. Furthermore, the C-lobe positions the ubiquitin 
such that Lys48 attacks the E2~ubiquitin thioester (bound to the N-terminal 
lobe/N-lobe via E2- HECT E3 interactions) resulting in a Lys48 linked di-
ubiquitin chain moiety on the HECT active site (HECT E3~ubiquitin + 
E2~ubiquitin  HECT E3~di-ubiquitin) (Wang and Pickart, 2005). Inherent 
flexibility of the C-lobe allows the ‘unfurling’ of the HECT permitting repeat 
events (chain extension) until a Lys48 linked tetra-ubiquitin chain is formed. 
Subsequently, a target lysine attacks the HECT E3~tetra-ubiqutin thioester 
resulting polyubiquitination of the substrate (en bloc) (Verdecia et al., 2003).  
 
An alternative ‘sequential addition’ model has also been proposed with respect 
to the Reverses SPT-phenotype protein 5 (RSP5) HECT E3 ligase (NEDD4L 
homolog in S. cerevisiae) wherein the ubiquitin is sequentially ligated onto the 
substrate (repeated cycles of E1~ubiquitin  E2~ubiquitin  E3~ubiquitin  
Substrate-ubiquitin) (Kim and Huibregtse, 2009). In this scenario, the catalytic 
cysteine on the C-lobe positions the HECT E3~ubiquitin thioester to allow 
nucleophilic attack by Lys63 of the substrate bound ubiquitin or the distal end of 
the polyubiquitin chain. Taken together, substrate ubiquitination is a multi-
faceted process involving ubiquitin, UBDs and various E2s with E3s at the 
helm. 
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1.6 RING E3 ligases: conductors of ubiquitin signalling 
 
As indicated earlier, E3 ligases are broadly classified as HECT domain and 
RING domain E3 ligases. HECT E3s mediate an additional step in the ubiquitin 
pathway where the ubiquitin moiety is transferred from the E2 onto a conserved 
cysteine in the HECT domain through a second transthioesterification reaction 
(Scheffner et al., 1995). The majority of the E3 ligase family contain a RING 
domain and act as a molecular scaffold enzymes on which the substrate and 
E2~ubiquitin interact in a catalytically productive manner (Pickart, 2001). 
Mechanisms of HECT E3 ligases and their role in cellular pathways have been 
reviewed elsewhere (Bernassola et al., 2008, Scheffner and Staub, 2007). The 
focus of this section will be on RING E3 ligases primarily as Parkin, the subject 
of this thesis, is a member of this family. Parkin bears two RING domains 
flanking an In-Between RING (IBR) domain and is the archetypal member of the 
RBR/TRIAD; the second largest RING subfamily in humans (Marin et al., 2004).  
RING motifs, discovered in 1991, were originally considered to be a novel DNA-
binding zinc finger motif (Freemont et al., 1991). The association with 
ubiquitination and inherent E3 ligase activity however, followed nearly a decade 
later (reviewed in (Joazeiro and Weissman, 2000)). Fortuitously, the discovery 
of Parkin and association with E3 ligase activity coincided with these reports 
(Kitada et al., 1998, Shimura et al., 2000).  
 
RING ‘finger’ domains (Figure 9) are globular domains with a cysteine-rich 
canonical sequence (InterPro IPR001841) that coordinate two zinc atoms in a 
unique cross-brace arrangement (Freemont et al., 1991, Barlow et al., 1994, 
Borden et al., 1995). Numerous variations have been reported including 
sequence variations (Cys/His swapping or Asp in lieu of Cys) fold variations 
(Lin11, Isl-1 and Mec-3 (LIM) domains and Plant Homeo Domains (PHDs)) and 
structural relations (B-box and U-box domains) (reviewed in (Borden and 
Freemont, 1996), (Aravind and Koonin, 2000, Tao et al., 2008)) (Figure 9). 
While the majority are associated with ubiquitination, Zn2+ coordinating PHDs 
lack E3 ligase activity (Aravind et al., 2003) and conversely U-box domains do 
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not coordinate Zn2+ however display ubiquitin ligase activity (Aravind and 
Koonin, 2000).  
 
Furthermore, RING bearing proteins Bard1, Bmi1 and MdmX exhibit ligase 
activity exclusively through heterodimeric complexes (Brca1/Bard1 (Hashizume 
et al., 2001), Ring1b/Bmi1 (Wang et al., 2004) and Mdm2/Mdmx (Linares et al., 
2003)). An interesting example of heterodimeric RING complex is the 600 kDa 
linear ubiquitin chain assembly complex (LUBAC) consisting of the haem-
oxidized IRP2 ubiquitin ligase-1 (HOIL-1) isoform HOIL-1L and HOIL-1L 
Interacting Protein (HOIP) (Kirisako et al., 2006). The LUBAC complex has 
been the only E3 ligase reported to orchestrate the synthesis of linear 
polyubiquitin chains with a range of E2s, however, the mechanistic details of 
these events are awaited (refer (Nagy and Dikic, 2010) for proposed theories).  
Figure 9: RING finger domains. Canonical sequences of RING and RING-like variants along with a cartoon 
representation of the Vmw110 RING domain determined by Nuclear Magnetic Resonance (NMR) spectroscopy (PDB 
1CHC) showing cross-brace arrangement. Sequence organisation of the two RING domains of Parkin is also shown. 
Domain names: RING is Really Interesting New Gene, Mdm2 is Double minute 2 protein, RBQ-1 is Retinoblastoma-
Binding Q protein-1, RBX1 is RING-box protein 1, LIM is named after three proteins Lin11, Isl-1 and Mec-3 where it was 
first found and PHDs is Plant Homeo Domains. ‘C’ and ‘H’ are symbols for residues cysteine (Cys) and histidine (His) 
respectively, while ‘x’ indicates any residue. Structure figures were generated using PyMOL (Schrodinger, 2010).    
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Functional homodimerisation is observed in several RING E3 ligases including 
c-Cbl (Kozlov et al., 2007, Peschard et al., 2007), TRAF6 (Yin et al., 2009), 
cIAP2 (Mace et al., 2008) as well as the C-terminus of Hsc70-interacting protein 
(CHIP), a U-box E3 ligase (Zhang et al., 2005). The asymmetric CHIP dimer 
obstructs a potential E2 binding while the cIAP2 dimer displays twin E2 binding 
site. Incidentally, the cIAP2 dimer interface requires a conserved aromatic 
residue located at -3 position from its C-terminus, a residue conserved in Parkin 
homologs as well (Schlehe et al., 2008). c-Cbl dimerises through a distal UBA 
domain while the TRAF6 shows an extensive dimer interface through N-terminal 
zinc fingers and together with the trimeric C-terminal region is suggested to 
form supramolecular assemblies (Yin et al., 2009).  
 
RINGs can function as monomeric units, with substrate recognition and E2 
recruiting elements borne on a single polypeptide chain. For example Fanconi 
anemia group protein L (FancL), a multi-domain E3 ligase, is responsible for the 
critical monoubiquitination of FancD2 as part of a DNA damage response 
pathway which is defective in Fanconi Anemia (FA) patients (Cole et al., 2010). 
Majority of the RINGs however function as part of multi-subunit complex; cullin-
RING ubiquitin ligases (CRLs) (Refer (Deshaies and Joazeiro, 2009) 
Supplementary Table 1 therein for a comprehensive list of RING E3 ubiquitin 
ligases). CRLs comprise a modular architecture comprising of rigid central cullin 
module (CUL 1, 2, 3, 4A, 4B and 5 comprise the cullin family) that docks RING 
domains (Rbx1 or Rbx2) and associated E2s on a conserved C-terminal region. 
N-terminus of the cullin modules binds cullin ‘adaptors’ (for example, S-phase 
kinase-associated protein 1 (SKP1) and the Elongin BC complex) that further 
associate with numerous ‘substrate receptors’ (members of the F-box family 
and Suppressor of cytokine signalling (SOCS) box family respectively); the 
latter conferring substrate specificity to CRLs.  (refer (Petroski and Deshaies, 
2005a) for an overview of CRL assembly and E3 ligase properties).  
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Enzymatic properties of RING E3 ligases include substrate recognition, E2 
activation and the concomitant ubiquitination of a target lysine on the substrate 
(Figure 10). Activation of E2s entails the binding RING E3 with E2~ubiquitin and 
concomitant thioester discharge of E2~ubiquitin. However, not all E2-E3 
interactions result in E2 activation, as observed in vitro for the c-Cbl-UBE2L3 
(UbcH7) (Huang et al., 2009) and Bard1/Brca1-UBE2L3 (UbcH7) (Brzovic et al., 
2003) interactions. Detailed mechanisms of this ‘activation’ are not completely 
understood however, RING/U-box induced conformation changes within 
E2~ubiquitin conjugate could play a role in this event. Certain internal residues 
within the E2 that could play a role in allosteric activation mechanics have also 
been identified (Ozkan et al., 2005).  
 
 
Figure 10: The RING-E2 interface. Multiple sequence alignments (top, generated using ClustalW (Chenna et al., 
2003)) depict select RING domains with their E2 interacting residues indicated above with coloured dots; purple, orange 
and red dots for c-Cbl - UBE2L3/UbcH7, TRAF6 - UBE2N/Ubc13 and cIAP2 - UBE2D2/UbcH5B interactions 
respectively. c-Cbl is Casitas B-lineage lymphoma proto-oncogene protein, TRAF6 is Tumor Necrosis Factor (TNF) 
receptor-associated factor 6, cIAP2 is Inhibitor of Apoptosis protein 2 and RING is Really Interesting New Gene domain. 
Sequence alignments with the two RING domains of Parkin are also shown. Cartoon representation of c-Cbl RING 
domain (PDB 1FBV) with E2 interaction residues shown as green sticks and zinc co-ordinating residues in blue sticks 
(bottom left). Structure figures were generated using PyMOL (Schrodinger, 2010). The enzymatic properties of the 
RING E3 ligases enable E2 activation and concomitant substrate ubiquitination (black dashed arrows, bottom right).  
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Substrate recognition, the other catalytic property of RING E3 ligases is 
established through a variety of protein-protein interactions mediated either by 
internal domains present in monomeric RING E3 ligases (Cole et al., 2010) or 
through the numerous substrate receptors associated with CRL complexes 
(Petroski and Deshaies, 2005a). A consensus site for substrate ubiquitination 
was long considered being absent, however the discovery of a TEK box 
sequence element neighbouring the target lysine on substrates of the anaphase 
promoting complex/cyclosome (APC/C) E3 ligase has altered this perspective 
(Jin et al., 2008). The presence of flanking basic residues could also affect the 
site of ubiquitination by lowering the pKa of the target lysine thereby facilitating a 
nucleophilic attack on the E2~ubiquitin thioester concluding in the ubiquitination 
of the former (Highbarger et al., 1996). Further mechanistic studies into 
E2~ubiquitin activation mechanics, target lysine selection and substrate 
ubiquitination for the numerous E3-substrate complexes identified are awaited. 
  
In summary, substrate ubiquitination is a multifaceted process influenced by 
several factors including; intrinsic E2 activity (linkage specific E2s or others), E2 
switching mechanisms (initiator/elongator), presence of UBDs on 
E2/E3/substrate (coupled monoubiquitination) and the monomeric/oligomeric 
state of E3/E2. Parkin, the focus of this study is a RING E3 ligase implicated in 
Parkinson’s disease. The following sections present an overview of the disease 
state, the molecular players involved as well as the E3 ligase properties of 
Parkin.   
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1.7 Introduction to Parkinson’s Disease 
 
Parkinson’s disease (PD) is a common neurological disorder that is both chronic 
and progressive and occurs due to loss of dopaminergic neurons in the 
substantia nigra pars compacta (SNc) (reviewed in (Cookson, 2005, Yang et al., 
2009)). Loss of dopamine, a catecholamine neurotransmitter, contributes to the 
movement disorder: bradykinesia (slowness of movement), resting tremor, 
muscular rigidity and postural instability. Presence of Lewy Bodies (LB, 
microscopic protein deposits detected accurately only upon autopsy) and 
eosinophilic cytoplasmic inclusions rich in alpha-synuclein and ubiquitin in 
surviving neurons, along with loss of dopaminergic neurons, is the pathological 
definition of idiopathic PD. 
 
Locus Gene Inheritance Function Reference 
PARK1, 4 SNCA AD Synaptic protein, LB (Polymeropoulos et al., 1997) 
PARK2 Parkin AR Ubiquitin RING E3 ligase (Kitada et al., 1998) 
PARK3 Unknown AD Unknown (Gasser et al., 1998) 
PARK5 UCH-L1* AD Ubiquitin C-terminal Hydrolase (Leroy et al., 1998) 
PARK6 PINK1 AR Mitochondrial Kinase (Valente et al., 2004) 
PARK7 DJ-1 AR Oxidative stress response (Bonifati et al., 2003) 
PARK8 LRRK2 AD Kinase and GTPase 
(Paisan-Ruiz et al., 2004, Zimprich 
et al., 2004) 
PARK9 ATP13A2 AR Possible ion pump (Ramirez et al., 2006) 
PARK10 Unknown AD Unknown (Li et al., 2002) 
PARK11 GIGYF2* AD Tyrosine kinase receptor signalling (Lautier et al., 2008) 
PARK12 Unknown X-Linked Unknown (Pankratz et al., 2002) 
PARK13 HTRA2 AD Mitochondrial Serine protease (Strauss et al., 2005) 
PARK14 PLA2G6 AR Phospholipases A2 (Paisan-Ruiz et al., 2009) 
PARK15 FBXO7 AR 
SCF Ubiquitin E3 ligase complex 
subunit 
(Di Fonzo et al., 2009, Shojaee et
al., 2008) 
PARK16 Unknown Unknown Unknown (Satake et al., 2009) 
 
Table 2: Parkinson’s Disease (PD) genes identified in Familial PD. AD and AR stand for autosomal dominant and 
recessive mode of inheritance respectively. * There are conflicting reports weather UCHL-1 (Healy et al., 2006) and 
GIGFY2 (Nichols et al., 2009, Vilarino-Guell et al., 2009) are the PD genes corresponding to PARK 5 and PARK11 loci 
respectively.  
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The presence of parkinsonian movement disorder symptoms in the absence of 
LB is termed as ‘Parkinsonisms’. PD affects approximately 1% of the population 
above the age of 50, with around 5% of the cases being rare familial forms with 
a younger age of onset (<45 years). Linkage and genotypic studies have 
identified several genes and loci associated with familial PD (Table 2). The 
following sections will introduce few of the molecular players of PD, describing 
genetic features, structural and functional features of the associated proteins, 
contribution to cellular pathway and how they contribute to the pathogenesis of 
the disease. 
 
1.8 -synuclein/SNCA: protein crowd dynamics 
 
The first dominant PD gene to be identified was the SNCA “synuclein, alpha 
(non A4 component of amyloid precursor)” (Polymeropoulos et al., 1997). The 
gene, expressed in several tissues including neurons, is a member of the 
synuclein family and codes for a 14kDa protein that is functionally undefined. 
Primary structure analysis reveals a central hydrophobic stretch (~30 residues) 
sandwiched between hydrophilic regions, on the N-terminus by imperfect 
KTEGV repeats and a variable C-terminal region rich in glutamic acid and 
proline (Tobe et al., 1992). The protein adopts no distinct secondary structure in 
solution however associates, via N-terminal amphiphatic helices, with lipid 
bilayers especially at pre-synaptic terminals suggestive of a regulatory role in 
membrane stability (Figure 11A) (Jakes et al., 1994, Davidson et al., 1998).  
 
Self-association is the defining feature of SNCA’s role in neurodegenerative 
diseases. The hydrophobic domain, also called non-amyloid component (NAC), 
is responsible for SNCA aggregation (Ueda et al., 1993). The C-terminal acidic 
tail counters the aggregation potential as demonstrated by in vitro and in vivo 
experiments (Murray et al., 2003, Tofaris et al., 2006, Periquet et al., 2007). 
Aggregated SNCA form oligomers, pores and other intermediates that are 
stabilized upon further aggregation to form heavily insoluble -pleated fibrils, 
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which are the major components of Lewy Bodies in PD and related 
synucleinopathies (Uversky, 2003, Spillantini et al., 1998).  
 
The intermediate oligomeric structures, termed protofibrils, are considered to 
enhance toxicity in dopaminergic neurons. Dopamine-SNCA adducts sustain 
these intermediates resulting in puncturing of synaptic membranes and vesicles 
(Lashuel et al., 2002, Xu et al., 2002, Conway et al., 2001). Familial PD 
mutations (A30P, E46K, A53T, WT duplication and triplication) affect the 
aggregative property of SNCA. While all mutations promote oligomerisation, the 
A30P mutation reduces both formation of insoluble fibrils and membrane 
association (Li et al., 2001, Fredenburg et al., 2007, Chartier-Harlin et al., 2004, 
Singleton et al., 2003). The viscous cytoplasmic environment (due to 
macromolecular crowding) along with enhanced SNCA expression observed in 
neurons renders them susceptible to downstream effects of SNCA mutations 
(Ueda et al., 1993, Uversky et al., 2002, Shtilerman et al., 2002). Taken 
together, aggregative toxicity has been attributed to a quantitative phenomenon, 
as phenotypes of SNCA point mutations are comparable to SNCA duplication 
Figure 11: SNCA (-synuclein) structure and pathways to neurotoxicity. A. Cartoon depicts primary sequence and 
associated regions of SNCA, with pathogenic mutations indicated above in red. The 14kDa protein bears imperfect 
KTEGV repeats, a central hydrophobic NAC (non amyloid component) and an acidic carboxy (C) terminal tail (not to 
scale). Figure adapted from (Cookson and Bandmann, 2010). B. Genetic defects (point mutations, duplications and 
triplications) as well as cellular stresses commonly found in sporadic Parkinson’s Disease (PD) (nitric oxide (NO), 
reactive oxygen species (ROS) and mitochondrial dysfunction) enhance the accumulation and self-aggregation of 
SNCA thus promoting neurodegeneration. SNCA aggregates inhibit critical cellular pathways (ubiquitin proteasome and 
autophagic pathways) and are detrimental to the mitochondria thereby further feeding into the cycle (green circular 
arrows) of SNCA accumulation and self-aggregation. Figure adapted from (Dawson et al., 2010).  
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and triplication. Toxic SNCA aggregation, observed in sporadic PD, is 
enhanced by other factors; environmental agents (reviewed in (Di Monte, 2003), 
Ser129 phosphorylation (Fujiwara et al., 2002), tyrosine nitration (Giasson et al., 
2000) and proteolysis of the C-terminal acidic tail (Kim et al., 2003b). 
 
Pathogenic SNCA aggregates are detrimental to basic cellular pathways further 
contributing to neuronal toxicity (Figure 11B). The ubiquitin proteasome 
pathway (UPP) is impaired by direct interaction of A53T SNCA (monomeric and 
aggregated forms) with subunits of the 26S proteasome and probably 
contributing to a system overload. This induces endoplasmic reticulum (ER) 
stress, overloading of the unfolded protein response pathway (UPR), 
culminating in apoptosis. Cytoplasmic discharge of dopamine vesicles 
generates reactive oxygen species (ROS) that amplifies oxidative stress leading 
to mitochondrial dysfunction, release of cytochrome C and culminating in 
caspase-mediated cell-death (Volles and Lansbury, 2002, Tanaka et al., 2001, 
Snyder et al., 2003, Smith et al., 2005a). Furthermore, mutant SNCA blocks the 
chaperone-mediated autophagy (CMA) pathway, via direct binding to lysosomal 
membrane receptors, thereby antagonizing the protein quality control system 
that contributes to fatality via macroautophagy (Webb et al., 2003, Stefanis et 
al., 2001, Cuervo et al., 2004). In summary, SNCA contributes to pathogenesis 
of familial and sporadic PD primarily due to its aggregative property that 
disrupts critical physiological processes, many of which involve other PD genes.  
 
1.9 PINK1: Mitochondrial homeostatic kinase 
 
Initially identified in a PTEN (Phosphatase and tensin homologue) activated 
expression profile screen, PTEN Induced putative Kinase-1 or PINK1 was 
subsequently associated with the autosomal recessive PARK6 locus (Unoki and 
Nakamura, 2001, Matsushima-Nishiu et al., 2001, Valente et al., 2004). The 
translated product is 581residues (~63kDa), migrates at ~66kDa on SDS-PAGE 
gel, and contains a highly conserved kinase domain (residues 156-509) with a 
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mitochondrial signal peptide at the very N-terminus (Figure12A). Expectedly, 
cellular localization is predominantly mitochondrial however a N-terminally 
processed (~54kDa) fragment is observed at the OMM (outer mitochondrial 
membrane). The preprotein remains cytoplasmic and is subject to regulation via 
chaperones (Heat shock protein (HSP) 90/ Cell division cycle 37 homolog 
(CDC37) complex) and the proteasome. The ratio of isoforms appears related 
to mitochondrial physiology as well as PD pathogenesis (Gandhi et al., 2006, 
Lin and Kang, 2008, Muqit et al., 2006, Weihofen et al., 2008).   
 
Ser/Thr kinase activity of PINK1 was initially confirmed through in vitro 
autophosphorylation assays, which proceeded to establish a kinase regulatory 
role for PINK1 C-terminus (Silvestri et al., 2005). Identification of Tumour 
necrosis factor receptor-associated protein 1 (TRAP1)/HSP75 as a substrate 
uncovered a protective role for PINK1 against ROS induced apoptosis, a 
feature absent in kinase inactive and PD linked PINK1 mutants (Pridgeon et al., 
2007). A recent biochemical study by Gandhi et al. elegantly established how 
PINK1 deficiency impaired calcium homeostasis lead to increased ROS, 
reduced respiration and ATP production, contributing to a fall in m 
(mitochondrial membrane potential) thus triggering cytochrome C mediated 
apoptosis (Gandhi et al., 2009). Dopaminergic neurons have been shown 
previously to prefer calcium channels for ‘autonomous pacemaking’ activities 
rendering them susceptible to impaired calcium homeostasis (Chan et al., 
2007). However, a biochemical link between kinase activity and the 
mitochondrial Na+/Ca2+ exchanger proved elusive. This study corroborated 
observations of reduced activity in complexes I and II of the electron transport 
chain (ETC) in neuronal tissues of PINK1 deficient mouse and fly (Gandhi et al., 
2009, Morais et al., 2009, Gautier et al., 2008).  
 
A central role for PINK1 in mitochondrial protein quality control and homeostasis 
is emerging around the cross talk between PINK1 and other PD genes: DJ-1, 
High temperature requirement protein A2 (HTRA2) and Parkin. DJ-1, 
associated with the PARK7 locus and autosomal recessive PD, is a putative 
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redox-dependent chaperone localised in several cellular compartments 
including mitochondrial IMS and matrix (Bonifati et al., 2003). It is a structurally 
dimeric protein with some PD linked mutations (Leu166Pro) located on along 
the dimer interface (Figure 12B). It has been suggested that acidification of a 
conserved cysteine (Cys106 in yellow) by ROS initiates migration into the 
mitochondria as part of the oxidative stress response (Canet-Aviles et al., 2004, 
Wilson et al., 2003). Indirect evidence of a mitochondrial H2O2 scavenging role 
involving Cys106 has also been presented (Andres-Mateos et al., 2007).  
Concurrently, neuronal cells from DJ-1 knockout mice showed increased 
sensitivity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) induced 
oxidative stress in vitro, while loss of dopaminergic neurons is observed in vivo. 
DJ-1 has been shown to alleviate PINK1 expression in SH-SY5Y cell lines and 
the two work together in neuronal defence against 1-methyl-4-phenylpyridinium 
induced cell death (MPP+; the toxic product of MPTP metabolism). (Kim et al., 
2005, Tang et al., 2006).  
 
HTRA2, associated with the PARK13 locus and autosomal recessive PD, is a 
serine protease residing in the mitochondrial IMS (inter-membrane space) 
(Strauss et al., 2005). The translated apoprotein bears a central protease 
domain flanked by a mitochondrial signal peptide and a putative 
Figure 12: Structure of PINK1 and DJ-1. A. Cartoon depicts the primary sequence profile of PTEN Induced putative 
Kinase-1 or PINK1. Pathogenic mutations are indicated above in red. The mitochondrial targeting sequence (MTS), 
predicted cleavage sites (inverted black triangles) and predicted transmembrane (TM) domain lie N-terminal of kinase 
domain (Figure not to scale, adapted from (Cookson and Bandmann, 2010). B. Structure of the Dimeric DJ-1 (PDB 
1SOA) highlights the coaxial dimer interface between C-terminal helices of the two monomers, coloured violet and 
green. Cys-106 (shown in yellow sticks) is a conserved cysteine plays a role in oxidative stress response while Leu-166 
(shown in red sticks) is pathogenic mutation site (Leu166Pro) present at the dimer interface. Figure adapted from 
(Wilson et al., 2003) 
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transmembrane domain on the N-terminus and a regulatory PSD-95/Discs-
large/Zona Occludens-1 (PDZ) domain at the C-terminus. Initially a pro-
apoptotic and stress response role for HTRA2 had been suggested (Vaux and 
Silke, 2003).  Under conditions of cellular stress, PINK1 has been reported to 
bind and induce HTRA2 phosphorylation at a Ser 142 (Ala141 being a PD 
linked mutation site) thereby activating protease activity, favourable for protein 
quality control in the mitochondria  (Figure 13) (Plun-Favreau et al., 2007). 
While a mitochondrial protective role for HTRA2 is generally accepted the 
details of this pathway, especially in PD pathogenesis, are yet to be elucidated. 
The inception of a metabolic pathway, downstream of PINK1 for HTRA2 has 
been laid out (Johnson and Kaplitt, 2009, Tain et al., 2009).  
 
A model of mitochondrial quality control pathway via protein ubiquitination and 
autophagy/lysosomal degradation is emerging around PINK1 and Parkin, a 
ubiquitin RING E3 ligase associated with the PARK2 locus and autosomal 
recessive PD (Kitada et al., 1998, Shimura et al., 2000). Genetic linkage 
between the two genes was first established in Drosophila, placing PINK1 
upstream in the pathway (Clark et al., 2006, Park et al., 2006, Yang et al., 
2006). Oxidative stress induced mitochondrial depolarization initiates PINK1 
dependant recruitment of Parkin to the OMM. Parkin catalyzes specific 
ubiquitination of mitochondrial proteins (Figure 13), like Voltage-dependent 
anion-selective channel protein 1 (VDAC1), thereby generating a molecular 
beacon for p62/SQSTM1/ sequestosome-1, the ubiquitin-autophagy adaptor, to 
induce mitochondrial autophagy/mitophagy (Geisler et al., 2010, Narendra et 
al., 2009). A parallel model positions PINK1/Parkin as a regulator of 
mitochondrial morphology (fusion and fission pathways), tweaking the route to 
mitophagy by enabling mitochondrial recycling (Dagda et al., 2009, Deng et al., 
2008, Lutz et al., 2009, Poole et al., 2008, Ziviani et al., 2010). However, certain 
fundamental questions remain unresolved, in particular the mechanisms by 
which PINK1 recruits Parkin to damaged mitochondria and directs Parkin’s E3 
ligase component to generate specific ubiquitin signals on the mitochondria. 
Clues towards answering the first part of the question come from two recent 
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reports; PINK1/DJ-1/Parkin complex has been reported to function as a 
cytoplasmic E3 ligase and cytoplasmic processing of Parkin by HTRA2 
abrogates its ligase activity (Park et al., 2009, Xiong et al., 2009). Structure-
function aspects of Parkin will be introduced in the following section. This is an 
exciting period for research in mitochondrial homeostasis, which promises to 
yield an informative model describing the roles of HTRA2, DJ-1 and PINK1 in 
autosomal recessive PD.  
 
 
1.10 Parkin: Ubiquitin RING E3 Ligase  
1.10.1 Gene structure and pathogenic mutations 
Parkin is encoded by one of the largest genes in the human genome; PARK2, 
comprising 12 exons, translating to a 465 amino acid product (52kDa) (Kitada et 
al., 1998). The gene (1.36 Mbs) makes up for nearly half of FRA6E (3.6Mbs), 
one of the most regularly observed regions of genomic instability, a common 
fragile site (CSF) (Denison et al., 2003). The gene is driven by a bi-directional 
promoter that regulates expression of PACRG (parkin co-regulated gene), a 
Figure 13: Mitochondrial homeostasis mediated 
by PINK1. Levels of full-length (and truncated) 
species of PTEN Induced putative Kinase-1/PINK1 
are stabilised by the Heat Shock Protein (HSP) 90 
and Cell division cycle 37 homolog (CDC37) 
chaperone complex. PINK1 has been reported to 
phosphorylate HTRA2 thereby inducing protease 
activity that could positively influence mitochondrial 
protein quality control. Upon oxidative stress, PINK1 
recruits Parkin to the outer mitochondrial membrane, 
possibly through its kinase activity. Parkin generates 
specific ubiquitin signals on membrane bound 
mitochondrial proteins that initiate the downstream 
events leading to mitochondrial autophagy. 
Furthermore, PINK1/DJ-1/Parkin assemble to form a 
cytoplasmic E3 ligase complex. Figure adapted from 
(Deas et al., 2009) 
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protein of unknown function regulated by the UPP and associated with 
Mycobacterium leprae infections (Mira et al., 2004, Taylor et al., 2007, West et 
al., 2003). Up to twelve variable transcript lengths of PARK2 have been 
observed in brains of humans and rats. However apart N-terminal truncated 
species of Parkin (arising due to an alternative translational start site at codon 
80) thee is limited evidence of physiological stabilised splice variants (Dagata 
and Cavallaro, 2004, Henn et al., 2005). The first report of PARK2 PD linked 
mutations identified various homozygous deletions of exons and subsequently 
the CSF core was narrowed to exons 2-8 (Kitada et al., 1998). However, 
varieties of mutations (multiplications and small deletions/insertions in exons, 
translated point (missense/nonsense) mutations and splice site mutations) have 
been identified thereafter spanning the entire gene. Figures 14A,B and Table 3 
list the PARK2 pathogenic exon rearrangements, nonsense-mediated 
truncations and missense mutations, collated from the PD Mutation Database 
(PDMD)  (http://grenada.lumc.nl/LOVD2/TPI/) and the Human Gene Mutation 
Database (HGMD) (http://www.hgmd.cf.ac.uk). 
Figure 14: Exon rearrangements and Nonsense mutations. A. An illustration of the Parkin transcript and locations of 
the observed exon rearrangements; deletions (Del), duplications (Dup) and Triplications (Tri). Figure (not to scale) 
adapted from (Mata et al., 2004). B. Primary structure of full-length Parkin (not to scale) is depicted along with 
truncations arising from nonsense mutations (right, with exon locations of mutations on the left). Both figures display the 
following colour scheme for Parkin domains: Ubiquitin-like Domain (UblD, green), Really Interesting New Gene 1 and 2 
(RING, dark brown), In-Between Ring (IBR, violet) and RING0 (light brown). 
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EXON MUTATION DOMAIN 
I Met1Leu 
Gly12Arg 
Val15Met 
Asp18Asn 
Lys32Thr 
Arg33Gln 
Pro37Leu 
Arg42His/Pro/Cys 
Ala46Pro 
Thr55Ile 
II 
Val56Glu 
Ubiquitin-like 
Domain 
(UblD) 
Ala82Glu  
Asp86Asn  
Gln100His  
III 
Arg104Trp  
Tyr143Cys 
Pro153Arg 
Lys161Asn 
IV 
 
Ser167Asn 
Met192Leu/Val 
V 
Ser193Ile 
Lys211Arg/Asn 
Cys212Gly/Tyr 
RING 0 
Arg234Gln  
VI 
Thr240Arg/Met 
Cys253Tyr/Trp 
Arg256Cys 
Val258Met 
Arg271Ser 
Asn273Ser 
Arg275Trp 
Asp280Asn 
Gly284Arg 
VII 
Cys289Gly 
RING 1 
Ile298Ser  
VIII 
Gln311His  
Gly328Glu 
Arg334Cys 
Ala339Ser 
IX 
Thr351Pro 
Arg366Trp 
X 
Val380Leu 
IBR 
Asp394Asn  
Arg396Gly  
Ala398Thr  
Arg402Cys/His  
Thr415Asn 
XI 
Cys418Arg 
Gly430Asp 
Cys431Phe 
Pro437Leu 
XII 
Cys441Arg 
RING 2 
Table 3: Parkin missense mutations. Pathogenic 
missense mutations collated from the PD Mutation 
Database (PDMD) and Human Gene Mutation 
Database (HGMD) are listed against exon (left) and 
domain (right) structure. The Ubiquitin-like Domain 
(UblD, green), Really Interesting New Gene 1 and 2 
(RING, dark brown), In-Between Ring (IBR, violet) 
and RING0 (light brown) constitute the domains of 
full-length Parkin. Bold letters indicate mutations in 
zinc-coordinating residues. Mutations Lys27Asn, 
Lys48Ala in the UblD, IBR zinc-coordinating 
Cys352Gly and Met434Lys in RING2 have been 
reported as pathogenic in the literature (Finney et al., 
2003, Henn et al., 2005, Matsuda et al., 2006, Safadi 
and Shaw, 2007, Tomoo et al., 2008). Since they do 
not appear on the PDMD and HMD lists, they have 
been excluded from the list. 
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Mutations described include homozygous, compound heterozygous (different 
mutation in each allele) and heterozygous mutations. Due to recessive 
inheritance of the gene, homozygous (loss of function) mutations are the most 
common cause of Autosomal Recessive Juvenile Parkinson’s (AR-JP) as well 
as Early-Onset Parkinson’s Disease (EOPD) (Kitada et al., 1998). Point 
mutations in the functional domains are linked to an earlier onset and faster 
disease progression than truncating mutations. The phenotypic correlation of 
heterozygous and compound heterozygous mutations is yet to be understood 
completely, however in the absence of AR-JP, these genotypes could increase 
susceptibility to late-onset PD (Gasser, 2007, Hardy et al., 2009).  
 
1.10.2 Protein structure and localization 
Encoded by one of the largest known genes the translated product however, 
stretches to a mere 465 amino acids with an apparent molecular weight of 52 
kDa. Classified as an archetypal RBR (RING-IBR-RING), a recent report of an 
additional Zn2+ binding domain (RING0) makes it a unique multi-domain E3 
ligase (Hristova et al., 2009, Marin et al., 2004). Signature sequences of the 
RING domains in human Parkin (UniProt O60260) are listed in Figure 15.  
 
RING1 and RING2 domains display a single minor linker length variation each 
from the canonical RING signature (InterPro IPR001841) while the IBR shows 
two linker length variations from the canonical IBR signature (InterPro 
IPR002867) (Figure 15, in red). The four domains, RING 1, IBR, RING 2 and 
RING0, have been shown to bind two zinc ions each, with structural evidence 
present for the IBR (Beasley et al., 2007, Hristova et al., 2009). Furthermore, 
RING0 is expected to co-ordinate the zincs in a bipartite manner similar to the 
IBR (described below). A total of nine missense mutations are observed in five 
zinc co-ordinating residues (Table 3), all of which would lead to global unfolding 
of the domain resulting in destabilization of Parkin and is likely to contribute to 
reduced E3 ligase activity (Gu et al., 2003, Wong et al., 2007).  
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The IBR structure, solved by nuclear magnetic resonance (NMR) spectroscopy, 
is unique and is suggestive of enabling E3 function (Beasley et al., 2007). The 
zinc co-ordinating ‘scissor-like’ fold contains a modular architecture; a C4 zinc 
finger followed by a C2HC zinc finger in a bilobal arrangement unlike the zinc 
cross-brace architecture observed in RING domains. While, pathogenic mutant 
Thr351Pro unfolds the IBR fold, mutations Gly328Glu and Arg334Cys retain 
wild-type architecture, instead affecting surface properties and perhaps zinc co-
ordination respectively. The authors suggest the overall domain architecture 
could bring together the flanking RING1 and RING2 domains, which in turn 
could have a bearing on the E3 ligase activity of Parkin. Furthermore, the 
structure brings residues Val380 (a pathogenic mutation site), Ser378 
(phosphorylation site) and Cys323 (potential nitrosylation site) in close proximity 
of each other. Any mutation/modifications at these residues could affect the IBR 
structure as well as have a bearing on the RING1 and 2 arrangements and 
consequently the E3 ligase potential of Parkin (Beasley et al., 2007).  
Figure 15: Parkin domain structure. A cartoon depicting the multi-domain features of full-length Parkin (465 residues) 
and along with individual domain boundaries (top left). Domain colours: Ubiquitin-like Domain (UblD, green), Really 
Interesting New Gene 1 and 2 (RING, dark brown), In-Between Ring (IBR, violet) and RING0 (light brown). Topology 
diagram of the canonical RING domain depicts the distinct RING domain cross-brace. Zinc co-ordinating Cys (C) and 
His (H) are numbered (blue circles) and Xn represents residue length of the interspaced linker regions (top right). 
Primary sequence organisation of zinc co-ordinating regions in Parkin compared with canonical RING and IBR 
sequences (bottom table). RING0 is composed of two zinc fingers, C4 and C3H, separated by a 26-residue linker 
(Hristova et al., 2009). ‘Xn’ represents residue length of the interspaced linker regions. Also shown in red are variations 
of RING 1, 2 and IBR from the canonical sequence.  
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At the N-terminus of the protein lies the Ubiquitin-like Domain (UblD) that 
shares the -grasp fold with Ubiquitin along with 32% of sequence identity 
(Figure 16). Interestingly, over 20% of the total missense mutations observed in 
Parkin are found spread throughout the UblD, some of which have been 
reported to cause drastic domain unfolding (Safadi and Shaw, 2007, Tomoo et 
al., 2008). Interestingly, HOIL-1 is the only other protein that bears a similar 
domain arrangement to Parkin, however the former bears an additional ubiquitin 
binding Npl4 type Zinc Finger (NZF) located N-terminal of its RING1 domain 
(Kirisako et al., 2006). Finally, the last three residues of Parkin (FDV) form a 
class II PDZ binding motif (X - where  is a hydrophobic residue and X is any 
residue) (Fallon et al., 2002). Nonsense mediated truncations Trp445X and 
Trp453X result in loss of this motif with the latter mutation observed to increase 
aggregation/insolubility of Parkin in cell culture conditions (Henn et al., 2005).  
 
On the tissue level, parkin transcripts were observed in several tissues including 
the SNc region of the brain (Kitada et al., 1998). Cellular localization of wild-type 
Parkin is predominantly cytoplasmic (Shimura et al., 2000) with co-localization 
observed with membranes of the ER (Imai et al., 2001), Golgi apparatus (Huynh 
et al., 2007), mitochondria (Darios et al., 2003) and synaptic vesicles (Zhang et 
Figure 16: Structures of the In-Between RING (IBR) domain and Ubiquitin-like domain (UblD) of Parkin. Bilobal 
domain architecture of IBR domain (Ser329 – Cys377) coloured in deep blue (PDB 2JMO). On the left is a backbone 
overlay of 20 structures deposited and middle is a cartoon representation of the same. Zinc atoms are shown as black 
spheres. Cartoon representation of the UblD (right, PDB 1IYF) coloured in green and the sites of missense mutations 
found in this domain shown as yellow sticks. Structure figures were generated using PyMOL (Schrodinger, 2010). 
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al., 2000), as well as neurites (Huynh et al., 2001) and aggresomes (Muqit et 
al., 2004). Missense mutations have been observed to cause redistribution of 
Parkin to detergent insoluble inclusion bodies and in some cases aggresomes 
(Cookson et al., 2003, Sriram et al., 2005, Wang et al., 2005). These studies, 
conducted in cell lines as over-expression experiments, have lead to the 
inception of an aggregation theory, which in tandem with mutation-mediated 
structural destabilization, negatively regulates Parkin’s E3 ligase activity and 
possibly explain its ‘loss of function’ (Henn et al., 2005, Schlehe et al., 2008, 
Wang et al., 2005).  
 
1.10.3 E3 properties: E2s, auto-ubiquitination, pathogenic mutations 
and solubility 
Shimura and colleagues ascertained the E3 ligase function of Parkin shortly 
after association with AR-JP was reported. As described earlier, RING E3 
ligases work as scaffold enzymes that select substrates, recruit the charged E2 
and facilitate transfer of ubiquitin E2 onto the target lysine of a substrate. 
UBE2L3/UbcH7 (Imai et al., 2000), UBE2L6/UbcH8 (Zhang et al., 2000), 
UBE2N/UBE2V1 heterodimer (Ubc13/UEV1) (Doss-Pepe et al., 2005), 
UBE2G2/Ubc7 and UBE2J2/Ubc6 (Imai et al., 2001) have been reported as 
cognate E2s for Parkin. Missense mutations, in particular, Thr240Arg proximal 
to RING1 and Thr415Asn proximal to RING2 have been observed to disrupt 
UBE2L3 and UBE2L6 binding respectively (Imai et al., 2000, Shimura et al., 
2000, Zhang et al., 2000). Furthermore, ubiquitin ligase activity, ascertained via 
auto-ubiquitination (or self ubiquitination), was abrogated by these mutations. 
RING2 and RING1 were also proposed to bind the individual components of the 
UBE2N/UBE2V1 (Ubc13/UEV1) heterodimer (respectively) (Doss-Pepe et al., 
2005).  Auto-ubiquitination is now the primary assay of choice used to 
demonstrate the E3 ligase activity of Parkin and several groups have 
subsequently provided improvements in the experimental design of this assay 
(Hampe et al., 2006, Matsuda et al., 2006, Hristova et al., 2009).  
 50 
Described, for the most part, as a single subunit (monomeric) E3 ligase, Parkin 
has been observed to function as the E3 component of a Skp1, Cullin, F-box 
(SCF) complex (Staropoli et al., 2003). In addition, Parkin has been shown to 
cooperate with the chaperone activity of HSP70, as well as, the E4 activity of 
CHIP (carboxyl terminus of the Hsc70-interacting protein; a U box E3 ligase) 
thus linking up with the UPR pathway (Imai et al., 2002). These properties not 
only add to the ligase potency but could also serve as points of regulation. 
Single subunit Parkin has been shown to synthesise K48-linked and K63-linked 
ubiquitin chains on substrates (Zhang et al., 2000, Doss-Pepe et al., 2005). 
Furthermore, Parkin mediated mono- and multi mono- ubiquitination of 
substrates was observed both in vitro and in vivo (Fallon et al., 2006, Joch et 
al., 2007, Moore et al., 2008). This multi-faceted property of ligase function is 
remarkable for a monomeric RING E3 and invites investigations into how Parkin 
modulates its ubiquitination potential. 
 
Auto-ubiquitination of Parkin has also been demonstrated as multi 
monoubiquitination in vitro (Matsuda et al., 2006) and in vivo (Hampe et al., 
2006). Interestingly, the proteasomal degradation of auto-ubiquitinated Parkin 
has been suggested by multiple reports (Choi et al., 2000, Zhang et al., 2000, 
Figure 17: Overview of Parkin’s E3 ligase properties. Multi-domain architecture of Parkin depicts the Ubiquitin-like 
Domain (UblD, green), Really Interesting New Gene 1 and 2 (RING, dark brown), In-Between Ring (IBR, violet) and 
RING0 (light brown). Parkin also co-operates with several E2s through either the RING1 or RING2 domain; 
UBE2L3/UbcH7 (RING1) (Imai et al., 2000), UBE2L6/UbcH8 (RING2) (Zhang et al., 2000), UBE2N/UBE2V1 
(Ubc13/UEV1) heterodimer (RING1/RING 2 respectively) (Doss-Pepe et al., 2005), UBE2G2 (Ubc7) and UBE2J2 
(Ubc6) (Imai et al., 2001). Also summarised are various ubiquitin signals (mono-, multi mono-, Lys48- and Lys63- linked 
poly- ubiquitination) generated by Parkin on different substrates. Furthermore, Parkin also exhibits auto-ubiquitination, a 
feature often used to confirm its E3 ligase activity (Hampe et al., 2006, Matsuda et al., 2006, Hristova et al., 2009).   
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Finney et al., 2003, Ardley et al., 2003, Junn et al., 2002). Taken together, 
monomeric Parkin co-operates with several E2s to mediate a variety of 
ubiquitin-based signals (Figure 17) on different substrates (described in section 
1.9.4) however mechanisms of these events are yet to be elucidated.   
 
Interestingly, disease mutations studied in the above reports, as well as others 
(Hampe et al., 2006, Matsuda et al., 2006, Sriram et al., 2005) have either 
impaired or enhanced ligase activity (measured using auto- and substrate 
ubiquitination levels) and provide clues towards understanding E3 ligase 
mechanisms of Parkin. Variations in ligase activity alongside aggregation and 
destabilization add to the complexity of understanding ‘loss of function’ in AR-
JP. Observed effects of pathogenic mutations on solubility/localization and 
ligase activity are summarised in Table 4. In majority of the cases, auto-
ubiquitination is accompanied with substrate ubiquitination. Non-conforming 
mutations might impair substrate interaction suggests disassociation of auto- 
and substrate ubiquitination. Cooperation of the RING domains has been 
proposed to be crucial for Parkin activity (Rankin et al., 2001). The absence of 
ligase activity in C-terminal truncations (in particular lacking the RING2 domain) 
as well as species with RING2 mutations portrays RING2 as the catalytic core 
(Matsuda et al., 2006, Hampe et al., 2006).  
 
Mutations of interest are the rows shaded in grey (Table 4), some representing 
exceptions to the above pattern. Mutations Arg42Pro and Arg275Trp are 
observed to form inclusions, show increased levels of auto-ubiquitination and 
enhanced non-degradative substrate ubiquitination despite reduced interaction 
with one of the substrates (Aminoacyl tRNA synthase complex-interacting 
multifunctional protein 2/AIMP2). Arg256Cys, formed inclusions and enhanced 
auto-ubiquitination (in vitro and in vivo) however did not exhibit substrate 
interaction and ubiquitination. In contrast, the soluble mutants Lys161Asn and 
Thr240Arg lack any manner of ubiquitination in vivo and were termed ‘ligase 
dead’ mutants (Sriram et al., 2005).  
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 Ligase activity Parkin 
Species 
Solubility 
Inclusion 
bodies Auto Sub. 
Wild-type + -   
Arg33Gln + ? ? ? 
Arg42Pro - +   
Val56Glu + ? ? ? 
Ala82Glu + -  ? 
Lys161Asn + - /   
Met192Leu + - ? ? 
Lys211Asn + -  ? 
Lys211X - + ? ? 
Cys212Tyr - + ? ? 
Thr240Arg + - /   
Arg256Cys - +   
Cys268X - + ? ? 
Arg275Trp - +   
Asp280Asn + -  ? 
Cys289Gly - +  ? 
Gln311X - +   
Gly328Glu + -   
Arg334Cys + +  ? 
Glu409X - + * * 
Thr415Asn + -   
Cys418Arg - +   
Gly430Asp + - /   
Cys431Phe - + /   
Pro437Leu + -   
Cys441Arg - +  ? 
Phe453X - + /   
Table 4: Phenotypic variations of mutant Parkin. Effects of pathogenic mutations (missense and nonsense) on 
solubility and ligase potential of Parkin are summarised in the table. Experiments were conducted either in vitro using 
‘purified’ proteins or in vivo as transient over-expression experiments in cell lines. Parkin species are coloured based 
on domain location of mutation; green - UblD, light brown – RING0, dark brown – RING1 and RING2, violet – IBR. 
‘Solubility’ was assessed by cell extraction using detergents (Triton-X) and comparing Parkin species in supernatant 
(soluble) versus pellet (insoluble) fractions. Presence of Parkin rich ‘Inclusion bodies’ was determined via antibody 
staining/immunofluorescence (IF) experiments. Auto-ubiquitination (‘Auto’) was tested either in vitro using ‘purified’ 
proteins or in vivo with co-transfections of tagged ubiquitin followed by immunoprecipitation (IP)/western blot (WB) 
detection techniques. Substrate ubiquitination (‘Sub.’) assays were conducted in vivo by co-transfections of tagged 
Parkin species, tagged substrates and tagged ubiquitin followed by IP/WB detection techniques.  
+/- indicates solubility/insolubility or presences/absence of inclusion bodies. /  - auto-ubiquitination observed in vitro 
however absent in vivo. * - Matsuda et al. use Lys416X instead of Glu409X. /  - auto-ubiquitination absent in vitro 
but observed in vivo suggesting trans action by other ubiquitin ligases. ? - not determined.  
Wang et al. utilized FLAG-Parkin species in study solubility and inclusion body formation in HEK293 and SH-SY5Y 
cells. Sriram et al. conducted solubility, inclusion body, auto- and substrate ubiquitination assays with myc-Parkin in 
SH-SY5Y cells. FLAG-AIMP2 and FLAG-synphillin-1 were substrates tested for ubiquitination. Henn et al. used 3xHA-
Parkin species and studied aggregation in N2a and SH-SY5Y cells. Hampe et al. and Matsuda et al. conducted in vitro 
auto-ubiquitination assays with GST-Parkin (UBE2L3/UbcH7) and MBP-Parkin (UBE2G2/Ubc7) respectively. 
References: (Wang et al., 2005, Sriram et al., 2005, Hampe et al., 2006, Matsuda et al., 2006, Henn et al., 2005) 
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However these mutations show robust auto-ubiquitination in vitro, supporting a 
possible disassociation of ligase properties (auto and substrate ubiquitination) 
(Hampe et al., 2006, Matsuda et al., 2006). The soluble Thr415Asn, located a 
few residues N-terminal of the first RING2 cysteine, consistently lacked ligase 
activity despite the experimental set-up. More recently, Parkin has been 
observed to mediate K27-linked polyubiquitination on mitochondrial membrane 
bound substrates (Geisler et al., 2010). The experiments conducted in HeLa 
and SH-SY5Y cells using FLAG-Parkin species corroborated the above 
observations for the most part. Notable exceptions were: Arg275Trp was 
soluble and Lys161Asn showed weak auto-ubiquitination. 
 
A tumour suppressive role for Parkin was uncovered in gliablastoma multiforme 
(GBM), colon cancer and lung cancer. Somatic mutations in Parkin, similar to 
those found in AR-JP (Figure 18), impaired auto-ubiquitination, binding and 
turnover of cyclin E. Parkin, as part of a SCF complex, had been previously 
shown to regulate cyclin E levels (Staropoli et al., 2003, Veeriah et al., 2010). 
 
1.10.4 E3 properties: substrates, ubiquitin signals and regulators 
Substrate recognition and ubiquitination are critical functions of an E3 ligase 
and Parkin has been reported to ubiquitinate a wide variety of substrates 
(introduced in the following sections). Each of the domains/motifs within Parkin 
Figure 18: Somatic PARK2 mutations. PARK2 mutations found in cancer (top, red arrows) and AR-JP (bottom, black 
arrows). Larger black-bordered red arrows with indicate sites of mutations shared between the two disease states. 
Figure adapted from (Veeriah et al., 2010)    
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has been implicated in substrate recognition however the ubiquitin ligase 
activity necessitates the RING domains. Ubiquitination signals generated on the 
substrate include; mono-, multi mono-, K48- and K63- linked poly- 
ubiquitination, while concomitantly catalysing auto-ubiquitination.  
 
1.10.4.1 Ligase activity: Monoubiquitination potential 
The UblD has been shown to direct Parkin’s ligase activity, in particular the 
monoubiquitination potential, to EPS15 and endophilin-A (Figure 19) (Fallon et 
al., 2006, Trempe et al., 2009). EPS15 is an adaptor molecule for epidermal 
growth factor receptor (EGFR) and regulates EGF internalization and trafficking. 
UblD interacted with tandem UIMs located at C-terminus of EPS15 contributing 
to monoubiquitination of the latter (termed coupled monoubiquitination, 
described earlier). In contrast, enhanced multiple ubiquitination (auto-
ubiquitination) of Parkin was observed, which Fallon et al. concluded as EPS15 
‘activation’ of Parkin. UblD interaction with the tandem UIMs of S5a/Rpn10, a 
subunit of the 26S proteasome, has been biophysically characterized and 
compared with the EPS15 UIMs interaction. It is noteworthy that Lys48 is the 
sole residue on the surface of UblD critical for both sets of interactions (Safadi 
and Shaw, 2010, Sakata et al., 2003). The UIMs of Rpn10 has been shown to 
assist formation of degradable chains on substrates in vitro and RPN10 is 
functionally regulated by monoubiquitination in vivo (Kim et al., 2009, Isasa et 
al., 2010).  
 
A conserved PaRK extension (Pro-x-Arg-Lys, where x is any amino acid) borne 
on the C-terminal tail of UblD is responsible for selective recruitment of Parkin 
to SH3 (SRC Homology-3) domains of endophilin-A and other select BAR (Bin–
Amphiphysin–Rvs) domain containing proteins implicated in synaptic vesicle 
dynamics. Residues Lys48 and Arg42 (a AR-JP mutation site) also play a 
critical role in this interaction. Upon recruitment, wild-type Parkin proceeds to 
weakly monoubiquitinate endophilin-A consequently affecting synaptic 
transmission (Trempe et al., 2009). The UblD is also recognised by 
Nrdp1/FLRF, a RING E3 ligase that regulates cellular levels of Parkin (Zhong et 
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al., 2005). Remarkably, Parkin’s C-terminal PDZ binding motif is the other 
region that plays a role in recognition of substrate for monoubiquitination. The 
PDZ binding motif mediates interactions with Protein interacting with Protein 
kinase C, alpha (PICK1) and Calcium/calmodulin-dependent serine protein 
kinase 3 (CASK) however only PICK1 was monoubiquitinated by the E3 thereby 
regulating synaptic transmission events (Joch et al., 2007, Fallon et al., 2002).  
 
1.10.4.2 Ligase activity: Non-degradative potential 
Indirect association between Parkin’s ligase activity and SNCA was established 
early on. Parkin ubiquitinated the O-glycosylated form of SNCA (Sp22) with 
UBE2L6/UbcH8 while ubiquitination of synphilin-1, an SNCA interacting protein, 
was observed with UBE2L3/UbcH7 (Chung et al., 2001, Shimura et al., 2001). 
Synphilin-1 recognition was mediated primarily by RING2 and the resulting 
Lys63-linked polyubiquitination enhanced the formation of LB like inclusions rich 
in synphillin-1, SNCA and Parkin (Lim et al., 2005). Interestingly 14-3-3, 
another SNCA interacting protein that functions as a molecular 
chaperone/adaptor/scaffold, was observed to bind the RING0 domain of Parkin 
and impair ligase activity (auto- and synphillin-1 ubiquitination). Binding to full-
Figure 19: Monoubiquitination potential. Parkin mediates monoubiquitination of substrates Epidermal growth factor 
receptor substrate 15 (EPS15) (Fallon et al., 2006), endophilin-A (Trempe et al., 2009) and Protein kinase C, alpha 
(PICK1) (Joch et al., 2007). Concomitant multiple ubiquitination of Parkin (auto-ubiquitination) also observed. Curved 
arrows indicate regions of substrate recognition; N-terminal Ubiquitin-like Domain (UblD) for EPS15 and endophilin-A 
while the C-terminal PSD-95/Discs-large/Zona Occludens-1 (PDZ) binding motif for PICK1). In addition, interaction with 
the Regulatory particle non-ATPase protein (RPN) 10 (subunit of 26S proteasomal) and Nrdp1/FLRF (E3 ligase that 
regulates cellular levels of Parkin) occurs through the UblD. Tandem ubiquitin interacting motifs (UIM) on EPS15 and 
RPN10 mediate interaction with UblD, while the binds the UblD of Parkin. Residue Lys48 is crucial for interaction with 
UIMs of Eps15 and RPN10 and the same residue forms part of the interface with the SH3 domain of endophilin-A. 
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length Parkin was observed at nanomolar affinities (Kd = 4.2 nM) and 
pathogenic mutations (Arg42Pro, Lys161Asn and Thr240Arg) appeared to 
disrupt this interaction (Sato et al., 2006). A similar inhibition of E3 ligase activity 
was observed upon Cyclin-dependent kinase 5 (Cdk5) mediated 
phosphorylation of Parkin at Ser131 in the RING0 domain. Furthermore, a 
phospho-dead mutation (Ser131Ala) displayed increased levels of auto-
ubiquitination along with the formation of SNCA/synphillin-1/Parkin rich inclusion 
bodies in human dopaminergic cells (Avraham et al., 2007).  
 
 
Parkin mediated K63 linked polyubiquitination of mutant, misfolded DJ-1 
(Leu166Pro) with the UBE2N/UBE2V1 (Ubc13/UEV1) heterodimer in SH-SY5Y 
cells. These signals were recognized by histone deacetylase (HDAC) 6 and 
sequestered by dynein motors to the aggresome (Olzmann et al., 2007). Parkin 
was also shown to interact with misfolded DJ-1 through the HSP70/CHIP 
complex (Moore et al., 2005). Furthermore, non-degradative multi 
monoubiquitination of HSP70 (via RING2-HSP70 interaction) was also 
observed in SH-SY5Y cells (Moore et al., 2008). Interestingly, Bcl-2-associated 
anthogene (BAG) 5, a molecular co-chaperone that bears four BAG repeats, 
Figure 20: Non-degradative ubiquitination. Parkin catalysed Lys63-linked polyubiquitination of substrates Synphilin-1 
(Chung et al., 2001) and mutant, misfolded DJ-1 (Leu166Pro) (Olzmann et al., 2007) resulting in the formation of 
inclusions bodies/aggresomes. Auto-ubiquitinated Parkin is also sequestered to inclusions/aggresomes. Ligase activity 
(auto- and synphillin-1 ubiquitination) of Parkin was impaired upon 14-3-3 binding (RING0 domain) and Cdk5 
phosphorylation at Ser131 (near RING0) (Sato et al., 2006, Avraham et al., 2007). In addition, Parkin mediated multi 
monoubiquitination of Heat shock protein (HSP) 70 is negatively regulated by binding of Bcl-2-associated anthogene 5 
(BAG5) at the RING0 region (Moore et al., 2008, Kalia et al., 2004).  
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was observed to negatively regulate the E3 ligase activity and neuroprotective 
function of Parkin as well as inhibit chaperone HSP70. BAG5 was observed to 
bind Parkin the RING0 region and impaired auto-ubiquitination (in vitro, using 
E2s UBE2G2/Ubc7 and UBE2J2/Ubc6) as well as the ubiquitination of 
synphillin-1 in HEK293T cells (Kalia et al., 2004). Non-degradative 
ubiquitination potential and negative regulation of E3 ligase activity of Parkin 
are summarised in Figure 20. 
 
1.10.4.3 Ligase activity: Ubiquitin mediated degradation 
Parkin catalyses K48 linked poly-ubiquitination on several substrates, a signal 
that facilitates proteasomal-mediated degradation. Septin5/CDCrel-1, a synaptic 
vesicle associated GTPase protein, was the first substrate to be identified for 
Parkin. Substrate selection was through the entire RBR region (although RING2 
was sufficient), substrate and auto-ubiquitination was observed with 
UBE2L6/UbcH8 and a fall in the rate of Septin5 turnover upon proteasomal 
inhibition and RING2 mutations (Zhang et al., 2000). In addition, Parkin 
mediated degradative ubiquitination of Sept5_v2/CDCrel-2, a close homologue 
of Septin5, and levels of both proteins were found to accumulate in AR-JP 
brains (Choi et al., 2003). Synaptotagmin-XI, another regulator of synaptic 
transmission, is recognised by RING1 and degraded by Parkin mediated 
ubiquitination in HEK293 cells (Huynh et al., 2003).  
 
The Parkin/CHIP/Hsp70 complex associates on G protein-coupled receptor 37 
(GPR37)/Pael-R as part of the UPR pathway. In cultured neuroblastoma cells 
(SH-SY5Y), over-expression of Pael-R leads to its unfolding and subsequently 
ER stress induced cell death. Hsp70 aids in the folding and ER translocation of 
Pael-R, however upon overloading of the ER translocation machinery, CHIP 
mediated the dissociation of Hsp70 allowing Parkin to associate with Pael-R via 
RING2 domain. Parkin mediated degradative ubiquitination of Pael-R occurs in 
the presence of CHIP that binds the RING0-RING1 domain of Parkin. The ER 
associated E2s, UBE2G2/Ubc7 and UBE2J2/Ubc6 co-operate with CHIP for its 
E4 activities on the Parkin substrate Pael-R (Imai et al., 2002, Imai et al., 2001).  
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Accumulation of substrates in Parkin knockout mice and AR-JP patients has 
been suggested as criteria for authentic Parkin substrates. AIMP2/p38/JTV1 is 
one such substrate that follows the criterion. AIMP2 recognition was mediated 
by RING1 domain however several pathogenic mutations disrupted AIMP2 
ubiquitination. Parkin mediated formation of LB like inclusions containing AIMP2 
in COS-7 and SH-SY5Y cells as well as in LBs idiopathic PD patients. AIMP2 
overexpression induced neuronal toxicity and dopaminergic cell death in cell 
culture and mice (Corti et al., 2003, Ko et al., 2005). Far upstream element 
(FUSE) binding protein 1 (FUBP1), a transcriptional activator of c-myc, is 
another protein whose levels are found elevated in AR-JP, PD and MPTP 
treated mice brains. AIMP2 was observed to bind FUBP1 and possibly function 
in the same pathway. Moreover, FUBP1 is subjected to proteasomal degraded 
by Parkin mediated ubiquitination in SH-SY5Y cells (Kim et al., 2003a, Ko et al., 
2006).   
 
A mutation in Parkin is not the only manner by which ligase activity can be 
impaired. S-nitrosylation of cysteine residues impair ligase activity in a ‘biphasic 
Figure 21: Ubiquitin mediated degradation. Parkin catalyses K48-linked polyubiquitination on various substrates 
targeting them for proteasomal degradation Substrates include Septin5 (Zhang et al., 2000), G protein-coupled receptor 
37 (GPR37)/Pael-R (Imai et al., 2001), Synaptotagmin-XI (Huynh et al., 2003), Aminoacyl tRNA synthase complex-
interacting multifunctional protein 2 (AIMP2)/ JTV1 (Corti et al., 2003) and Far upstream element (FUSE) binding protein 
1 (FUBP1) (Ko et al., 2006). Ligase activity is impaired by pathogenic mutations, S-nitrosylation of cysteines and 
covalent modification by dopamine (DA). Reduced Parkin solubility is also observed due to reactive oxygen species 
(ROS), toxic -synuclein/SNCA aggregates and DA modification. This ‘loss of function’ contributes to an accumulation 
of substrates in Parkin knockout mice and Autosomal Recessive Juvenile Parkinson’s patients. However, only AIMP2 
and FUBP1 have been observed to accumulate in such conditions (Ko et al., 2005, Ko et al., 2006). 
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manner’ (initial increase followed by inactivity) as observed in vivo and MPTP 
induced PD mice. Dopamine (DA) modification of Parkin leads to a similar ‘loss 
of function’ phenotype through covalent modification as well as decrease in 
solubility. Effect of ROS, SNCA aggregation and other cellular stresses 
contributes to Parkin’s insolubility and increases aggresome formation. (Chung 
et al., 2004, Kawahara et al., 2008, LaVoie et al., 2007, LaVoie et al., 2005, 
Muqit et al., 2004, Yao et al., 2004). Loss of ligase activity by cellular and 
environmental factors brings forth a role for Parkin in sporadic PD. The 
degradative ubiquitination potential of Parkin and affect of cellular factors are 
summarised in Figure 21.  
 
1.10.5 Neuroprotective functions of Parkin 
The neuroprotective role of Parkin is functionally linked with its ubiquitin E3 
ligase activity, introduced in the previous sections. However, a global pathway 
placing the numerous substrates and neuroprotective properties of Parkin in 
perspective of a physiological pathway, explaining the pathological ‘loss of 
function’ in PD, is yet to emerge.  
 
Parkin over-expression has been shown to counter neurotoxicity associated 
with SNCA in cellular studies and animal model systems (Lo Bianco et al., 
2004, Yamada et al., 2005, Yang et al., 2003, Yasuda et al., 2007). 
Furthermore, Parkin overexpression alleviates the detrimental effects of several 
cellular and environmental toxins (Jiang et al., 2004, Paterna et al., 2007, 
Vercammen et al., 2006). The mechanisms of neuroprotection from Parkin over-
expression are yet elucidated, hampered by the absence of a direct genetic or 
biochemical link between SNCA and Parkin (von Coelln et al., 2006, Chung et 
al., 2001). Furthermore, an equivalent loss of dopaminergic neurons observed 
in wild type and Parkin null mice treated with environmental toxins (Perez et al., 
2005, Thomas et al., 2007) suggested that Parkin over-expression could 
contribute to non-physiological phenotypes (Dawson and Dawson, 2010).  
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In recent years, a novel role for Parkin in mitochondrial homeostasis is 
emerging and involves interaction with other PD genes: PINK1 (Narendra et al., 
2009, Geisler et al., 2010, Vives-Bauza et al., 2010), DJ-1 (Irrcher et al., 2010, 
Hao et al., 2010) and Leucine-Rich Repeat Kinase 2 (LRRK2) (Smith et al., 
2005b, Venderova et al., 2009). Animal models (Palacino et al., 2004, Stichel et 
al., 2007, George et al., 2010) and fly systems (Clark et al., 2006, Park et al., 
2006, Yang et al., 2006) support the physiological basis of the Parkin-
Mitochondria connection. Studies identifying the ligase role in mitochondrial 
homeostasis will help assign Parkin’s physiological and pathological functions 
(Figure 22).  
Figure 22: Pathways to Neurodegeneration. E3 ligase properties of Parkin can be impaired by genetic mutations (in 
Autosomal Recessive Parkinson’s Disease (PD)) or by nitric oxide (NO), reactive oxygen species (ROS), dopamine 
(DA) or in sporadic PD. Consequently, the accumulation/deregulation of substrates (known and as yet unknown) or the 
loss of Parkin mediated ubiquitin signals could be detrimental to protein quality control pathways and in particular 
mitochondrial homeostasis. Mutations in PTEN Induced putative Kinase-1/PINK1, a mitochondrial kinase that functions 
upstream of Parkin, impair its kinase activity. The breakdown of Parkin and PINK1 activities could lead to mitochondrial 
dysfunction, the mechanistic details of which are still emerging, ultimately leading to neurodegeneration. Figure adapted 
from (Dawson et al., 2010). 
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1.11 Aims of this Study 
 
Parkin, a multi-domain ubiquitin RING E3 ligase, has been observed to recruit 
different E2s (UBE2L3/UbcH7, UBE2L6/UbcH8, UBE2N/UBE2V1 
(Ubc13/UEV1) heterodimer, UBE2G2/Ubc7 and UBE2J2/Ubc6) (Imai et al., 
2000, Zhang et al., 2000, Doss-Pepe et al., 2005, Imai et al., 2001) to mediate 
ubiquitination on a variety of substrates, while concomitantly exhibiting auto-
ubiquitination (Zhang et al., 2000). Substrate modification events include; 
monoubiquitination of EPS15, an adaptor molecule for EGFR (Fallon et al., 
2006), multi monoubiquitination of HSP70, a molecular chaperone (Moore et al., 
2008), Lys63 linked polyubiquitination of synphilin-1, an -synuclein/SNCA 
interacting protein (Chung et al., 2001) and Lys48 linked polyubiquitination of 
AIMP2, subunit of aminoacyl-tRNA synthase complex (Corti et al., 2003) (Refer 
Figures 19-21 for mores substrates), while multi-monoubiquitination was the 
favoured auto-ubiquitination signal (Matsuda et al., 2006, Hampe et al., 2006). 
The multi-faceted properties exhibited by monomeric/single-subunit Parkin 
make it an attractive model system to examine how RING E3 ligases modulate 
their ubiquitination potential. 
 
Furthermore, neuroprotective properties and the molecular basis of 
pathogenesis in AR-JP and idiopathic PD are linked with the ubiquitin E3 ligase 
activity of Parkin, however the molecular features of the pathway are far from 
clear. Pathogenic AR-JP mutations have been observed in every domain of 
Parkin and have variable effects on its E3 ligase activity (reduced solubility, 
reduced/enhanced auto- and substrate- ubiquitination, summarised in Table 4). 
Mutations of particular interest are Arg42Pro, Lys161Asn, Thr240Arg and 
Thr415Asn that lie in the UblD, RING0, RING1 and RING2 domains of Parkin 
respectively. The Arg42Pro Parkin mutant was observed to form cytoplasmic 
inclusion bodies/aggresomes (using transient over-expression studies in 
HEK293 and SH-SY5Y cells) as well as catalyse enhanced ubiquitination of 
itself and AIMP2 (enhanced auto- and substrate ubiquitination respectively) 
(Wang et al., 2005, Sriram et al., 2005). Several reports have previously 
 62 
suggested that auto-ubiquitinated Parkin is subject to proteasomal degradation 
(Choi et al., 2000, Zhang et al., 2000, Finney et al., 2003, Ardley et al., 2003, 
Junn et al., 2002). In accordance, Henn et. al. noted the proteasomal turnover 
of Arg42Pro to be three-fold greater than that of wild type Parkin (Henn et al., 
2005). In contrast, Parkin mutants Lys161Asn, Thr240Arg and Thr415Asn do 
not form inclusion bodies or ubiquitinate AIMP2. Nevertheless, robust auto-
ubiquitination (in vitro) was observed exclusively with the Lys161Asn and 
Thr240Arg Parkin mutants while the Thr415Asn mutant was termed ‘ligase-
dead’ (Wang et al., 2005, Sriram et al., 2005, Hampe et al., 2006, Matsuda et 
al., 2006). Investigations into E3 ligase properties of various AR-JP mutations of 
Parkin could uncover further insights into enzyme regulation and shed some 
light over pathological ‘loss-of-function’ mechanisms. 
 
Thus, the broader aims of this study were the structure-function analysis of 
Parkin, a model RING enzyme, to decipher fundamental mechanisms of RING 
E3 ligase mediated ubiquitination and examine how these are deregulated in 
the context of AR-JP. Couple of observations on the E3 ligase properties of 
Parkin, made prior to commencement of this study, helped direct the objectives 
of this research. The first came from an article by Matsuda and colleagues who 
observed the in vitro auto-ubiquitination of MBP Parkin (purified recombinant 
human Parkin with MBP tagged at the N-terminus) with multiple E2s (Matsuda 
et al., 2006). Further, the report demonstrated that MBP IBR-RING2 (Parkin 
truncation bearing IBR-RING2 domains) underwent auto-ubiquitination, and the 
ubiquitin moiety was attached both the MBP tag and the Parkin polypeptide. 
However, when presented in trans, free/unbound MBP was not ubiquitinated by 
the MBP IBR-RING2 species. The authors proposed that MBP Parkin is 
‘primed’ for ligase activity with the N-terminal tag operating as a pseudo-
substrate.  
 
The second observation came from experiments carried out by Simon Leslie 
and Dr. Helen Walden. Leslie and Walden had previously established the 
expression and purification protocols of recombinant human Parkin (wild type 
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and 111C, a truncation that lacked the first 110 residues of Parkin) in 
Escherichia coli. The protein production strategy made use of an N-terminal 
6xHis-smt3 (SUMO, S. cerevisiae) affinity cum solubility tag for the bacterial 
expression of human Parkin. Furthermore, production of full-length Parkin using 
the 6xHis-smt3 tag enabled the cleavage of the fusion protein immediately prior 
to the N-terminal methionine (by ubiquitin-like-specific protease 1 (Ulp1)), 
generating wild type Parkin with no overhang or leader sequence. In vitro auto-
ubiquitination assays undertaken to assess ligase activity of this material (as 
well as 111C produced using the same strategy) led to some interesting 
observations. Wild type Parkin (with no overhang or leader sequence) 
consistently lacked auto-ubiquitination activity while 111C Parkin exhibited 
robust auto-ubiquitination. Taken together, these observations suggested that 
modifications to the N-terminus of Parkin (presence of N-terminal MBP tag or 
deletion of the first 110 residues) influenced Parkin in a way that ‘activated’ the 
ubiquitination potential of the E3 ligase. The following chapters will describe the 
methods (Chapter2) and experiments (Chapters 3-5) carried out during the 
course of this study, investigating the E3 ligase properties of Parkin, its 
regulation and effects of AR-JP mutations on this regulation.  
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Chapter 2. Methods 
 
2.1 Molecular Biology 
 
All experiments carried out in this study made use of recombinant protein 
expressed and purified from E. coli. The following section describes the cloning 
methods and expression constructs generated. A recombinant vector bearing 
the PARK2 (Parkin, Homo sapiens) open reading frame cloned within the 
ChampionTM pET SUMO (Invitrogen) vector was available in the Walden group 
at the start of the study. The construct encoded a 6xHis-smt3 (SUMO, S. 
cerevisiae) affinity cum solubility tag that was used for expression and 
purification of wild type Parkin. Furthermore, this construct served as template 
for all subsequent genetic manipulations (point mutations, domain 
deletions/truncation and sequence insertions, Table 5) generated using the 
Phusion® Mutagenesis kit (Finnzymes) based on manufacturer’s protocol.  
 
Point mutations made include Val15Met, Lys27Asn, Lys32Ala, Arg33Gln, 
Arg42Pro, Ile44Ala, Ala46Pro, Lys48Ala, Arg51Pro, Ser131Glu (and the 
Ser131Ala + Lys48Ala double mutant), Lys161Glu, Thr240Arg and Thr415Asn. 
Deletions/truncations made include: UblD (deletion of Gly77 to Val465/C-
termius), UblD (deletion of Met1 to Lys76), 95C (deletion of Met1 to Gly94), 
321C (deletion of Met1 to Ala320) and RING2 (deletion of Thr414 to Val465/C-
terminus) (Table 5). Certain point mutations were also made in a couple of the 
deletion/truncation constructs: Lys48Ala in the UblD construct, Thr415Asn in 
UblD construct. Sequence insertions include; incorporation of TEV protease 
site at several locations between the UblD and RING0 domains of wild type 
Parkin (Parkin-TEV, experiments described in results section 3.4.2) and 
insertion of a V5 epitope (GKPIPNPLLGLDST) encoding sequence immediately 
after the 6xHis-smt3 sequence in UblD construct giving the V5-UblD construct.  
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Vector 
Affinity  
Tag 
Cleavage 
enzyme 
Construct Name 
Figure 
(cartoons represent material used for experiments) 
Associated 
Results 
section(s) 
pET 
SUMO 
6xHis 
smt3 
Ulp1 
Wild type/WT 
Parkin          
All sections 
pET 
SUMO 
6xHis 
smt3 
Ulp1 
V15M-, K27N-, 
K32A-, R33Q-, 
R42P-, A46P- and 
R51P- Parkin 
         
3.3 and 5.5 
pET 
SUMO 
6xHis 
smt3 
Ulp1 
K48A- and K48R-
Parkin          
4.2, 4.3 and 
5.5 
pET 
SUMO 
6xHis 
smt3 
Ulp1 I44A-Parkin 
         
5.2 
S131E-Parkin 
         pET 
SUMO 
6xHis 
smt3 
Ulp1 
S131E+K48A 
Parkin          
4.3 
K161N-Parkin 
         
T240R-Parkin 
         
T415N-Parkin 
         
pET 
SUMO 
 
6xHis 
smt3 
Ulp1 
 
UblD + T415N 
                     
5.2 and 5.3 
pET 
SUMO 
6xHis 
smt3 
Ulp1 UblD 
                     
3.2, 4.2, 4.3, 
and all of 5 
pET 
SUMO 
6xHis 
smt3 
Ulp1 321C 
                                                
5.2 and 5.4 
Parkin-Thio 
             pET 
SUMO 
6xHis 
smt3 
Ulp1 
 
RING2 
          
3.2 
pET 
SUMO 
6xHis 
smt3 
Ulp1 Parkin TEV 
          
3.4.2 
95C 
                                   pET 
SUMO 
6xHis 
smt3 
Ulp1 
UblD-Intein-CBD          
3.4.3 
UblD          
UblD K48A 
         
4.2 
pET 
SUMO 
6xHis 
smt3 
Ulp1 
V5-UblD   4.4 
6xHis-UblD   (6xHis tag was retained) 
pRSF-
T6 
6xHis - 
6xHis-UblD K48A 
  (6xHis tag was retained) 
4.2 
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In addition, the pET RSF Duet-1 (Novagen) vector was modified to incorporate 
the TEV protease site (ENLYFQ|GS, TEV protease cleaves between residues 
Q and G). The original vector bore two multiple cloning sites (MCS 1 and 2)) 
each driven by a set of regulatory elements (T7 promoter, lac operator, and 
ribosome binding site (rbs)). A 6xHis coding sequence preceded MCS1 while S 
tag (KETAAAKFERQHMDS) coding sequence succeeded MCS2.  The vector 
was modified to incorporate a TEV protease site coding sequence upstream of 
MCS1 and downstream of 6xHis coding sequence between the 6xHis and 
MCS1, using the Phusion® Mutagenesis kit. The resulting vector, called pET 
RSF T6, was used as destination vector following the Restriction-free (RF) 
cloning technique (van den Ent and Lowe, 2006). 
pRSF- 
T6 
6xHis 
TEV 
protease 
14-3-3   4.3 
6xHis-UBE2L3/ 
UbcH7   (6xHis tag was retained) 
4.3 and 5.3 
pRSF- 
T6 
6xHis - 
6xHis-UBE2L6/ 
UbcH8   (6xHis tag was retained) 
4.3 
6xHis-Ub 
(Wild type/WT)    (6xHis tag was retained) 
All sections 
F4A, L8A, I44A, 
V70A and D58A   
6xHis-Ub 
 (6xHis tag was retained) 
5.2 and 5.3 
pRSF- 
T6 
6xHis - 
K0, K48 and K63 
6xHis-Ub   (6xHis tag was retained) 
5.5 
Table 5: List of expression constructs. Salient features of expression constructs used in this study are listed – parent 
vector, affinity purification tags, cleavage enzymes used to remove tags, construct name, cartoon representation of 
purified material (not to scale) and references to Results sections where the material is used are provided. pET SUMO 
(Invitrogen) and pRSF-T6 (modified pRSF Duet-1, Novogen) were the two parent vectors, both bear a kanamycin 
resistance gene and bacterial expression driven by a T7lac promoter. N-terminal hexa-histidine (6xHis) tag serves as an 
affinity purification tag in both vectors and in addition, pET SUMO vector features the smt3 (Small Ubiquitin-like 
Modifier/SUMO, S. cerevisiae) solubility tag, cleavable by ubiquitin-like-specific protease 1 (Ulp1). Tobacco etch virus 
(TEV) protease is used to cleave 6xHis tag from recombinant protein expressed by the pRSF-T6 constructs. Construct 
names and cartoons (not to scale) refer to purified recombinant material used in the respective experimental sections. 
6xHis affinity tags are retained where required. Approximate domain location and nature of point mutations are 
described or indicated by red stars. Details of TEV sites of the Parkin TEV constructs are presented in section 3.4.2. 
Parkin domains are: Ubiquitin-like Domain (UblD, green), Really Interesting New Gene 1 and 2 (RING, dark brown), In-
Between Ring (IBR, violet) and RING0 (light brown). Ub is ubiquitin, V5 is an epitope tag – GKPIPNPLLGLDST, Thio is 
Thioredoxin, Intein is the Mxe GyrA Intein (Mycobacterium xenopi) protein and CBD is chitin binding protein.  
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Briefly, the RF cloning technique followed a two-step protocol; amplification of 
target gene by polymerase chain reaction (PCR) followed by a linear 
amplification reaction. Primers (50bases) were designed such that the 5’ half 
(first 25 bases) and 3’half (last 25 bases) of each primer were complementary to 
the regions flanking the insertion site (on the destination vector) and fragment of 
interest (on the template DNA) respectively. The first set of PCR reactions (RF 
step I) with template DNA (that contained the fragment of interest) and the long 
primers resulted in a PCR product encoding the region of interest, flanked by 25 
base pair sequences complementary to the destination vector. This PCR 
product functions as the primer pair for the destination vector and extends 
around the circular plasmid during a linear amplification reaction (RF step II), 
thus incorporating the PCR fragment into the destination vector (refer (van den 
Ent and Lowe, 2006) for more details).  
 
In this study, the pET RSF T6 vector served as destination vector for majority 
for RF cloning reactions, while the MCS1 region (downstream of the 6xHis-TEV 
protease site encoding sequence) served as the site for insertion. Expression 
constructs for 6xHis tagged versions of ubiquitin, 14-3-3, UBE2L3/UbcH7 and 
UBEL6/UbcH8 were generated using the RF cloning method, each with TEV 
protease site to enable cleavage of the N-terminal affinity tag. Complementary 
DNA (cDNA) clones for Ubiquitin C (H. sapiens, IMAGE 4076286) and 14-3-3 
(H. sapiens, IMAGE 3543571) were purchased from the IMAGE consortium, 
while E2s (H. sapiens) were available in the Walden lab. These served as 
template DNA for the RF step I reaction (Table 5). In addition, Ubiquitin mutants 
(K0, K48only, K63only, Phe4Ala, Leu8Ala, Ile44Ala, Val70Ala and Asp58Ala) 
were made using the Phusion® Mutagenesis kit and with assistance from 
Laurence Lewis (Walden Lab). Expression constructs for 6xHis-UblD and 
6xHis-UblD K48A were generated through RF cloning method, using wild-type 
Parkin and K48A-Parkin constructs as template for the RF step I reaction. 
pThioHis A (Invitrogen) served as template for Thioredoxin, which was inserted 
at the C-terminal of Parkin resulting in the Parkin-Thio, construct. pTXB1 (New 
England Biolabs/NEB) served as template for the Mycobacterium xenopi gyrA 
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Intein gene (Mxe GyrA Intein) + Chitin Binding protein (CBD) + (STOP codon), 
all of which was inserted downstream of the Gly94 codon in wild type Parkin to 
give UblD-Intein-CBD construct (Table 5). Furthermore, the RF primers were 
designed such that upon incorporation of the Intein-CBD coding sequence, the 
glycine 94 would be mutated to an alanine. The presence of an alanine would 
improve the autocatalytic cleavage of the C-terminal Intein, as recommended in 
the IMPACT (Intein Mediated Purification with an Affinity Chitin-binding Tag, 
New England Biolabs) manual.   
 
PCRs were carried out in 50 μL reactions comprising of - 0.1 Unit Phusion® 
High-Fidelity DNA Polymerase (Finnzymes), 1x of associated enzyme buffer, 
200 μM deoxynucleotide triphosphates (dNTPs), 0.5 μM of each primer, 3% 
Dimethyl sulfoxide (DMSO) and 2-10 ng of template DNA. Thermal cycling 
reactions (Eppendorf) (Table 6) were carried out in either TC-312 (Techne) or 
GS1 (G-Storm) thermal cyclers, in using thin-walled PCR tubes (Eppendorf). 
Reaction products were analysed by agarose gel electrophoresis in Tris-
Acetate- Ethylenediaminetetraacetic acid (EDTA)/TAE buffer (40 mM Tris 
Acetate and 1 mM EDTA). Mutagenesis reactions were ligated using Rapid 
DNA Ligation Kit (Roche) as per manufacturer’s protocol. RF step I products 
were subject to a reaction clean up using QIAquick PCR Purification Kit 
(Qiagen) prior to RF step II. ‘Linear amplification’ products of RF step II were 
Step Mutagenesis RF 
Initial denaturation 98˚C for 30 s 95˚C for 10 s 
Denaturing 98˚C for 10 s 95˚C for 10 s 
Annealing 66˚C for 30 s 55˚C for 10 s 
Loop 
Elongation 
25-30x 
72˚C for 30 s per 
kilobase 
35x 
68˚C for 120 s per 
kilobase 
Final elongation 72˚C for (Elongation time + 30 s) - 
Table 6: Thermal cycler reaction programs. Reaction programs used for Mutagenesis and Restriction-free (RF) 
cloning reactions. The same program was used to both steps of the RF method, however elongation times for RF step 
II were calculated based on total size of the insert and destination vector.  
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subject to Dpn1 digestion (to eliminate any unmodified destination vector) for 2 
hours at 37˚C before transformation into suitable host cells.  
 
Transformation of mutagenesis/RF products was carried out using chemically 
competent MAX Efficiency® DH5™ Competent Cells (Invitrogen) as per 
manufacturer's protocol and plated on antibiotic selective Luria Broth (LB) agar 
plates. Colonies were picked, grown overnight in LB (4 mL cultures) for plasmid 
DNA preparation using QIAprep Spin Miniprep Kit or outsourced to Equipment 
Park (plasmid DNA prep service, part of the LIF core facility). DNA sequencing 
using BigDye terminator reactions and capillary sequencing (Applied 
Biosystems 3730 DNA Analyser) was carried out by Equipment Park. Quality of 
sequence data was analysed using 4Peaks software while sequence 
alignments with template (using MegAlign, Lasergene software suite) were 
carried out to verify results of the intended cloning/mutagenesis experiment. 
Positive constructs were transformed (40-50 ng of plasmid DNA per 
transformation) into chemically competent BL21 (DE3) (Stratagene) E. coli 
expression strains (as per manufacturer’s protocol), grown overnight (5ml Luria 
Broth (LB) with 50 μg/mL kanamycin) and an aliquot of the overnight culture 
was frozen in cryovials (Corning) as 20% v/v glycerol stocks and stored at -
80˚C. Plasmid DNA stocks each construct were also maintained at -20˚C.  
 
2.2 Expression and Purification of Proteins 
2.2.1 Purification of Parkin (RING domain) constructs 
The expression and purification of the wild type/WT Parkin construct was 
previously established in the Walden Lab by Simon Leslie. The original protocol 
was successfully adopted, in its entirety, for all pET SUMO based Parkin 
constructs containing a RING domain. The expression and purification protocols 
for pET SUMO based UblD constructs (WT, K48A mutant, and V5 tagged 
species) are described in section 2.2.2.  
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2.2.1.1 Growth, Expression and Harvest of cells 
Expression preps were normally carried out in 6/12 L Luria Broth (LB) culture 
volumes. A starter culture (50-100 mL LB with 50 μg/mL kanamycin), initiated 
from fresh transformations of the desired constructs, was grown at 37˚C 
shaking at 190 rpm. This involved transformation (40-50 ng of the construct 
plasmid) into chemically competent BL21 (DE3) (Stratagene) E. coli expression 
strains (following manufacturer’s protocol) and the entire transformation reaction 
(transformed cells in super optimal broth (SOC) media) was used to inoculate 
the starter culture. After overnight growth, 5 mL of this culture was used to 
inoculate 1 L LB media (with 50 μg/mL kanamycin) held in a 2 L flask. For 
constructs that comprised of a RING domain, the media was further 
supplemented with 500 μM zinc chloride.  
 
Cultures were grown at 37°C shaking at 190 rpm until optical density at 600 nm 
(OD600) reaches 0.4 (roughly 2.5-3 hours). Incubator temperature was lowered 
to 16˚C and cultures were allowed to grow shaking at 190 rpm until OD600 of 
0.7-0.8 (roughly 1-1.5 hours after). At this point, protein expression was induced 
using 25μM Isopropyl -D-1-thiogalactopyranoside (IPTG). Cultures were grown 
for another 12-14 hours (overnight) at 16°C shaking at 190 rpm. Cells were 
harvested by centrifugation at 4000 RCF using Beckmann JS4.2 rotor (J6MC 
centrifuge) for 15 min at 4˚C. From this stage onwards, samples were 
maintained at 4˚C or chilled in an ice-bucket (wherever possible). 
 
2.2.1.2 Extraction of soluble material and affinity purification 
Harvested cell pellets were re-suspended in cold T500i buffer (75 mM Tris pH 
8.0, 500 mM NaCl, 25 mM imidaizole, 250 μM tris (2-carboxyethyl) phosphine 
(TCEP), 5 mL T500i buffer/1 L cell culture pellet) supplemented with Complete-
EDTA free protease inhibitor cocktail tablets (Roche) (1 tablet for every 20ml of 
T500i buffer used for re-suspension). Re-suspended cells were transferred in 
pre-chilled 50 mL Falcon tubes (Corning,  15 mL/falcon) or 100 mL Duran 
bottles ( 40 mL/bottle) depending on the total volume of the re-suspension. 
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The re-suspended cells (maintained in ice-bucket), were burst open by 
sonication (Soniprep 150 set at 15 microns amplitude using 19 millimetre probe) 
- 15-20 s pluses (for Flacon volumes)/ 40-60 s pulses (for bottle volumes), 
repeated 5-6 times with intermittent pauses (1 min). Subsequently samples 
were transferred into pre-chilled Oak ridge centrifuge tubes (Nalgene) and 
clarified by centrifugation at 37000 RCF for 45 min at 4°C using the F0630 fixed 
angle rotor (Allegra X-24R centrifuge). The supernatants of the high-speed 
centrifugation step contain soluble fraction of the affinity tagged recombinant 
protein (6xHis-smt3-(Parkin species). 
 
Supernatants were bound to Nickel-nitrilotriacetic acid (Ni-NTA) beads (Qiagen) 
pre-equilibrated with T500i buffer, by batch binding method (1 mL of Ni-NTA 
beads was sufficient for material obtained from a 3 L culture). Binding was 
carried out in 50 mL Falcon tubes placed on a roller at 4°C. After 30 min of 
binding, the unbound flow-through was collected, beads were washed with 10 
column volumes (cv) of T500i buffer, and flow-through sample was reapplied to 
beads. The ‘bind-wash-bind’ step was repeated 3-4 times and enabled 
enrichment of the affinity tagged material.    
 
2.2.1.3 Affinity tag cleavage and sample concentration 
Ni-NTA beads bound with 6xHis-smt3- tagged Parkin species were equilibrated 
with T200 buffer (50 mM Tris pH 8.0, 200 mM NaCl, 250 μM TCEP) and were 
subject to on-cleavage with Ulp1. The beads were made up to a 50% v/v 
suspension (in T200 buffer), the requisite amount of Ulp1 protease was added 
(1mg of Ulp1 for every mL of Ni-NTA beads) and the cleavage reaction was 
allowed to proceed overnight at 4°C on a roller. Ulp1 is a cysteine protease that 
specifically cleaves the smt3/SUMO moiety at its C-terminus, releasing the C-
terminally fused protein (in this case, a Parkin species). Furthermore, the 6xHis-
smt3 tag remained bound to the Ni-NTA resin while, the cleaved protein is 
collected in the flow-through.  
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Following the cleavage reaction, samples were loaded onto a clean glass 
column and the cleavage flow-through was collected. The beads were further 
washed with 10 cv of T500i buffer in order to extract any cleaved material 
bound non-specifically to the beads. Cleavage flow-through and wash fractions, 
containing the cleaved or ‘de-tagged’ Parkin species, were pooled and the 
material was concentrated using appropriate Centriprep concentrators 
(Millipore) – YM10 (10 kDa molecular weight cut-off (MWCO)) for 321C and 
YM30 (30 kDa MWCO) for all other Parkin RING domain based constructs 
 
2.2.1.4 Size Exclusion Chromatography (SEC) 
Samples containing ‘de-tagged’ Parkin species were concentrated until the final 
volume is 1.5 mL. Concentrated samples were further purified by SEC runs 
(Superdex 75 16/60pg or 100/300 GL for 321C species, Superdex 200 26/60pg 
for all other RING domain based constructs) using the ÄKTApurifier™ fast 
protein liquid chromatography (FPLC) system (GE Healthcare). Wild type 
Parkin, various point mutants and domain truncation/deletion species of Parkin 
(except 321C, discussed in 2.2.1.5), eluted off the SEC as monomers (Figure 
23). Sodium dodecyl sulfate – polyacrylamide gel electrophoresis analysis 
(SDS-PAGE) of SEC elutes confirmed a purity of >95% for all Parkin species. 
 
Protein quantifications were carried out using NanoDrop® ND-1000 UV-Vis 
Spectrophotometer. Theoretical extinction coefficients () and protein molecular 
weights, calculated using ProtParam software (http://www.expasy.ch/tools/ 
protparam.html) were used to determine protein concentrations. Pure protein (in 
T200 buffer containing 10% v/v glycerol) was flash-frozen using liquid nitrogen 
and stored at -80°C. Protein yields/litre of LB culture; 2-3 mg/L for 321C, 1-1.5 
mg/L for wild type, V15M-, K32A-, R33Q-, I44A-, K48A-, R51P, K161N-, S131E-
, S131E + K48A Parkin species as well as the UblD, 95C truncations and 
Parkin-Thio construct. Low yielding constructs (0.5 – 0.8 mg/L) include K27N-, 
R42P-, A46P-, T240R-, T415N-, UblD + T415N Parkin and the RING2.  
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2.2.1.5 Additional features of the 321C Parkin prep 
During SEC purification of the 321C Parkin species (MW ~16 kDa, pI 5.85), 
majority of the protein appeared to migrate as a monomer however partial 
oligomerisation was also observed (Figure 47). The nature of 321C oligomeric 
species was also explored through SEC experiments using the Superdex 75 
10/300 GL column. Dilutions of the ‘oligomer’ (0.5, 1, 2 and 5 mg/mL) and 
increasing concentrations of the ‘monomer’ (2, 5, 10 and 15 mg/mL) were 
separately analysed by SEC to determine if the two species had a 
concentration dependent dynamic equilibrium. Run were conducted in T200 
buffer as was the case during the purification of 321C. However, no changes 
were observed in SEC profiles and two species eluted at their respective 
volumes (9.5 – 10.5 mL for oligomer and 11.5 to 12.5 mL for monomer).  
 
The oligomeric species could just be a facet of the over-expression in E. coli. 
Another possibility could be the truncated nature of 321C, thus potentially 
exposing binding surfaces (normally occupied by the N-terminal regions of 
Parkin) contributing to soluble aggregation. Further investigations are required 
to understand the oligomerisation properties of 321C. As monomeric 321C 
retained its monomer nature even at high concentrations (~1 mM) and was the 
major species of the SEC purification step, all experiments involving 321C were 
carried out using the monomer fraction.  
Figure 24: Multiple states of 321C. A chromatogram trace of a Superdex 75 10/300 GL run showing multiple states of 
321C (~16 kDa, calibration markers for 14 kDa and 35 kDa are shown for reference) and coomassie blue stained gel 
(inset) of indicated fractions (9.5 to 12.5 mL – a, b, c, d, e and f) showing purity of protein sample. Protein contained in 
fractions e and f (11.5 to 12.5 mL) were pooled and used as monomeric Parkin. 321C material was run in 50mM Tris pH 
8.0, 200 mM NaCl and 250 μM tris (2-carboxyethyl) phosphine (TCEP) buffer. Traces were generated using GraphPad 
Prism 5.0c (GraphPad Software, San Diego California). 
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A small portion of 6xHis-smt3 tag (MW 13.5 kDa, pI 5.87) was also observed to 
leach off Ni-NTA beads during the Ulp1 mediated on-column cleavage reaction 
(2.2.1.3) and co-migrated with 321C ‘monomer’ during SEC as well as on SDS-
PAGE analysis. To ensure pure 321C material, the pooled ‘monomeric’ 
fractions were subject to an additional affinity purification step using fresh Ni-
NTA beads (~1 mL) to separate the 6xHis-smt3 moiety from 321C. Flow-
through of this step was further subject to anti-His western blot to confirm the 
absence of the 6xHis-smt3 moiety. 
 
In addition, remnants of Ulp1 (MW - 25.5 kDa, pI 6.75) were occasionally 
observed to co-migrate with the monomeric fraction. The monomeric fractions 
off the SEC step were pooled and buffer exchanged with T25 buffer (100mM 
Tris pH 8.5, 25 mM NaCl, 250 μM TCEP). Subsequently, an anion exchange 
chromatography step was carried out to separate the two species. The buffer 
exchanged protein was loaded on to a MonoQ GL 5/50 (GE Healthcare) column 
and subject to an elution gradient  (25 - 750 mM NaCl) stretching over 20 cv 
using ÄKTApurifier™ FPLC system. 321C was observed to elute between 120-
150 mM salt while the Ulp1 eluted earlier (between 50-70 mM salt) thus 
resulting in 321C material devoid of Ulp1. In summary, certain additional 
purifications steps were required to ensure purity of >95% for the 321C 
material. Protein quantifications were carried out using NanoDrop® ND-1000 
UV-Vis Spectrophotometer using values MW - 16 KDa and  - 30000 (estimated 
using ProtParam). Pure protein (in T200 buffer containing 10% v/v glycerol) was 
flash-frozen using liquid nitrogen and stored at -80°C.  
 
2.2.2 Purification of 6xHis tagged constructs 
The following protocol applies to all pRSF-T6 based constructs listed in Table5 
(6xHis-UblD, 6xHis-UblD K48A, 14-3-3, 6xHis-UBE2L3/UbcH7, 6xHis-
UBE2L6/UbcH8 and 6xHis-Ubiquitin (WT, and mutants) as well as the pET-
SUMO based UblD constructs (UblD, UblD K48A, V5-UblD). All constructs (with 
the exception of 6xHis-UblD K48A) yielded healthy amounts of pure material (2-
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5mg/litre of LB culture) thus prep were carried out in culture volumes of 2-4L LB 
(depending on downstream requirement). Expression and affinity purification of 
the above constructs followed a similar protocol as described in sections 2.2.1.1 
to 2.2.1.2 with few changes at certain steps. Cell cultures were allowed to grow 
at 37˚C with shaking at 190 rpm until OD600 reached 0.6, at which point 
incubator temperature was reduced to 16˚C and protein expression was 
induced with 0.5 mM IPTG. Extracts containing soluble over-expressed 6xHis 
tagged protein were obtained and affinity purification of the tagged species 
following Ni-NTA batch method was carried out (as in section 2.2.1.2). The 
following sections describe the subsequent purifications steps for the respective 
construct. 
 
2.2.2.1 Purification of Ubiquitin and E2s 
Ni-NTA beads bound with 6xHis- Ubiquitin species/E2 species were equilibrated 
in T200 buffer and proteins were batch eluted with imidazole (2x5 cv of T200i 
buffer). Elutes rich in 6xHis tagged proteins were pooled, and concentrated to 
final volume of <5 mL. All protein concentration steps for Ubiquitin species were 
carried out with Amicon Ultra-15 (Millipore) Ultracel-3 (3 kDa MWCO) 
concentrators while the E2 species were concentrated using the Utracel-10 (10 
kDa MWCO). A further SEC step (Superdex 75 16/60pg) was undertaken to 
polish off the purification. Ubiquitin species were mainly used for in vitro 
ubiquitination reactions thus 6xHis tags were retained as they served as a 
useful epitope for western blot detection of the ubiquitinated products.  
 
Protein yields of 4-5 mg/litre of LB culture were observed for all the ubiquitin 
species expressed. 6xHis-E2s species (yields of 2-3 mg/litre of LB culture) were 
used as baits in pull-down assays (results section 4.3) and in thioester 
discharge assays (results section 5.2), both of which required the 6xHis tag to 
be retained. Protein quantifications were carried out using NanoDrop® ND-1000 
UV-Vis Spectrophotometer using the given values for MW and  (estimated 
using ProtParam); 6xHis-Ubiquitin (WT and mutants): MW - 10.9 KDa and  - 
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1500, 6xHis-UBE2L3/UbcH7: MW - 20.9 KDa and  - 19900, UBE2L6/UbcH8: 
MW - 19.9 and  - 18500. Pure protein (in T200 buffer containing 10% v/v 
glycerol) was flash-frozen using liquid nitrogen and stored at -80°C. 
 
2.2.2.2 Purification of 14-3-3 
The recombinant fusion protein 6xHis-14-3-3 was batch eluted using T200i 
buffer as described above. Eluted protein was diluted to a final imidazole 
concentration of <50 mM and concentrated to final volume of <5 mL using 
Amicon Ultra-15 (Millipore) Ultracel-10 (10 kDa MWCO) concentrators. The 
6xHis-14-3-3 fusion protein was subject to TEV protease action (1mg of 6xHis-
TEV protease was used to cleave 10mg of the fusion protein) to cleave the N-
terminal 6xHis affinity tag. Cleavage reaction was allowed to proceed overnight 
at 4°C on a roller. The cleavage reaction sample was further purified using SEC 
(Superdex 200 26/60pg) where the 14-3-3 was observed to run as a dimer. 
Fractions with pure protein were pooled and subject to an additional affinity 
purification step using fresh Ni-NTA beads (~1 mL) to eliminate uncleaved 
fusion protein and 6xHis-TEV protease. Protein quantifications was carried out 
using NanoDrop® ND-1000 UV-Vis Spectrophotometer using the given values 
for MW and  (estimated using ProtParam) using values MW – 28.2 KDa and  - 
28900. Pure protein (in T200 buffer containing 10% v/v glycerol) was flash-
frozen using liquid nitrogen and stored at -80°C. 
 
2.2.2.3 Purification of UblD constructs 
Affinity purified material from the pRSF-T6 based UblD constructs (6xHis-UblD 
and 6xHis-UblD K48A) were batch eluted off the Ni-NTA beads using T200i. 
Subsequent steps in purification were similar to that for ubiquitin (described in 
section 2.2.2.1). In contrast, affinity purified material from the pET-SUMO based 
UblD constructs (UblD, UblD K48A, V5-UblD) were not eluted and instead 
subject to Ulp1 mediated on-column cleavage reactions, as descried in section 
2.2.1.3. A further SEC step (Superdex 75 16/60pg) was undertaken to polish off 
the purification (as described in 2.2.2.1). Amicon Ultra-15 (Millipore) Ultracel-3 
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(3 kDa MWCO) protein concentrators were successfully used for concentrating 
all recombinant proteins described in this section. During the purification 
process, it was observed that UblD (WT or K48A mutant), when in solution, was 
susceptible to precipitate at protein concentrations approaching 8-10 mg/mL. 
Attempts to stabilize the protein by the incorporation of glycerol (5% v/v), 
changing buffers (50 mM (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES) pH 8.0 or phosphate buffered saline (3.2 mM Na2HPO4, 0.5 mM 
KH2PO4, 1.3 mM KCl, 135 mM NaCl, pH 7.4)) or changing salt (200-500 mM 
NaCl or potassium chloride (KCl)) however proved unsuccessful. Thus, during 
UblD based experiments, care was taken to ensure the protein concentrations 
of UblD species did not exceed 8 mg/mL.  
 
Protein yields of 1.5-2 mg/litre of LB culture were observed for all UblD based 
constructs except 6xHisUblD K48A (0.5-1 mg/litre of LB culture). 6xHis-UblD 
species (WT and K48A) were used as baits in pull down assays while native 
UblD and UblD K48A were used in K48A-Parkin interaction experiments both of 
which are described in results section 4.2). V5-UblD was used for peptide array 
interaction experiments (results section 4.4). Protein quantifications were 
carried out using NanoDrop® ND-1000 UV-Vis Spectrophotometer using the 
given values for MW and  (estimated using ProtParam); 6xHis-UblD (WT and 
K48A): MW - 11.1 KDa and  - 12500, UblD (WT and K48A): MW – 8.8 KDa 
and  - 11000, V5-UblD: MW – 10.4 and  - 11000. Pure protein (in T200 buffer 
containing 10% v/v glycerol) was flash-frozen using liquid nitrogen and stored at 
-80°C. 
 
2.2.3 Expressed Protein ligation.  
The 95C construct of Parkin was expressed and purified as described in section 
2.2.1. Expression, affinity purification and Ulp1 mediated on-column cleavage 
reaction of UblD-Intein-CBD fusion construct was carried out as described in 
2.2.1.1 to 2.2.1.3. The flow-through of Ulp1 cleavage (UblD-Intein-CBD, in T200 
buffer) was incubated with 10 mM 2-Mercaptoethanesulfonic acid (MESNA, 
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Sigma) at room temperature for 4-6 hours followed by an overnight incubation 
at 4˚C. MESNA is a thiol regent that induces autocatalytic cleavage of the 
Intein-CBD tag located at the C-terminus of the construct (Figure 32A).  The 
protein products of a complete reaction would be 1-94M (UblD with C-terminal 
thioester derivative) and Intein-CBD tag. A Gly94Ala mutation was also made to 
improve autocatalytic cleavage of the C-terminal Intein as was suggested in the 
IMPACT manual (described in 2.1). However, despite the extended MESNA 
treatment and the Gly94Ala mutation, only about 10-15% of the UblD-Intein-
CBD fusion was cleaved to release the 1-94M molecule (yield of 0.8-1 mg from 
a 4 L prep). Following MESNA treatment, free Intein-CBD tag and unprocessed 
UblD-Intein-CBD fusion protein was bound to Chitin affinity beads (NEB, binding 
capacity of 2mg/mL of resin) based on suppliers protocol. An additional SEC 
step (Superdex 75 10/300 GL) was undertaken in EPL buffer - 100mM Tris pH 
8.5, 25 mM NaCl, in order to separate any left over Ulp1, polish up the 
purification as well as serve as a buffer exchange step  
 
Chemical ligation reactions containing 1-94M with 95C (10:1 molar ratio) and 
95C only were carried out overnight at 16˚C in EPL buffer + 10mM MESNA 
resulting in the formation of Parkin EPL species in the former reaction. The 
ligation however was not complete and only about 15-20% of the input 95C was 
observed ligated with 1-94M species resulting in a mixture of 95C and Parkin 
EPL species. Subsequently, a SEC (SD75 10/300 GL) run separated the 
unligated 1-94M species, however residual 95C (pI 6.9) species could not be 
completely separated from Parkin EPL (pI 7.0) despite an anion exchange 
chromatography step (25-500 mM salt gradient). Samples of freshly prepared 
95C and Parkin EPL mixture and the MESNA treated 95C species were used 
for auto-ubiquitination analysis.       
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2.3 In vitro Ubiquitination assays 
2.3.1 Auto-ubiquitination assays 
Auto-ubiquitination can be described as an event where an enzyme (usually an 
ubiquitin E3 ligase or in certain cases ubiquitin conjugating enzyme/E2) 
catalyses its own ubiquitination. In this study, the auto-ubiquitination properties 
of Parkin, a RING E3 ligase were explored. The auto-ubiquitination event can 
be recreated in a test tube reaction wherein purified proteins that make up the 
basic components of the ubiquitination machinery (ubiquitin, E1, E2 and 
E3/Parkin, Figure 1), are mixed together in an appropriate buffer (alkaline pH, 
MgCl2), provided an energy source (ATP) and temperature (37˚C) to facilitate 
ubiquitination. The reaction protocols used in this study were adapted from 
(Matsuda et al., 2006). Reaction components were either purchased from 
Boston Biochem (human recombinant E1/UBA1, ubiquitin E2s: UBE2L3/UbcH7, 
UBE2L6/UbcH8, UBE2N/UBE2V1 (Ubc13/UEV1) heterodimer, 6xHis-
UBE2G2/Ubc7 and UBE2D2/Ubc5B) or purified in-house (6xHis-Ubiquitin (WT 
and mutants) and Parkin (various species, Table5). Compositions of a typical 
reaction are described in Table 7.  
Component 
(working stock concentrations) 
Volume /  
25 μL reaction Final concentration  
Reaction buffer 10x (500 mM Tris pH 8.0, 20 mM 
DTT, 50 mM MgCl2)  
2.5 μL 
1x - 50 mM Tris pH 8.0, 
2 mM DTT, 5 mM MgCl2 
ATP (25 mM) 4 μL 4 mM 
Glycerol (75% v/v) 1.2 μL ~ 5% 
E1/UBA1 (110 kDa, 227 nM) 1.6 μL 15 nM 
E2 - UBE2L3/UbcH7 (18 kDa, 14 μM) 2 μL 1.1 μM 
6xHis-Ubiquitin (10.9 kDa, 184 μM) 0.7 μL 5 μM 
E3 - various Parkin species 1-2 μL 0.77 – 1 μM 
Water 11-12 μL - 
Table 7: Auto-ubiquitination assay. Setup of a typical auto-ubiquitination assay is described. Components are listed 
along with their molecular weights (protein) and concentrations of their working stocks. Also shown are volumes of each 
component used for 25 μL assay reactions and the final concentrations of each component. Final concentration of 
glycerol takes into account glycerol contributions from E2 and E3 buffer solutions. All other E2s were used at 1.1 μM 
except for UBE2N/UBE2V1 (Ubc13/UEV1) heterodimer (0.5 μM). Ubiquitin concentrations were constant irrespective of 
species used. Full-length Parkin (wild type and mutants) and Parkin-Thio species were used at 0.77 μM, while Parkin 
truncations/deletion (UblD, RING2 and 321C) were at 1 μM. Reactions were carried out at 37˚C for an hour.  
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Working stocks of reaction components were made for efficient assay setup, 
and stored at -80˚C. E1 and Ubiquitin (WT and mutants) were stored in 50 mM 
HEPES pH8.0, E2s in 50 mM HEPES pH 8.0, 50 mM NaCl, 10% (v/v) glycerol, 
1mM DTT while E3 (Parkin species) were stored in 50 mM Tris pH 8.0, 200 mM 
NaCl, 250 μM TCEP, 10% (v/v) glycerol. All reactions were conducted in 25 μL 
volumes containing 50 mM Tris pH 8.0, 2 mM DTT, 5 mM MgCl2, 4 mM ATP 
and 5% glycerol at 37˚C for an hour (unless specified otherwise). For assays 
with wild type Parkin and EPS15 UIMs (WT/ mutant) (section 3.4.1) as well as 
K48A Parkin and UblD (WT/K48A) (section 4.2), the indicated quantities of 
EPS15 UIMs species or UblD species were added and final reaction volume 
was made up to 25 μL with water. Reactions were terminated by boiling 
samples (100˚C) in 2X SDS loading buffer (150 mM Tris pH 6.8, 4% SDS, 10% 
glycerol, 200 mM -mercaptoethanol (ME) and bromophenol blue) for 5 
minutes. 1/20th and 1/8th of the reaction sample was subject to western blot 
analysis by anti-Parkin (Anti-Human Parkin (1A1) Mouse IgG Monoclonal, IBL) 
and anti-6xHis (Mouse monoclonal, GE Healthcare) antibodies respectively.  
 
2.3.2 Thioester discharge assay 
During ubiquitination, RING E3s catalyse the activation of the E2~ubiquitin 
thioester conjugate and the concomitant ligation of ubiquitin on the substrate. 
The rates of ubiquitin discharge from the E2~ubiquitin thioester conjugate can 
be monitored through a thioester discharge assay. The assay design is 
analogous to a pulse-chase experiment. The charging of an E2 with ubiquitin 
forms the pulse chase, followed by an arrest phase where the reaction is 
depleted of ATP and MgCl2 thereby preventing any further formation of the 
E2~ubiquitin thioester conjugate (via E1) in the event of a discharge. The 
reaction is then chased by introduction of a RING E3, which enhances the 
activation/discharge of the E2~ubiquitin thioester conjugate. The experimental 
setup for this study (Results section 5.2) was adapted from (Ozkan et al., 2005) 
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Pulse reactions were setup as 50 μL reactions (300 nM E1, 2 μM 6xHis-E2, 50 
μM 6xHis-Ubiquitin and 5 mM ATP in reaction buffer 50 mM HEPES pH 8.0, 2 
mM DTT, 5 mM MgCl2 as described in Table 8), and carried out at 37˚C for 10 
minutes to facilitate the ubiquitin charging of the E2 (E2~ubiquitin). 
Subsequently, reactions were arrested by ATPase treatment (10 min at room 
temperature) and a buffer exchange process to remove MgCl2. Addition of 2.5 
units of Ayprase (Sigma, 0.1 units/μL) served as ATPase for this step, in the 
process taking up the total sample volume to 75 μL. Samples were buffer 
exchanged into 50 mM Tris pH 8.0, 50 mM NaCl using Zeba™ Spin Desalting 
Columns (Pierce) according to manufacturer’s protocol.  
 
 
Chase reactions were initiated by addition of 2 μM RING E3 (Parkin species) 
and total reaction volume was made up to 100 μL with buffer (50 mM Tris pH 
8.0, 50 mM NaCl). 10 μL samples were collected at defined intervals and mixed 
with 10 μL 2xNon-Reducing sample buffer (NR sample buffer - 4 M Urea, 150 
mM Tris pH 6.8, 5 mM EDTA, 2% SDS, 10% glycerol and bromophenol blue) to 
terminate reactions. In addition, a zero time point sample was collected in 
reducing conditions (2xNR sample buffer + 200 μM ME). 1/10th of each time-
point sample was subject to western blot analysis using anti-His antibody 
Reaction Component 
Volume 
(50 μL reaction) 
Final Concentration 
Reaction buffer 10x (500 mM Tris pH 8.0, 20 mM DTT, 
50 mM MgCl2) 
5 μL 50 mM HEPES pH 8.0,  
2 mM DTT, 5 mM MgCl2 
ATP (25 mM) 10 μL 5 mM 
E1/UBA1 (110 kDa, 4 μM) 3.8 μL 304 nM 
E2/6xHis-UBE2L3/UbcH7 (20.2 kDa, 12.4 μM) 8 μL 2 μM 
6xHis-Ubiquitin (10.9 kDa, 184 μM) 13.6 μL 50 μM 
Water 9.6 μL - 
Table 8: E2 charging reactions. Compositions of ‘Pulse’ reactions that facilitate charging of E2 (UBE2L3/UbcH7) with 
ubiquitin are described above. Components are listed along with their molecular weights (protein) and concentrations of 
their working stocks. Also shown are volumes of each component used for 50 μL assay reactions and the final 
concentrations of each component. E1/UBA1 is purchased from Boston Biochem, while 6xHis-UBE2L3/UbcH7 and 
6xHis-Ubiquitin (various species) are purified in-house.  Reaction mixtures were incubated at 37˚C for 10 minutes to 
facilitate formation of the thioester linked E2~ubiquitin conjugate. 
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(Mouse monoclonal, GE Healthcare) to observe rate of thioester discharge of 
the E2~ubiquitin (both bearing N-terminal 6xHis tags).  
 
2.3.3 Western blotting/Immunoblotting 
Indicated quantities of reaction products (auto-ubiquitination assay and time 
point samples of thioester discharge assay) were resolved by SDS-PAGE (125 
volts for 85 min) using Novex® 8-16% Tris-Glycine Gels (1.5 mm, 10/15wells, 
Invitrogen) pre-cast gels. Protein transfers onto polyvinylidene fluoride (PVDF) 
or nitrocellulose membranes were carried out using iBlot® Dry Blotting System 
(Invitrogen) set at program P2 (23 volts for 7 min and 20 s). Blocking, antibody 
binding and washing of membranes were carried out using Tris-buffered saline 
(TBS - 20 mM Tris pH 7.5, 150 mM NaCl, 0.1% (v/v) Polysorbate 20/Tween20 
(Sigma) supplemented with either 5% (w/v) milk or 3% (w/v) bovine serum 
albumin/BSA (Sigma) depending on antibody (refer Table 9). 
Antibody Host, Isotype Dilution Membrane Buffer 
Secondary (HRP) 
Antibody 
Anti-Human Parkin (1A1, 
IBL) 
1/5000 PVDF 
Anti-His (GE Healthcare) 
Mouse IgG 
monoclonal 
1/2000 PVDF 
5% (w/v) 
Milk in TBS 
polyclonal goat anti-
mouse HRP - 1/1000 
(DAKO) 
Anti-Human UblD (In-house/ 
Pettingill Technology) 
Anti-Human IBR-RING2 (In-
house/Pettingill Technology) 
Rabbit polyclonal   
anti- sera 
1/5000 
polyclonal goat anti-
rabbit HRP - 1/1000 
(DAKO) 
FK1 (Enzo Lifesciences)  
Mouse IgM 
monoclonal 
Anti-mouse IgM HRP – 
1/5000 (Abcam) 
FK2 (Enzo Lifesciences) 
Mouse IgG 
monoclonal, 
Biotin conjugate 
1/1000 
 
Nitrocellulose 
 
Strep-tactin HRP - 
1/4000 (IBA) 
Anti-V5 HRP (Invitrogen) 
Mouse IgG 
monoclonal 
HRP conjugate 
1/5000 PVDF 
3% (w/v) 
BSA in TBS 
 
- 
Table 9: Antibody reference list. Features of all antibodies used in this study are listed including: antibody name and 
supplier, host species used to generate antibody, isotype and secondary modification (if any), working dilution for 
antibody, membrane preference, binding buffers used and associated secondary antibody. IgG and IgM are 
immunoglobin G and M respectively, PVDF is polyvinylidene fluoride, HRP is horseradish peroxidase, BSA is bovine 
serum albumin and TBS is Tris-buffered saline (20 mM Tris pH 7.5, 150 mM NaCl, 0.1% (v/v) Polysorbate 20/Tween20). 
Pettingill Technology Ltd generated polyclonal rabbit anti-sera against recombinant UblD and 321C.  
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Membranes were blocked at room temperature for an hour, followed by 
overnight incubation with primary antibody (at 4˚C). Membranes were washed 
three times (10 min each) with blocking buffer before binding of secondary 
antibody (diluted in blocking buffer) for 1-2 hours at room temperature. 
Membranes were washed as before and then developed using 
chemiluminescent reagents Amersham™ ECL Western Blotting Detection 
Reagents (GE Healthcare) and exposed to Amersham Hyperfilm ECL (GE 
Healthcare). 
 
2.4 Protein interaction assays 
2.4.1 Pull-down interaction assays 
Pull-down assays involved immobilization of bait proteins, which were 
subsequently allowed to interact with different prey protein. The bait-prey 
complex was then subject to salt washes to determine an interaction preference 
of the bait for the prey. In this study, Ni-NTA beads were used to immobilise 
6xHis tagged bait species and any associated prey was detected by SDS-
PAGE coomassie staining/immunoblotting techniques. 40-50 μL Ni-NTA beads 
(maximum binding capacity of 8-10 μg/μL) were saturated with 6xHis-UblD bait 
species (WT or K48A). The baits were then incubated with 0.5mg of Parkin 
species (prey); wild type, K48A-Parkin and UblD in 50 mM Tris pH 7.5, 25 mM 
NaCl, 250 μM TCEP, 5% glycerol, for 2-3 hours at 4˚C.  
 
Beads were subsequently washed with in 10 cv of binding buffer followed by 
washes with increasing salt concentration. 10 μL beads were boiled with 2x 
SDS loading buffer after each wash, to be resolved by SDS PAGE and 
analysed by coomassie staining/western blotting (20x dilutions of each sample) 
techniques to compare binding preferences of the UblD species for each of the 
Parkin species (results section 4.2). A similar experiment was carried out using 
6xHis-E2s (UBE2L3/UbcH7 or UBE2L6/UbcH8) as baits and Parkin prey 
 85 
species wild type, UblD, T240R-Parkin (for UBE2L3/UbcH7) or T415N-Parkin 
(for UBE2L6/UbcH8) (results section 4.3). 
 
2.4.2 Peptide array interactions assays 
Peptide arrays (30x20 spot grid) representing the 465 residues of human full-
length Parkin as a series of overlapping peptides (21 residues), each 
individually spotted on cellulose membrane were synthesised by the Peptide 
Synthesis Laboratory, LRI (described in section 4.4). Arrays were activated for 
interaction assays by washing with 50% v/v Ethanol, 10% v/v glacial acetic acid 
solution (15 min) followed by several washes with array interaction buffer/ AI 
buffer (50mM Tris pH 8.0, 200 mM NaCl, 250 μM TCEP, 0.05% Polysorbate 
20/Tween20). Recombinant UblD protein (purification described in section 
2.2.2) was labelled at Cys59 using Fluorescein-5-Maleimide (Thermo Scientific) 
following manufacturer’s protocol to generate the fluoro UblD probe while 
Fluorescein-N-Terminal Ubiquitin was commercially available (Boston Biochem) 
and was used as the fluoro Ub probe. V5-UblD was expressed and purified as 
described in section 2.2.2.  
 
Protein probes (0.5mg of V5-UblD, 50 μg of fluoro UblD/Ub), diluted in 25 mL of 
AI buffer, were incubated with the array for 2-3 hrs at room temperature with 
continuous rocking. While using fluoro-probes, arrays were protected from 
prolonged exposure to direct light. Subsequently, 3-5 washes/10 min each) with 
interaction buffer were carried out to eliminate background and reduce non-
specific interactions between the probe and membrane/peptides. Arrays treated 
with V5-UblD were detected via immunoblotting technique (as described in 
2.3.3) using V5 HRP (Invitrogen) antibody. Peptide spots that gave a signal on 
the anti-V5 HRP blot suggested interactions between V5-UblD and the 
peptides. Fluoro-probes were detected using fluorescence image scanners 
(Molecular Dynamics STORM 860) and associated imaging software 
(ImageQuantTL) available at LIF Equipment Park.  
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Arrays were stripped of non-covalently bound proteins by incubating with 
stripping buffer (100 mM Tris pH 6.8, 6 M Guanidine Hydrochloride, 1% SDS, 
100 mM ME) at 50˚C for 30 minutes with occasionally shaking. Subsequently, 
arrays were treated with several washes with water followed by re-activation of 
the array with 50% v/v Ethanol, 10% v/v glacial acetic acid. Protein stripping 
efficiency was examined by redetection with anti-V5 HRP. Stripping efficiency of 
arrays probed with fluoro UblD/Ub was poor thus preventing the re-use of the 
array. Fresh arrays were made in order to repeat the assays.  Interaction 
assays were conducted at least twice and consistently positive spots were 
analysed as described in section 4.4.    
 
2.4.3 Nuclear Magnetic Resonance (NMR) spectroscopy experiments 
The heteronuclear single quantum coherence (HSQC) presented in this study 
were conducted with Prof. Gary S. Shaw’s group at the University of Western 
Ontario, Canada. Parkin truncations (321C and UblD) were expressed and 
purified in the Walden lab and shipped to Canada for these studies. 15N-labelled 
UblD (Safadi and Shaw, 2007) and ubiquitin (Hamilton et al., 2001) samples 
were prepared by Dr. Kathryn R Barber based on previously published 
protocols, HSQC experiments were set up and carried out under the guidance 
of Prof. Shaw. A Bogue Research Fellowship awarded by University College 
London (UCL) supported the 7-week research visit.  
 
Briefly, the experiment detects correlations between the 1H atoms and the 
directly bonded NMR active 15N  (or 13C) atoms (Maudsley and Ernst, 1977). 
The magnetic field experienced by the nucleus (and including those containing 
isotopically labeled atoms) is affected by the electron distribution around the 
nucleus (which includes covalently and non-covalently bound atoms). Variations 
in the local electron density (for example, due to residue-residue interactions 
during protein binding events) thus affect the local magnetic field, which is 
reflected in the resonant frequencies (or chemical shifts). These can be 
measured (in parts per million/ppm) with reference to an internal standard that 
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is not affected during the course of the experiment (Hammes, 2005). NMR 
samples prepared for HSQC analysis were 15N -labeled and were hence used 
to detect any changes in local chemical environment of the amide backbone 
and side chain amino groups upon protein-protein interactions.  
 
All NMR experiments were collected on a Varian Inova 600 MHz spectrometer 
equipped with a triple resonance probe using xyz gradients. 1H-15N HSQC 
spectra were collected using the sensitivity-enhanced method at 25ºC (Kay et 
al., 1992). Samples (400 μL) were setup in the absence and presence of 
unlabelled protein. UblD samples: 15N-labelled UblD (125 μM) and 15N-labelled 
UblD (125 μM) with UblD (125 μM), 321C-UblD samples: 15N-labelled UblD 
(120 μM) in the absence and presence (3 samples) of 321C (40 μM, 120 μM 
and 200 μM), 15N-labelled Ub (140 μM) in the presence (3 samples) of 321C 
(70 μM, 140 μM, 280 μM). All samples were set up in 20mM Tris pH 7.0, 150 
mM NaCl, 1 mM DTT, 20 M 4,4-dimethyl-4-silapentane-1-sulfonic acid (DSS) 
and 10% D2O/90% H2O. Identical spectral parameters were used to collect 
1H-
15N HSQC spectra of each set of samples (runs lasted about 85 minutes each). 
1H chemical shifts were referenced directly using a DSS internal standard. 
Spectra were processed using a 60º-shifted cosine bell weighting function in 
both 1H and 15N dimensions and baseline corrected using NMRPipe (Delaglio et 
al., 1995) and visualised using NMRView (Johnson and Blevins, 1994). 
Reference peak lists for 15N-UblD and 15N-Ub (from the Shaw lab) were used 
for automatic peak assignment (with minor manual adjustments) in NMRView, 
using tolerance levels of 0.2 and 0.02 parts per million (ppm) along nitrogen and 
proton dimensions respectively. Combined changes in chemical shifts were 
calculated using the equation ((H)2 + (0.2*N)2 )1/2 and plotted as histograms 
using GraphPad Software, San Diego California). H and N represent 
change in proton and nitrogen chemical shifts.  
 
The following chapters (Chapters 3-5) describe experiments carried out in this 
study and their results. 
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Chapter 3 Results: Regulation of Parkin’s Auto-
ubiquitination. 
 
3.1 Background/Preliminary work 
 
The groundwork for the biochemical characterisation of Parkin’s E3 ligase had 
been carried out by Simon Leslie and Dr. Helen Walden before the start of this 
study. In particular, expression and purification protocols for recombinant 
human Parkin (wild type and 111C, a truncation that lacked the first 110 
residues of Parkin) from E. coli were available. The use of a 6xHis-smt3 served 
the dual role of a solubility tag during expression of in E. coli and subsequent 
affinity (Ni-NTA) purification. More importantly, cleavage of the fusion protein 
with Ulp1, a cysteine protease that specifically cleaves the smt3/SUMO moiety 
at its C-terminus, generated Parkin species with no N-terminal sequence 
overhang.  Wild type Parkin (51.7 kDa) purified in this manner migrated at 50-
52 kDa when resolved by SDS-PAGE and eluted as a monomer at the 
corresponding molecular weight during SEC. In addition, 111C Parkin, originally 
designed based on a breakdown product observed with purified wild type Parkin 
when left at 4°C for 3-4 days, was expressed and purified using the same 
strategy.  
 
Subsequently, in vitro auto-ubiquitination assays were undertaken to assess 
ligase activity of the purified material (wild type and 111C). The setup of such 
an assay included the reconstitution of basic components that make up the 
ubiquitination pathway (E1, E2, E3, ubiquitin) in a test tube reaction with an 
appropriate reaction buffer (alkaline condition, MgCl2) and energy source (ATP) 
to facilitate the ubiquitination event (refer Methods 2.3.1). In contrast to ligase 
activity established in numerous reports ((Zhang et al., 2000, Corti et al., 2003, 
Fallon et al., 2006, Matsuda et al., 2006, Hampe et al., 2006, Chung et al., 
2001, Olzmann et al., 2007) and others), full-length Parkin consistently lacked 
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auto-ubiquitination activity with UBE2L3/UbcH7. However, 111C Parkin when 
tested in a similar assay, was competent for auto-ubiquitination (data not 
shown). Matsuda and colleagues had earlier established in vitro auto-
ubiquitination of MBP tagged Parkin with various E2s (Matsuda et al., 2006). 
Further, the report demonstrated that MBP IBR-RING2 (a Parkin truncation) 
ubiquitinated both the tag and Parkin polypeptide (presence of a Thrombin 
protease site between MBP and IBR-RING2 enabled the proteolytic uncoupling 
of the two proteins upon Thrombin action followed by immunoblotting analysis). 
However, when presented in trans, free/unbound MBP was not ubiquitinated by 
the MBP IBR-RING2. The authors suggest that MBP Parkin is ‘primed’ for E3 
ligase activity with the N-terminal fusion tag operating as a pseudo-substrate.  
 
The experimental design was adapted in the Walden lab by Simon Leslie with 
tagged Parkin species; MBP-Thrombin protease site-Parkin (expression 
construct gifted by the Tanaka group), Glutathione S-transferase (GST)-TEV 
protease site-Parkin (purified from insect cell expression systems) and 6xHis-
smt3 Parkin (Data not shown). Auto-ubiquitination reactions with MBP Parkin 
were set up in parallel with reactions containing untagged Parkin and free MBP 
(Figure 25). While the MBP Parkin fusion protein readily auto-ubiquitinated 
Figure 25: Ubiquitination of fusion tags. Results of 
auto-ubiquitination reactions with MBP Parkin show 
robust auto-ubiquitination of the fusion protein (lane 2, 
lane 1 has no ubiquitin).  Reaction products were 
subject to thrombin to allow proteolytic uncoupling of 
MBP and Parkin. Immunoblots with Anti-Parkin and Anti-
MBP reveal bulk of ubiquitination occurs on the MBP tag 
(lane 3).  Auto-ubiquitination reactions with untagged 
Parkin in presence free MBP reveals an absence of any 
modification on either species (lane 4). Brackets indicate 
ubiquitination. MBP is Maltose binding protein. 
Reactions (25 μL), were carried out for 2 hours at 4˚C, 
thrombin cleavage was carried out overnight at 4˚C. 
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(lane 2, Figure 25), with a majority of the ubiquitination occurring on the MBP 
tag (lane 3, Figure 25), auto-ubiquitination of the untagged Parkin (or 
ubiquitination of the free MBP tag) was absent. A similar profile was observed 
with GST-TEV protease site-Parkin and 6xHis-smt3 Parkin fusion proteins (data 
not shown). In summary, modifications to the N-terminus of Parkin (fusion 
tags/truncations) appear to positively influence the E3 ligase activity of Parkin. 
The following sections describe the experiments carried out, as part of this 
study, investigating how the N-terminal region of Parkin could influence the E3 
ligase activity of Parkin.  
 
3.2 Auto-ubiquitination activity 
 
RING E3 ligase activity could be described as a bi-substrate enzymatic 
reaction, where the RING domain catalyses the activation of E2~ubiquitin 
thioester conjugate while concomitantly ligating the ubiquitin onto the substrate. 
In the same way, auto-ubiquitination could be described as an event where the 
RING E3 recognises itself as a substrate and catalyses self-ubiquitination. In 
both cases, the transfer of ubiquitin is a trans event, i.e. from E2 to 
substrate/E3. Auto-ubiquitination can thus be used to attest E3 ligase activity. 
The above observations presented an interesting model system where wild type 
Parkin did not recognize itself as a substrate. While, a truncation of the N-
terminus (111C) or the presence of bulky N-terminal tags (MBP-, GST- and 
smt3-) appeared to facilitate auto-ubiquitination. At the minimum, the loss of the 
UblD (represented by 111C) appeared to permit the self-recognition and 
subsequent auto-ubiquitination of Parkin. 
 
To further investigate the above findings, the following expression constructs 
were cloned through deletion/RF cloning mediated insertions (as described in 
methods 2.1) of the pET SUMO wild type/WT Parkin expression construct 
already available: UblD (Gly77 to C-terminus), RING2 (Lys413X, similar to 
the pathogenic truncation Glu409X) and Parkin-Thio (Parkin with a C-terminal 
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Thioredoxin tag). The above constructs were expressed and purified based on 
protocols established in the Walden group, and tested alongside wild type 
Parkin in auto-ubiquitination assays with UBE2L3/UbcH7 (Figure 26).  
 
Consistent with previous observations, wild type Parkin lacked auto-
ubiquitination activity (Figure 26A, top panel). Furthermore, this reflected 
positively on the reproducibility of protocols established for wild type Parkin 
(protein production, purification and setup for in vitro ubiquitination assays). The 
cooperation of the RING domains has been proposed to be crucial for Parkin 
Figure 26: Parkin’s auto-ubiquitination profile. A. The presence (wild type/WT Parkin) or absence (UblD) of the 
Ubiquitin-like Domain (UblD) influences the auto-ubiquitination potential of Parkin (top panel). While wild type Parkin 
lacks activity, UblD exhibits robust auto-ubiquitination activity. Absence of the carboxy-terminal RING2 domain 
(RING2) abrogates auto-ubiquitination however attachment of a bulky tag at the carboxy-terminal (Parkin-
Thioredoxin/Thio) does not impair catalytic properties of RING2 (bottom panel). Auto-ubiquitination reactions (25 μL) 
using UBE2L3/UbcH7 as the E2 were carried out at 37˚C for an hour. Cartoons depict domain arrangement of the 
Parkin species used in the assay. B. Latent auto-ubiquitination activity of wild type (WT) Parkin is revealed by the 
increase in assay reaction time. Reactions (25 μL) were carried out at 37˚C and room temperature (RT) at the indicated 
time points (hrs – hours) using UBE2L3/UbcH7 as the E2. WT lane contains only wild type Parkin.  
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activity (Rankin et al., 2001) and other studies have shown RING2 to be the 
catalytic core for Parkin’s E3 ligase activity (Hampe et al., 2006, Matsuda et al., 
2006). Auto-ubiquitination profile of RING2 and Parkin-Thio together show that 
Parkin requires RING2 to be present for auto-ubiquitination and the attachment 
of a bulky tag at its C-terminus did not impair its ligase activity (Figure 26A, 
bottom panel). Robust auto-ubiquitination of the UblD species confirmed 
whether the UblD was the minimum domain preventing self-recognition for auto-
ubiquitination (Figure 26A, top panel). Interestingly, an increase in assay 
reaction times resulted in auto-ubiquitination of wild type Parkin, suggesting in 
part that bacterially produced wild type Parkin was capable of E3 ligase activity 
(Figure 26B). 
 
Subsequently, auto-ubiquitination of UblD and not wild type Parkin was 
observed with all E2s known to function with Parkin (Figure 27). Reactions 
(performed for 90 minutes) show moderately lower levels of activity with 
UBE2N/UBE2V1 (Ubc13/UEV1) heterodimer and UBE2L6/UbcH8 relative to the 
other E2s tested. UBE2D2/UbcH5B supported the auto-ubiquitination activity of 
UblD and has been observed to facilitate monoubiquitination of Parkin 
substrate PICK1 in vitro (Joch et al., 2007) however, an interaction with Parkin 
could not be detected in co-immunoprecipitation experiments conducted 
elsewhere (Olzmann et al., 2007, Shimura et al., 2000, Zhang et al., 2000). 
Lack of auto-ubiquitination with wild type Parkin with any of the associated E2s 
an unexpected observation. The above observations suggest ubiquitin ligase 
activity of wild type Parkin is latent and various secondary factors enable E3 
activity. The presence of bulky N-terminal (and C-terminal) tags presumably 
altered the tertiary structure of Parkin thereby ‘priming’ ligase activity. 
Correspondingly, increasing the assay reaction time may well have perturbed 
the protein leading to a gradual improvement in auto-ubiquitination. In addition, 
N-terminal truncations (UblD and 111C) readily exhibit auto-ubiquitination. 
Taken together, ubiquitin ligase activity towards Parkin (the substrate, in the 
case of auto-ubiquitination) appears to be intrinsically suppressed by the UblD.  
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3.3 Auto-inhibition of ligase activity: Role for the UblD 
 
The UblD is structurally similar to Ubiquitin, forming a -grasp globular domain 
however, shares low (~30%) sequence identity with Ubiquitin (Vijay-Kumar et 
al., 1987). However, there is a high degree of sequence conservation across 
species (90% identity across higher vertebrates and 75% overall similarity) 
(Figure 25A). Several pathogenic mutations are found within the UblD including 
20% of the missense mutations found within the Parkin. Point mutations are 
spread throughout the UblD (Figure 28A) and some of them have reported to 
cause domain unfolding (Safadi and Shaw, 2007, Tomoo et al., 2008). The 
effect of pathogenic mutations Arg33Gln, Arg42Pro and Ala46Pro as well as 
mutations Lys27Asn and Lys48Ala on the globular structural of the UblD have 
been analysed by a combination of biophysical techniques and molecular 
dynamics simulations (Safadi and Shaw, 2007, Tomoo et al., 2008). Lys27Asn, 
Arg33Gln, Arg42Pro and Ala46Pro caused global unfolding of the while the 
Lys48Ala mutation had no detrimental affect to UblD’s globular structure 
(Sakata et al., 2003, Safadi and Shaw, 2007, Tomoo et al., 2008). In addition, 
all the residues show a good degree of conservation across higher vertebrates 
(Figure 28A). Lys27Asn and Lys48Ala are not listed in the PD and Human 
Figure 27: Auto-ubiquitination profile with different E2s. UblD was observed to auto-ubiquitinate with all the E2s 
tested however similar modification of wild type Parkin was not observed. Auto-ubiquitination reactions (25 μL) of wild 
type (WT) Parkin (0.77 μM) and UblD (1 μM) were conducted with various E2s (UBE2L3/UbcH7 (1.1 μM), 
UBE2L6/UbcH8 (1.1 μM), UBE2N/UBE2V1 (Ubc13/UEV1) heterodimer (0.5 μM), UBE2G2/Ubc7 (1.1 μM) and 
UBE2D2/UbcH5B (1.1 μM). Reactions were conducted at 37˚C for 90 minutes. Brackets indicate ubiquitinated UblD 
species. UblD is Ubiquitin-like Domain. 
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Gene mutation databases (PDMD, HGMD) however have been reported in the 
literature as pathogenic.  
 
To further investigate the role of UblD in Parkin’s E3 ligase activity, the affects 
of four UblD point mutations (Lys27Asn, Arg33Gln, Arg42Pro and Ala46Pro) on 
the auto-ubiquitination profile of Parkin were examined (Figure 28C). Tested 
alongside was a mutation at Arg51 (Arg51Pro), a residue that was weakly 
conserved between species (Figure 28A and 28C). Auto-ubiquitination of Parkin 
mutants Lys27Asn, Arg33Gln, Arg42Pro and Ala46Pro (all reported to unfold 
the UblD) but not wild type confirmed a regulatory role for the domain in 
Parkin’s E3 ligase activity. The Arg51 residue is located within a loop in the 
UblD structure and displays weak conservation between species. Thus, a 
severe mutation (Arg51Pro) is expected to have negligible effect to structural 
integrity of the UblD and the mutant should behave like the wild-type protein in 
auto-ubiquitination assays. Lack of auto-ubiquitination with Arg51Pro confirmed 
the rationale behind the mutation.  
 
Residues Val15 and Lys32 were also mutated  (Val15Met, Lys32Ala) and 
tested in similar assay (data not shown). Val15, located on strand 2, 
contributes to the core hydrophobic network within the UblD structure (helix 1 
and strands 1,2 and 5) (Tomoo et al., 2008). Val15Met full-length Parkin did not 
auto-ubiquitinate in the assay. Given its location and nature, the mutation is not 
expected to destabilise the global structure. However, the mutation could 
substantially affect spatial orientation of the central helix against the concave 
surface presented by the five-stranded sheet. Alternatively, at the genetic level 
Val15Met could present an alternative start codon for protein translation 
(analogous to the Met80 that yields an endogenous UblD Parkin (Henn et al., 
2005)) yielding a N-terminal UblD truncation that would be unstructured. 
Residue Lys32 residue located on the surface of the central helix is another 
pathogenic mutation site (Lys32Thr). The intended Lys32Ala mutation was 
expected to maintain the hydrogen bond network stabilizing the helix and retain 
the wild type structure however robust auto-ubiquitination was observed.  
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These observations suggest secondary roles for the numerous UblD pathogenic 
mutations that require further investigations. Nevertheless, point mutations that 
have been shown to unfold the UblD structure appear to augment auto-
ubiquitination of Parkin. Along the same lines, bulky N-terminal tags could 
displace UblD in the context of the full-length protein and perturb the tertiary 
structure of Parkin.  Given that the UblD was the minimum domain preventing 
self-recognition and subsequent auto-ubiquitination, the above experiment 
confirms a role UblD as an auto-inhibition module. More importantly, the series 
of observations are indicative of a dynamic tertiary conformation for Parkin and 
UblD possibly will participate in an intra-molecular interaction with the rest of the 
molecule. 
 
3.4 Validation of UblD as Auto-inhibitory module 
3.4.1 Substrate UIM strategy:   
Inhibition of auto-ubiquitination was offset by the presence of bulky N-terminal 
tags, domain truncation (UblD) and by certain UblD pathogenic mutations. The 
UblD has been shown to recognize the UIMs of EPS15 resulting in Parkin 
mediated monoubiquitination of EPS15 as well as multi monoubiquitination of 
Parkin (Fallon et al., 2006). Custom peptides representing the EPS15 UIMs and 
mutant peptides were synthesised by the Peptide Synthesis Laboratory (PSL), 
a Core Technology facility at the London Research Institute. EPS15 bear two C-
terminal tandem UIMs with UIM II is predicted to be double-sided UIM based on 
sequence comparison with Hrs UIM ((Hirano et al., 2006) and (Figure 29A)). 
UIMs interact with the hydrophobic patch on Ubiquitin (Ile44 and surrounding 
residues), a surface that is conserved on the UblD (Figure 29A). Point 
mutations, similar to those disrupting the Hrs UIM - Ubiquitin interaction, were 
designed for the Eps15 UIMs and synthesised as peptides (Figure 29A). EPS 
15 UIMs incubated with wild type Parkin are likely to interact with the UblD, 
consequently disrupting the auto-inhibitory state while mutant UIMs should have 
little or no effect on wild type Parkin. To test this hypothesis, the peptides were 
used in auto-ubiquitination assays with wild type Parkin (Figure 29B).  
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Weak auto-ubiquitination of full length Parkin (0.77 μM) was observed at high 
concentrations (50x molar excess) of EPS15 UIMs (EPS15 WT UIMs) in the 
presence of UBE2L3 however, mutant UIMs (EPS15 m UIMs) had no effect 
Parkin. As the in vitro ubiquitination reaction mixture contained ubiquitin (~5x 
molar excess), UIM-ubiquitin interactions could also occur. Furthermore, weak 
affinities observed between UBDs and ubiquitin could partially explain low auto-
ubiquitination activity observed in vitro. The interaction had an affinity of 318 ± 
21 μM by surface plasmon resonance (SPR) (Hirano et al., 2006), while the 
affinity of Parkin’s UblD to both the UIMs was 139 ± 19 μM by NMR and 193 ± 
30 μM by isothermal calorimetry (ITC) (Safadi and Shaw, 2010).  
 
Figure 29: Parkin - EPS15 Ubiquitin Interaction Motifs (UIMs) assay. A. Alignment of ubiquitin and UblD sequences 
(top, generated using ClustalW (Chenna et al., 2003)) show conservation of residues that participate in the ubiquitin –
HRS UIM interaction (gold circles). Also shown are sequences of wild type and mutant (m) EPS15 UIM peptides (I, II 
and Im and IIm respectively, Ala to Gln mutations are highlighted) used in this assay, aligned with UIM consensus 
signature for single-sided and double-sided ubiquitin interactions (x is any residue, z is bulky hydrophobic/polar, e is 
negatively charge,  is hydrophobic). HRS is Hepatocyte growth factor–Regulated tyrosine kinase Substrate, EPS15 is 
Epidermal growth factor receptor substrate 15 B. Auto-ubiquitination reactions (25 μL) with wild type (WT) Parkin (0.77 
μM) in the presence of 50x molar excess of EPS15 wild type (WT) or mutant (m) UIMs shows activation of ligase 
potential with the former. Reactions were conducted at 37˚C for an hour. Brackets indicate ubiquitinated species.   
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While the above experiment contained the UIMs as two peptides, a better 
strategy might have been to synthesise them as a single polypeptide chain. Due 
to the residue content of the UIMs, difficulties were observed during the 
purification of the synthesised peptides and a longer peptide (UIMs I and II) 
would have compounded the issue. Experiments with EPS15 UIMs purified as 
recombinant protein from E. coli were planned. However, due to technical 
difficulties faced during cloning of the expression construct, the material could 
not be purified nor were assays conducted. Nevertheless, the experiment 
proved to be a partially successful as is showed UblD mediated auto-inhibition 
of E3 ligase activity in wild type Parkin could be suppressed by UblD 
interactions with substrate domains.   
 
3.4.2 TEV protease induced Parkin auto-ubiquitination:    
Another strategy used for validating the role of the UblD as an auto-inhibitory 
module was the TEV protease induced activation assay. As stated earlier, 
purified Parkin stored at 4°C for 3-4 days was susceptible to breakdown leading 
to the 111C truncation. In addition, a limited proteolysis assay using subtilisin A 
(serine endopeptidase with broad specificity) on wild type Parkin revealed 
additional proteolytic susceptible sites in the neighbourhood of residue 110 - 
Gly84, His124, Gly135 and Ser141 (data not shown, Figure 30 black arrows). 
Taken together, the region between the UblD and RING0 (Gly77 to Asn144) 
appeared unstructured and surface exposed, consequently amenable to 
incorporate a modification such as a TEV protease site. It was speculated that a 
stably integrated TEV site within this region should have little effect on auto-
ubiquitination profile of wild type Parkin. Proteolytic cleavage would then 
disengage the UblD from the rest of the protein thus permitting auto-
ubiquitination. A Parkin-TEV variant, inducible for auto-ubiquitination upon TEV 
protease action would be a useful tool to study mechanisms of E3 ligase 
activity.  
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To put the theory to test, a number of mutations were designed to incorporate a 
TEV protease within this region and were tested in auto-ubiquitination assays 
(Figure 30). Unfortunately, several of these mutations rendered Parkin capable 
of auto-ubiquitination prior to TEV protease activity (red squares and blue circle 
Figure 30). Surprisingly, the two species that were stable (yellow triangle and 
green star, Figure 30) either did not cleave or did not auto-ubiquitinate. These 
sites overlapped the Cdk5 phosphorylation site (Ser131, indicated in the figure), 
a region that has been shown to regulate Parkin’s ligase activity (Avraham et 
al., 2007). There appeared to be a secondary role of this region that required 
further investigations. The Parkin-TEV variant, while an attractive concept, 
proved to intractable in the absence of structural information to guide the assay 
design. 
  
Figure 30: Protease induced Parkin auto-ubiquitination. Strategy and summary of for the Tobacco etch virus (TEV) 
protease induced auto-ubiquitination of Parkin-TEV experiments. Cartoon indicates linker region of Parkin (red box) that 
was targeted for incorporation of TEV protease sites (top left). Shown along side are consensus and optimal sequences 
of a TEV protease site (top right, ‘*’ indicates any residue, dashed line indicates peptide bond hydrolysed by TEV 
protease). Sequence of the Gly77 to Ser145 (UblD to RING0) linker region (middle), with subtilisin A susceptible sites 
indicated with black arrows. Residues marked by thin black lines served as sites for the insertion of sequences 
encoding the TEV protease site (in black are Parkin residues retained, in blue are residues mutated/inserted). Parkin-
TEV variants were either unstable (exhibited auto-ubiquitination, TEV protease cleavage was either observed (red box) 
or absent (blue circle)) or stable but were not cleaved by TEV protease action (auto-ubiquitination absent, yellow 
triangle). Another Parkin-TEV variant (green star) was stable, cleaved by the protease, however was inactive. This site 
overlapped serine 131 (encircled), the location of cyclin-dependent kinase 5 (Cdk5) mediated phosphorylation of Parkin.  
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3.4.3 Expressed Protein Ligation of Parkin 
A strategy involving protein-protein ligation was designed to validate the auto-
inhibitory role for UblD. As the UblD was constitutively active towards auto-
ubiquitination, reattaching the UblD, a folded globular protein should in theory, 
revert the species to an auto-inhibited state as observed with wild type Parkin. 
Thus, the structural reconstitution of an auto-inhibited Parkin state is made 
possible through this strategy. Given that inhibition of auto-ubiquitination is a 
novel observation, one that contradicts several critical aspects of Parkin 
biology, it was felt necessary present multiple lines of evidence to shore up this 
observation.  The experiment involved the use of Expressed Protein Ligation 
(EPL) a technique successfully used incorporate amino acids analogs, synthetic 
labels and probes and post-translational modifications exclusively at specific 
locations on a desired protein (reviewed in (Schwarzer and Cole, 2005) and 
(Muralidharan and Muir, 2006)). EPL involves an autocatalytic chemical ligation 
reaction between protein fragments and is analogous to intein/extein splicing 
process observed during protein translation (Figure 31 and (Muir, 2003).  
 
Briefly, the process of chemically ligating protein A to protein B requires the 
former to bear an N-terminal cysteine residue, while the latter requires a 
Figure 31: Expressed Protein Ligation 
(EPL). EPL involves autocatalytic chemical 
ligation of two protein fragments (A to B). 
Protein A is expressed with a carboxy (C-) 
terminal Intein fusion that can be cleaved by 
a thiol reagent (2-Mercaptoethanesulfonic 
acid (MESNA) is depicted) resulting in a 
reactive thioester derivative at the C-
terminus. Protein B bears an amino (N-) 
terminal cysteine expressed using a fusion 
tag. Proteolytic cleavage of the protein B 
reveals the N-terminal cysteine, which 
attacks the C-terminal thioester derivative 
leading to the autocatalytic ligation (EPL) of 
the two proteins. Figure adapted from Intein 
Mediated Purification with an Affinity Chitin-
binding Tag (IMPACT) manual (New 
England Biolabs). 
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thioester linked leaving group moiety at the C-terminus. Recombinant 
expression of protein A fused with a C-terminal Intein tag, followed by an intein-
mediated, thiol induced cleavage that facilitates formation of a C-terminal 
thioester derivative. The two proteins can then be ligated by autocatalytic 
chemical ligation reaction in the presence of thiol reagents (Figure 31). 
 
The strategy for the Parkin EPL experiment involved production of the UblD 
with a C-terminal Intein tag and the UblD truncation with a N-terminal cysteine 
(Figure 32A). Ligation of these fragments would yield full length Parkin EPL 
species, predicted to resemble the tertiary structure of wild type Parkin as well 
as its auto-ubiquitination profile. Two cysteines are present in the proximity of 
the UblD; Cys59 - present within the UblD and Cys95 present in the UblD-
RING0 linker region. Due to its location, Cys95 was selected as the preferred 
site for the UblD truncation (95C) and was cloned, expressed and purified. 
The Mycobacterium xenopi gyrA Intein gene (Mxe GyrA Intein) and Chitin 
Binding Domain (CBD) (from the pTXB1 vector, New England Biolabs) was 
cloned as a fusion construct C-terminal to residue 94 of Parkin (see 2.1 and 
2.2.3 for details).  
 
The UblD-Intein-CBD fusion protein was cleaved using 2-
mercaptoethanesulfonic acid (MESNA) as the thiol reagent, further purified to 
remove free Intein-CBD tag and residual uncleaved fusion protein (see Methods 
for details).  UblD with C-terminal thioester derivative (1-95M) was used for 
chemical ligation with 95C. The ligation reaction was incomplete despite an 
overnight incubation, however Parkin EPL was successfully synthesised (Figure 
32B) Size-exclusion chromatography eliminated residual the 1-95M species, 
however the residual 95C could not separated completely despite a subsequent 
anion exchange chromatography (monoQ) step. Nevertheless, unligated 95C 
and the mixture of Parkin EPL and 95C were assayed for auto-ubiquitination 
(Figure 32C). To differentiate between Parkin EPL and 95C, differential 
antibodies; anti IBR-RING2 and anti UblD, were used (Figure 32C).  
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As expected, 95C readily auto-ubiquitinated, represented by the slow migrating 
bands in both the lanes in the anti-IBR-RING2 western blot. The weaker profile 
observed in the second lane corresponds to the lower amount of 95C present in 
the reaction. The anti-UblD blot does not pick up the 95C species in either lane, 
however readily recognizes the Parkin EPL species. Moreover, absence of any 
higher molecular weight bands suggests that auto-ubiquitination does not occur 
with Parkin EPL. Thus, Parkin EPL resembles wild type in its auto-ubiquitination 
profile, possibly its auto-inhibited tertiary structure, and validating the role for 
the UblD as the auto-inhibitory module. 
 
To conclude this section of results, the above experiments demonstrate that 
full-length Parkin does not auto-ubiquitinate with any of its cognate E2s. The N-
terminal UblD appears function as an auto-inhibitory module for Parkin’s auto-
ubiquitination. Bulky N-terminal tags, truncations lacking the UblD, 
Figure 32: Parkin Expressed Protein Ligation (EPL) assay. A. Strategy for Parkin EPL assay. The UblD-Intein-Chitin 
Binding protein (UBD) fusion was cleaved and activated for EPL through thiol action (M - 2-mercaptoethanesulfonic 
acid or MESNA) generating the 1-94M (residues 1-94 with C-terminal thioester derivative) species. 95C Parkin was 
expressed and purified as a smt3/SUMO (Small Ubiquitin-like Modifier) fusion and cleaved by Ubiquitin-like protease 1 
to reveal the amino terminal cysteine. Ligation of the two species resulted in Parkin EPL. B. Coomassie stained gels of 
reactions set up for expressed protein ligation step. 95C alone and 95C with 10X excess 1-94M (on left) were treated 
with 10 mM MESNA overnight at 16˚C. Reaction products (on right) revealed partial ligation of 1-94M to 95C. C. Auto-
ubiquitination reactions (25 μL) with 95C (1 μM) and mixture of 95C/Parkin EPL (1 μg of mix) revealed the latter species 
did not auto-ubiquitinate (detected by anti-UblD immunoblot) while 95C readily auto-ubiquitinated (anti-IBR-RING2 
immunoblot). On left is a coomassie stained gel of the E3 species used in the assay.  
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destabilizing/pathogenic mutations within the UblD, and UblD directed substrate 
interactions disrupt this inhibition resulting in a constitutively active molecule. 
Re-ligating the UblD onto UblD Parkin truncation restores its auto-inhibitory 
function. Furthermore, the above observations suggest auto-inhibition could be 
mediated by an intra-molecular interaction between the UblD and Parkin’s C-
terminus. Intra-molecular interaction as a possible mechanism for auto-inhibition 
will be explored in the following chapter.   
 104
Chapter 4. Results: Intra-molecular interaction of 
Parkin   
 
4.1 Background 
 
Auto-ubiquitination, like substrate ubiquitination by RING E3 ligases, involves 
E2 activation and substrate recognition. Absence of auto-ubiquitination of full-
length Parkin implies either one of both those events are disrupted. Thus, auto-
inhibition mediated by the UblD involves disruption of self-recognition or the 
masking of target lysines on the Parkin surface, both of which require an intra-
molecular interaction between the UblD and the catalytic C-terminus of Parkin 
(Figure 30). Several other questions arise from this hypothesis; could substrate 
interactions (as is the case with UblD - EPS15 and endophilin-A) disrupt this 
interface or alternatively can ubiquitination of substrates occur independent of 
this interface? Could substrate and auto-ubiquitination occur as mutually 
exclusive events?  
 
To investigate substrate ubiquitination, the bacterial expression and purification 
of recombinant AIMP2 (‘authentic’ Parkin substrate, see 1.10.4.3 and (Corti et 
al., 2003, Ko et al., 2005)) was attempted using MBP, GST and 6xHis-smt3 
tags, with little or no success. While a small percentage soluble MBP-AIMP2 
could be affinity purified, soluble material was not observed with the other two 
Figure 33: Model for auto-inhibition of Parkin’s ligase activity. Cartoon describing two possible states of Parkin 
(active and latent) with UblD mediated intra-molecular interaction rendering the ligase inactive/latent. Mechanisms of 
activation and inhibition are yet to be described in detail.  
 105
fusion proteins. Moreover, removal of the MBP tag using thrombin protease 
resulted in precipitation of recombinant AIMP2 (data not shown). The 
expression and purification of AIMP2 required further optimisation however 
could not be addressed within the time frame of this study. The following 
sections describe experiments investigating the intra-molecular interaction 
within Parkin, the nature of the interface and the mechanism of auto-inhibition.   
 
4.2 Lysine 48 mediated intra-molecular interaction of Parkin 
 
Lysine 48, located in the 3-4 loop, is conserved across Parkin species and 
with Ubiquitin (Figure 28 A and B). Ubiquitin mediated proteasomal degradation 
of substrates is signalled by Lys48-linked polyubiquitin chains, underlying its 
importance in the ubiquitin (Chau et al., 1989).  Lys48Ala UblD mutation has 
been reported as an AR-JP mutation in numerous studies (Finney et al., 2003, 
Henn et al., 2005, Safadi and Shaw, 2007, Tomoo et al., 2008) however, is not 
listed in the mutation databases (PDMD and HGMD). The Lys48 side chain 
appears to have no conformational constrains within the UblD structure and the 
Lys to Ala mutation does not lead to domain unfolding (Safadi and Shaw, 2007, 
Tomoo et al., 2008). The residues in strands 3 and 4 of UblD form the 
interaction interface with Rpn10 with Lys48 playing a significant role in this 
interface (Sakata et al., 2003). Recently, the residue has also been shown to 
participate in interactions with EPS15 UIM and the SH3 domain of endophilin-1 
(Safadi and Shaw, 2010, Trempe et al., 2009). As the residue participates in a 
contrasting set of interactions (proteasome and substrates), Lys48 is an ideal 
candidate to be engaged in the proposed intra-molecular inhibitory interaction. 
 
Mutations Lys48Ala and Lys48Arg (a conserved substitution observed in zebra 
fish Parkin, Figure 28A) were tested for auto-ubiquitination. Lys48Ala Parkin 
(K48A-Parkin) was capable of auto-ubiquitination while Lys48Arg lacked this 
profile (Figure 34A). In addition, full-length Parkin species (WT and K48A) when 
subjected to proteolytic digest with a broad-spectrum endopeptidase (subtilisin 
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A), showed divergent digestion profiles (Figure 34B). 100 μg of respective 
Parkin species in 100 μL of buffer containing 50 mM Tris pH 8.0, 200 mM NaCl, 
250 μM TCEP and 5% (v/v) glycerol were digested overnight at 4°C with 
indicated quantities of protease (% w/w). K48A-Parkin was susceptible to 
digestion even at low protease concentrations, while wild type Parkin was more 
resistant indicative of a shielded tertiary structure. In the context of Parkin’s 
intra-molecular interaction, the above results revealed a potential interaction 
surface on the UblD that can be modified (K48A) to ‘open-up’ the molecule. 
More importantly, a correlation between intra-molecular interaction and auto-
inhibition could now be examined within an enzymatic assay.  
 
Accordingly, pull-down experiments were carried out using, 6xHis-UblD (wild-
type and K48A) as bait and different Parkin species (wild-type, K48A-Parkin 
and UblD) as the prey, in order to establish an interaction preference (Figure 
35). K48A-Parkin was also subject to auto-ubiquitination in the presence of 
increasing concentrations of free UblD and UblD K48A, to examine the effect of 
trans interactions (with the C-terminus of K48A-Parkin) on the auto-
ubiquitination profile of K48A-Parkin (Figure 36). Pull-down experiments 
(section 2.4.1 for methods) using 6xHis-UblD as the bait protein showed a 
Figure 34: Role for Lysine 48 in Parkin auto-inhibition. A. Auto-ubiquitination reactions with wild type (WT), K48A- 
and K48R- Parkin show activity only in lanes with K48A-Parkin (indicated by brackets) suggesting a role for the charged 
nature of the residue in auto-inhibition of Parkin ligase activity. Reactions (25 μL) were conducted with 0.77 μM of each 
of the Parkin species and UBE2L3/UbcH7 (1.1 μM) at 37˚C for an hour. B. Divergent digestion profiles observed for WT 
and K48A- Parkin species reveal the latter (on right) to be prone to subtilisin A proteolysis even at low protease 
concentrations (indicated above in weight per weight percentage) suggesting an exposed conformation for the mutant. 
In contrast, WT Parkin is observed to be more resistant to proteolysis indicative of a closed tertiary structure. Proteolytic 
digests were carried out overnight at 4°C in 100 μL reactions containing 100 μg of respective Parkin species.   
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stronger binding of the bait to K48A-Parkin and the UblD species when 
compared wild type (Figure 35, left panel). In contrast, the 6xHis-UblD K48A 
bait protein lacked a preference for the prey or exhibit any stable interactions 
(Figure 35, right panel) suggesting the mutation alters the UblD surface 
responsible for the interaction with C-terminus of Parkin.  
 
Concomitantly, increasing concentrations of free UblD (8-32 fold molar excess 
with increments of 8) in a K48A-Parkin auto-ubiquitination assay (0.77 μM in 25 
μL reactions) gradually reduced levels of auto-ubiquitination (Figure 36, on left). 
At least a 16 fold molar excess of UblD was required to observe significant 
reduction in activity and complete inactivation could not be observed. On the 
other hand, a similar excess of UblD K48A in a similar assay did not 
Figure 35: Intra-molecular interaction - role for Lysine 48. Results of pull-down assays with 6xHis-Ubiqutin-like 
Domain (UblD, left panel) or 6xHis-UblD K48A (right panel) as bait proteins with wild type (WT) Parkin, K48A-Parkin and 
UblD (first, second and third row respectively, also shown as cartoons in centre) as the prey species.  6xHis-UblD 
displays an interaction preference for K48A-Parkin and UblD species over WT Parkin suggesting the carboxy-terminal 
UblD binding surface mutant Parkin species is available for interaction (in trans) with the bait UblD species. The same 
surface, in WT Parkin would be occupied by the amino-terminal UblD domain hence occluded from interaction. 6xHis-
UblD K48A shows weak interactions with the prey species suggesting the Lys48Ala mutation perturbs UblD surface 
responsible for interaction with carboxy terminus of Parkin. Baits were bound to nickel-nitrilotriacetic acid (Ni-NTA) 
beads (40 μL) were incubated with 0.5 mg of each of the prey species in 50 mM Tris pH 7.5, 25 mM NaCl, 250 μM 
TCEP, 5% glycerol, for 2-3 hours at 4˚C. Beads were washed (10 column volumes) with binding buffer and subsequent 
washes of increasing salt concentration (indicated below third row), with samples (10 μL) taken at every step for sodium 
dodecyl sulfate – polyacrylamide gel electrophoresis (SDS-PAGE) and coomassie/immunoblot (anti-Parkin) detection. 
Input lanes represent 5% of prey species used in the pull downs. Samples are diluted 20 fold for immunoblots and 
probed with anti-Parkin antibody that recognises a carboxy terminal epitope on Parkin.  
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significantly impede auto-ubiquitination. (Figure 36, on right) Overall, the 
interaction of UblD appears weak, however sufficient to regulate auto-
ubiquitination in the K48A Parkin species, confirming the presence of an intra-
molecular inhibitory interaction within Parkin, mediated by the UblD. 
 
Attempts to further quantify UblD interaction with K48A-Parkin through 
isothermal calorimetry (ITC) based experiments were met with a few technical 
challenges. Briefly, ITC measures the heat change (indirectly, using a reference 
cell) arising from a sample cell (containing protein ‘a’ of the two-protein 
complex, a - b) upon interactions with a ligand (protein b), injected at high 
concentrations through a syringe until the complex is saturated. The raw data 
generated from the experiment is computed to give values for binding affinity 
(Ka), enthalpy changes (H), and binding stoichiometry (n) for the interaction 
(refer (Freyer and Lewis, 2008) for practical aspects of ITC). The ITC 
experiment for this study was designed such that K48A-Parkin was held in the 
Figure 36: Inhibition of ligase activity - role for Lysine 48. Auto-ubiquitination assays with K48A-Parkin conducted in 
the presence of increasing quantities of UblD species (wild type, left and Lys48Ala, right). Reduction in levels of auto-
ubiquitination is observed with increasing quantities of UblD (at least a 16 fold excess), however a similar inhibition was 
not observable upon titration with UblD K48A. Reactions (25 μL) containing 0.77 μM of K48A-Parkin and 
UBE2L3/UbcH7 (1.1 μM) were mixed with indicated (8, 16, 24 and 32 fold molar excess) quantities of UblD/UblD K48A 
and incubated at 37˚C for an hour.  
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sample cell and the UblD (ligand) injected at high concentrations. As described 
earlier (see 2.2.2.3), UblD was unstable at concentrations exceeding 8 mg/mL 
and proved tricky to accommodate within the experimental setup. Sequential 
ITC runs, with UblD at a stable concentration (6 mg/ml), were planned in order 
to achieve complex saturation however the K48A-Parkin was observed to be 
precipitate after extended incubations in the sample cell (held at 25˚C, with 
each run lasting for 80-90 minutes). Finally, the protein locations were 
swapped, placing UblD in the sample cell and K48A-Parkin in the syringe. The 
latter species (~52 kDa) could be concentrated up to 0.45 mM, however when 
injected at concentrations of 0.20 to 0.25 mM, protein precipitation was 
observed in the sample cell which was analysed to be K48A-Parkin. Further 
optimisation of protein material was required to generate quantitative data for 
the interaction however, could not be addressed within the course of this study.  
 
Interestingly, 6xHis-Ubiquitin baits exhibited faint binding with the K48A Parkin 
and UblD species, with prey being washed away at physiological salt levels 
(150 mM). However, increasing concentration of inactive ubiquitin (Arg74X) did 
not impair auto-ubiquitination of K48A-Parkin (data not shown), as was 
observed with UblD. The relevance of a Parkin-ubiquitin interaction will be 
discussed at a later stage. In context of wild type Parkin, cross talk between 
UblD and the RING domains would be expected for the former to influence the 
‘business-end’ of the E3 ligase (Figure 30). Thus, spatial orientation of the UblD 
could be influenced by the ‘linker-region’ (Gly77 to Asn235 including the RING0 
domain), as well as secondary interactions along the molecule. The ‘linker-
region’ is subject to several levels of regulation (phosphorylation, binding of 
adaptors 14-3-3 and BAG5) as well as involved in substrate recognition (Pael-
R) (Sato et al., 2006, Imai et al., 2001, Avraham et al., 2007, Kalia et al., 2004). 
However, the interplay between intra-molecular inhibitory interaction within 
Parkin established here and the above events requires further investigations.  
 
The above observations introduce the molecular basis of UblD mediated 
inhibition of Parkin’s auto-ubiquitination. A direct correlation of UblD’s 
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interaction with Parkin’s C-terminus and regulation of auto-ubiquitination was 
established. Furthermore, Lysine 48 (and neighbouring residues), previously 
shown to direct Parkin interactions with substrates and the proteasome, is 
critical for the intra-molecular auto-inhibitory interaction. These data represent 
first experimental investigations into the inherent regulation of Parkin’s ligase 
activity and could hold a greater significance in the disease perspective as well 
as for understanding mechanisms of RING E3 regulation.  
 
4.3 UblD interaction: Effect on Parkin E2s and Adaptors 
 
UblD mediated intra-molecular interaction could possibly occlude the E2-RING 
interaction thereby inhibiting auto-ubiquitination. The effect of UblD mediated 
intra-molecular interaction on Parkin-E2 binding was tested in pull-down assays 
using 6xHis-UBE2L3/UbcH7 and 6xHis-UBE2L6/UbcH8 as baits and wild type 
Parkin and UblD as prey proteins (Figure 37A). In addition, auto-ubiquitination 
assays with wild-type Parkin were carried out in the presence of increasing 
quantities of UBE2L3/UbcH7 and UBE2L6/UbcH8 (Figure 37B) to examine 
possible competition of binding regions.  
 
A small degree of Parkin-E2 binding was observed however, the bound Parkin 
species washed away at salt levels greater than 50mM NaCl, in contrast to the 
binding observed in UblD based pull-downs. The levels of wild-type Parkin 
pulled-down were comparable to UblD for both the E2s (Figure 37A) 
suggesting the UblD interaction surface on the C-terminus of Parkin is distinct 
from the Parkin-E2 interaction surface. The use of E2~ubiquitin thioester 
conjugates as baits may well have improved the observed levels of E2-E3 
interactions thereby revealing subtle differences between the binding events 
(UblD with E2~ubiqutin versus WT with E2~ubiqutin) however, this was not 
planned as part of the original experiment and requires further investigation. 
Nevertheless, an increase in E2 concentration in auto-ubiquitination assays 
(and consequently an increased E2~ubiquitin concentration in the reaction) 
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showed no induction of Parkin’s auto-ubiquitination (Figure 37B) collectively 
suggesting that, E2 interaction events and intra-molecular inhibition occur 
independently.  
 
 
As introduced earlier, the Gly77 to Asn235 linker-region is subject to regulation 
by Cdk5 phosphorylation (at Ser131) and the binding of adaptors 14-3-3 and 
BAG5 (Sato et al., 2006, Avraham et al., 2007, Kalia et al., 2004). In addition, 
each of the events resulted in either abrogation of auto-ubiquitination (all three) 
or Parkin mediated substrate ubiquitination (binding of BAG5 and Cdk5 
phosphorylation inhibited synphillin-1 ubiquitination). Binding of the 14-3-3 
protein with Parkin was observed to nanomolar affinities (Kd = 4.2 nM) by SPR 
technique (Sato et al., 2006), and provides an attractive target to study how an 
intra-molecular interaction within Parkin would influence adaptor interaction. In 
addition, binding of 14-3-3 was observed independent of the phosphorylation 
status of Parkin, although the authors do not rule out a phospho event 
enhancing binding (Sato et al., 2006).  
Figure 37: E2 binding assays. A. Pull-down assays using 6xHis tagged UBE2L3/UbcH7 or UBE2L6/UbcH8 show 
similar levels of interaction with both the prey proteins: wild type (WT) Parkin and UblD, while the beads only control 
(left panel) shows no interaction. 50 μL nickel-nitrilotriacetic acid (Ni-NTA) beads were saturated with 6xHis tagged E2s 
and acted as baits for 0.5 mg of prey proteins (indicated above) in 50 mM Tris pH 7.5, 25 mM NaCl, 250 μM Tris (2-
carboxyethyl) phosphine (TCEP) buffer, 5% (v/v) glycerol). Binding was carried out for 2-3 hours at 4˚C. Input lanes (I) 
represent 5% of prey proteins. Bead lanes (B) indicate prey pulled down after 10 column volume (cv) low salt wash (50 
mM). Samples were diluted 20 fold for immunoblots. B. Auto-ubiquitination assays with wild-type Parkin (0.77 μM) with 
increasing quantities of E2 (1x, 2x and 5x indicate 1.1, 2.2 and 5.5 μM respectively) to ascertain if excess E2 could 
relieve UblD mediated auto-inhibition. Lack of auto-ubiquitination suggests E2 interaction events and intra-molecular 
inhibition occur independently. Reactions (25 μL) were conducted at 37˚C for an hour. v/v is volume per volume. 
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The following experiments were designed to examine the relationship between 
Parkin-adaptor regulatory mechanisms and the UblD mediated intra-molecular 
inhibitory interactions. A phosphomimetic mutation of Parkin was designed 
(Ser131Glu) alongside a double mutant (Lys48Ala + Ser131Glu) to examine 
(indirectly) if phosphorylation on the linker-region could regulate the ‘open’ state 
of Parkin (Figure 38). Furthermore, the mutant (Ser131Glu) was also used in 
binding assays with 14-3-3 alongside WT Parkin (Figure 39) to study if the 
adaptor could alter the ‘open’ state of Parkin. The S131E-Parkin retained wild 
type characteristics in an auto-ubiquitination assay, however the double mutant 
was observed to auto-ubiquitinate, suggesting the two events might not co-
operate as was predicted (Figure 38).   
 
 
A phosphomimetic mutation (Ser to Glu) may not adequately represent the 
physiological phosphorylation state however, comparing rates of auto-
ubiquitination (K48A-Parkin versus S131E+K48A Parkin) could reveal the finer 
aspects of Parkin phosphorylation and requires further work. Additional 
phosphorylation sites (Ser101, Ser131 (‘linker’ sites), Ser296 (RING1-IBR 
linker) and Ser378 (IBR)) have also been observed to regulate Parkin’s 
response to the UPR pathway (Yamamoto et al., 2005). More recently, the 
‘activation’ of Parkin’s E3 ligase activity mediated by PINK1 phosphorylation 
was observed (Kim et al., 2008, Sha et al., 2010) as well as contested 
Figure 38: Phosphomimetic Parkin mutant 
assay. Auto-ubiquitination assays with wild type 
(WT), Ser131Glu (phosphomimetic mutant) and 
Ser131Glu + Lys48Ala (double mutant) species 
of Parkin  (0.77 μM each) show ligase activity 
with the double mutant species, while the 
phosphomimetic mutant resembles WT-Parkin in 
its auto-ubiquitination profile. Reactions (25 μL) 
were conducted with UBE2L3/UbcH7 (1.1 μM) at 
37˚C for an hour.  
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(Narendra et al., 2010). Auto-inhibition, presented here for the first time, 
represents a fundamental regulation of Parkin’s activity. However, modifications 
such as phosphorylation, could tweak other functional facets of Parkin’s activity 
(substrate interaction, binding of adaptors) thereby regulating the E3 ligase 
potential of Parkin.   
 
 
Parkin-14-3-3 interactions, analysed using size exclusion chromatography 
(SEC), were largely absent regardless of the Parkin species used as a binding 
partner. The 31kDa protein migrates as a dimer on a size exclusion column 
(purple dashed trace (Figure 39)) while all the Parkin species (~52kDa) traced 
identical profiles, represented by the brown dashed trace of WT Parkin. Low salt 
levels (50mM) were maintained in the interaction buffer to promote binding, and 
Figure 39: Interactions with 14-3-3 . Results of size exclusion chromatography (SEC) based analysis of 14-3-3 
interactions with Parkin. The elution profiles overlaid are; monomeric wild type (WT) or Ser131Glu (phosphomimetic 
mutant) Parkin (brown dashes, 1x - 0.5 mg), dimeric 14-3-3  (violet, 1x - 0.3 mg), WT Parkin with 14-3-3  in 1:5 molar 
ratio of monomers  (maroon) and Ser131Glu with 14-3-3  in 1:5 molar ratio of monomers (teal). Absence of a shifted 
elution profile representing a trimeric protein complex (Parkin (WT/S131E) with dimeric 14-3-3) indicates a lack of 
protein complex formation during SEC analysis. Values along x-axis indicate elution volumes in (mL). Indicated fractions 
a to e (12 mL to 14.5 mL) for each run were analysed by sodium dodecyl sulfate – polyacrylamide gel electrophoresis 
(SDS-PAGE) and stained with coomassie brilliant blue. Monomeric molecular weights of individual proteins are 
indicated in brackets. SEC runs (250 μL samples) were conducted using Superdex 200 10/300 GL in 50 mM Tris pH 
8.0, 50 mM NaCl and 250 μM Tris (2-carboxyethyl) phosphine (TCEP) buffer. Calibration markers for 75 kDa and 158 
kDa are shown for reference. Traces were generated using GraphPad Prism 5.0c (GraphPad, San Diego, CA). 
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increasing levels of 14-3-3 (1x, 2x and 5x) were also tested however, the 
expected offset representing a trimeric complex (Parkin and dimeric 14-3-3 - 
114kDa) or a tetrameric (166 kDa) complex was not observed. S131E-Parkin 
(Figure 39, teal coloured trace), K48A-Parkin and K48A+S131 Parkin species 
(data not shown) were also tested for 14-3-3 interactions however, protein 
complex formation was once again not observed. In addition, 14-3-3 showed 
no effect on in vitro auto-ubiquitination profile of K48A Parkin as well as of the 
double mutant (K48A+S131E) (data not shown). Sato and colleagues had 
demonstrated 14-3-3 interactions with Parkin purified from insect cell 
expression systems, hence post-translation modifications can be expected to 
assist the interaction. Material used in the above assays was purified from a 
bacterial expression system and similar modifications are not expected.  
 
Further investigations into 14-3-3 - Parkin interactions (optimization of an ITC 
based binding assay, effect of pathogenic mutations on binding (mutants 
Ala82Glu, Lys161Asn and Lys211Asn were cloned, expressed and purified), 
use of multi phosphomimetic mutants/phospho peptides for interaction analysis) 
were required to understand the molecular basis of how the E3 ligase is 
regulated by 14-3-3. However, certain developments in other aspects of this 
study, in particular the details of C-terminal regions on Parkin that were 
expected to be involved in the intra-molecular inhibitory interactions presented 
themselves (discussed below). Subsequently, experiments relating to the 
description of the novel intramolecular inhibitory interaction were taken up, 
leaving insufficient time to appropriately address the questions arising from this 
section.    
 
4.4 UblD interaction mapping  
 
The above results (section 4.2) demonstrate intra-molecular interaction 
mediated by the UblD regulates auto-ubiquitination of Parkin. The molecular 
detail of this interaction would help understand how the regulation occurs and 
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whether the mechanism influences substrate ubiquitination. While the above 
experiments benefited from the UblD structure, apart from the IBR structure, no 
other information was available to direct experiments. Consequently, peptide-
array interaction experiments were designed to identify possible candidate 
regions to guide subsequent biochemical and biophysical experiments. A target 
protein can be split into an array of overlapping peptide fragments followed by 
‘SPOT synthesis’ of each peptide on a cellulose membrane (technique and 
applications reviewed in (Hilper et al., 2007)).  The membrane is incubated with 
the probe protein to allow peptide interactions, washed stringently, and 
analysed to determine the peptide spots retaining interaction with the probe 
protein (analogous to epitope mapping).  
 
Peptides arrays of Parkin were synthesised by the Peptide Synthesis 
Laboratory, LRI. The peptides stretched over 21 residues with a +1 residue shift 
for each subsequent peptide in the array until the whole Parkin sequence is 
mapped (spot n = residues n to n+20, where n lies between 1 and 445). UblD 
tagged with the V5 epitope tag  (GKPIPNPLLGLDST) and labelled with a 
fluorophore (thioether linkage between UblD Cys59 and Fluorescein-5-
Maleimide) was used as probes (V5-UblD and Fluoro UblD, respectively, Figure 
40A and B). In addition, based on the weak binding observed in the pull-down 
assays, fluorescein-N-terminal Ubiquitin was also used as a probe (Fluoro Ub, 
Figure 40C). Concomitantly, probes were made to interact with a +3 shift sparse 
array, i.e. a +3 residue shift along the Parkin sequence in each subsequent 
peptide spot, and was used to confirm hits obtained from the fine (+1 shift) 
interaction assay (data not shown). The arrays that were generated represented 
the entire Parkin sequence however, for the purpose of this study, interacting 
peptides observed in the UblD were not pursued further and excluded from the 
figures. Positive interactions were those that were represented in both the array 
types, fine (+1 shift) and sparse (+3 shift).  Positive interactions observed were 
classified as major hits when they covered at least five consecutive peptide 
spots (Figure 40D), while interactions observed in 3-5 consecutive peptide 
spots were listed as minor hits (Figure 40E). 
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Figure 40: Peptide array interactions. Parkin peptide array showing peptide spots interacting with probes A. V5-UblD, 
B. Fluoro UblD and C. Fluoro Ub. Positive interaction spots are classified as D. major and E. minor. Rectangles in A, B 
& C represent major and minor hits - green for UblD, yellow for Ub and black dashed/white for minor hits. Interaction 
with V5-UblD was detected by anti-V5 horseradish peroxidase antibody. Image Storm scanner (595nm) was used to 
detect interactions of the fluorophore labelled probes. Grid reference in D and E represents positive interaction spots 
and stated alongside is the nature of probe, associated sequence, PD mutations and other features. Zinc co-ordinating 
residues are in bold. * Indicates the features listed do not include substrate interactions. Cartoons representing domain 
arrangement of Parkin are not to scale and the locations of the observed interactions, indicated by brackets (green for 
UblD, yellow for Ub and black dashed for minor hits) are approximate. UblD is Ubiquitin-like domain, Ub is ubiquitin, 
RING is Really Interesting New Gene and IBR is In-between RING. E2s – UBE2L3/UbcH7, UBE2L6/UbcH8. 
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Distinct interaction regions were observed for UblD and ubiquitin apart from 
spots L 2-8 representing the sole overlapping region. The two major hits 
observed with the UblD (F 21-27 and L 2-8) appear to with have common 
characteristics with the reported Parkin-E2 binding patches (Shimura et al., 
2000, Zhang et al., 2000, Ardley et al., 2001). A major ubiquitin interacting 
region (C 21-27) was situated in the RING0 domain leading into the C4 zinc 
finger, N-terminal half of the predicted bipartite zinc co-ordinating region. In 
addition, the C-terminal of the second zinc co-ordinating region predicted in 
RING0 was a minor site (E 11-14) of ubiquitin binding. Interestingly, the N-
terminal zinc-finger is observed analogous to the ubiquitin interacting NZF-like 
zinc finger present in HOIL-1 (Figure 41A) (Hristova et al., 2009, Kirisako et al., 
2006), however a possible ubiquitin-RING0 interaction has not yet been 
examined. 
 
Over 20 PD mutations were collectively represented within the major and minor 
hits of the array interactions. More importantly, several missense mutations of 
interest (grey shaded rows in table 4) appear in major interaction hits (red 
glyphs (Figure 40)); destabilizing Arg256Cys (F 21-27) formed aggresomes, 
exhibited enhanced auto-ubiquitination (in vitro and in vivo) however lacked 
substrate ubiquitination, soluble mutations Lys161Asn (C 21-27) and Thr240Arg 
(F 21-27) that lack substrate ubiquitination in vivo however show robust auto-
ubiquitination in vitro, and finally the soluble Thr415Asn (L 2-8) ‘ligase-dead’ 
mutation.  
 
The major hits C 21-27, F 21-27 and L 2-8 are, from this point forwards, 
generically referred to as UblD/Ub Binding Regions (UBRs) I, II and III 
respectively. A high degree of sequence conservation across species was 
observed in all regions. While this was expected of UBRs I and II as they 
coincide with genuine domains of Parkin (RING0 and RINGI respectively). 
However UBR III, incidentally displays a superior sequence identity (92% to 
55%) across species between the three UBRs, does not overlap with any 
known Parkin domains/motifs (Figure 40D and 41).  
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UBR III also bears four lysine residues or potential targets for ubiquitination, 
which could be masked by the UblD interaction as a regulatory mechanism 
against auto-ubiquitination. Furthermore, several PD mutations appeared to 
Figure 41: Parkin UblD/Ub Binding Regions (UBRs). A. Sequence alignments (of amino-terminal zinc finger motif of 
Parkin’s RING0 domain with Npl4 type Zinc Finger (NZF)-like zinc finger present in Haem-oxidized IRP2 ubiquitin 
ligase-1 (HOIL-1). Predicted zinc co-ordinating cysteines are in bold blue letters. UBR I overlaps the RING0 domain 
(see cartoon and top panel in B). B. Cartoon representation of Parkin with approximate locations of UBR I, II and III (not 
to scale). Multiple sequence alignment depicts sequence conservation of the UBRs I, II and III (top, middle and bottom 
respectively) across Parkin homologues. Also indicated are sites of pathogenic mutations found in each UBR (yellow 
and red glyphs for missense mutations and black for nonsense mutations, nature of mutations are listed alongside). 
Zinc-coordinating cysteines are in bold letters. All sequence alignments were generated using ClustalW (Chenna et al., 
2003). UblD is Ubiquitin-like domain, RING is Really Interesting New Gene and IBR is In-between RING.  
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punctuate the UBR III that is a shared UblD and Ub interaction patch, all of 
which would suggest a decisive role for this region.  
 
In summary, pull-down experiments demonstrate an interaction between the 
UblD and C-terminus of Parkin (UblD). Lys48 in the UblD is crucial residue for 
this interface and increasing concentrations of free UblD but not Lys48Ala UblD 
are capable of reducing auto-ubiquitination of full-length K48A Parkin. Full-
length Parkin and UblD appeared to bind E2s (UBE2L3/UbcH7 and 
UBE2L6/UbcH8) equally well, demonstrating that an E2 was not competing with 
UblD for Parkin interaction. In addition, several factors (kinase action, binding of 
adaptors) have been reported to regulate Parkin’s E3 ligase activity. The intra-
molecular interaction of Parkin, mediated by the Lys48 surface of UblD is an 
inherent feature of molecule, one that principally establishes inhibition of auto-
ubiquitination. Finally, peptide based interaction mapping proposes an 
unexpected Parkin-ubiquitin interaction as well three UBRs to investigate 
mechanisms of UblD mediated auto-inhibition. The concluding chapter will 
describe experiments designed to validate the UBRs and propose a model for 
Parkin ligase activity.  
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Chapter 5. Results: Novel Interactions of Parkin   
 
5.1 Background 
 
The enzymatic activity of RING E3 ligases involves substrate recognition, 
activation of E2s and facilitating substrate ubiquitination (trans event: 
E2~ubiquitin  Substrate). The significance of a potential RING E3-ubiquitin 
interaction within this pathway is not immediately clear. Alternatively, inhibition 
of Parkin auto-ubiquitination/self-recognition may involve UblD mediated 
masking of target lysines. In theory, the UBR III containing four lysines could be 
concealed from ubiquitin (on a charged E2) by the UblD thereby inhibiting auto-
ubiquitination of Parkin. Could an intra-molecular inhibition involve co-operation 
between the three UBRs? UBRs III and I suggest ubiquitin binding while UBRs 
II and III display UblD interaction. Functional co-operation could be mediated by 
an enclosed structure of Parkin, further supporting the importance of an intra-
molecular interaction (Figure 42). A trade-off between UblD and ubiquitin 
interactions could also play a crucial role in the synthesis of ubiquitin chains by 
Parkin. 
Figure 42: Molecular dynamics of Parkin. Cartoons (not to scale) representing location of Parkin UblD/Ub Binding 
Regions (UBRs) I, II and III (top, UblD is Ubiquitin-like Domain, Ub is ubiquitin, RING is Really Interesting New Gene, 
IBR is In-between RING). UblD mediated intra-molecular interaction in Parkin that inhibits auto-ubiquitination (bottom 
left) and proposed trade-off between UblD/Ub and UBRs interactions that could regulate ubiquitination events (bottom 
right).   
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The following sections describe experiments exploring the dynamics of an intra-
molecular UblD based interaction, a probable Parkin-ubiquitin interaction and 
how these events could influence the RING E3 ligase properties.     
 
5.2 Validation of Peptide Interaction Array  
 
The UBR III presented an attractive region to focus validation experiments, 
primarily due to its ability to potentially interact with both UblD and ubiquitin. 
Auto-ubiquitination assays with ubiquitin mutants were designed to identify a 
functional relevance of the ubiquitin interaction. Point mutations in the 
hydrophobic (Phe4Ala, Leu8Ala, Ile44Ala and Val70Ala) and acidic (Asp58Ala) 
patches were introduced and used as source ubiquitin in UblD auto-
ubiquitination assays (Figure 43A). Assays were also conducted in the absence 
of the E3 to observe if the mutants impaired charging of the E2 
(UBE3L3/UbcH7) (Figure 43C). Concomitantly, select PD missense mutations 
represented in the UBRs (UBR I - Lys161Asn, UBR II - Thr240Arg and UBR III - 
Thr415Asn, Figure 41) were also purified and tested in auto-ubiquitination 
assays (K161N-, T240R- and T415N-Parkin) (Figure 43D). 
 
Unexpectedly, auto-ubiquitination of the UblD species was completely 
abrogated by the Ile44Ala mutation and marginal activity was observed with the 
Lue8Ala and Val70Ala mutations (Figure 43A). Together these residues form 
the core hydrophobic patch on ubiquitin. Similar loss of activity was observed 
when the Ile44Ala ubiquitin mutant was used with K48A-Parkin, pathogenic 
UblD mutations (Lys27Asn, Arg33Gln, Arg42Pro and Ala46Pro) as well the 
321C truncation (Glu321 to C-terminus, contains IBR-RING2) (Figure 43B). The 
levels of UblD auto-ubiquitination with wild type ubiquitin, and ubiquitin 
mutants Phe4Ala and Asp58Ala were comparable (Figure 43C) moreover, the 
formation of E2~ubiquitin thioester conjugate (UBE2L3/UbcH7) was not 
significantly effected by any of the mutations (Figure 43C).  
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Figure 43: Auto-ubiquitination assays with Ubiquitin and Parkin mutants. A. Reduced auto-ubiquitination observed 
with hydrophobic patch mutants of ubiquitin (Leu8Ala, Ile44Ala and Val70Ala) while the acidic patch mutant (Asp58Ala) 
shows no effect on UblD auto-ubiquitination profile. B. Auto-ubiquitination of Parkin mutants (Lys27Asn, Arg33Gln, 
Arg42Pro, Ala46Pro, Lys48Ala and 321C (deletion of Met1 to Ala320 in Parkin) was impaired due to Ile44Ala mutation 
on the hydrophobic patch of ubiquitin. C. None of the ubiquitin mutants however, significantly effect formation of the 
E2~ubiquitin thioester as the charged E2 species (UBE2L3/UbcH7~ubiquitin) was observed in non-reducing conditions 
and in the absence of an E3 (no E3 assay). ClustalW generated sequence alignment of ubiquitin and UblD (human) 
indicating conservation of residues (bottom). Inverted black triangles indicate location of residues mutated in ubiquitin 
for the UblD assay. D. Auto-ubiquitination assays with Parkin mutants (residue location depicted on cartoon of Parkin 
structure); Ile44Ala (UblD hydrophobic mutant), Lys161Asn (UBR I mutant), Thr240Arg (UBR II mutant), Thr415Asn 
(UBR III mutant) and UblD+T415N (UblD containing Thr415Asn mutation). Auto-ubiquitination was observed with all 
mutants, except the ‘ligase-dead’ T415N-Parkin as well as UblD+T415N Parkin. All ubiquitination assays were 
conducted as 25 μL reactions containing 0.77 μM of full-length Parkin species or 1 μM 321C and UblD+T415N species 
or no E3, in the presence of 1.1 μM UBE2L3/UbcH7 at 37˚C for an hour. Brackets indicate ubiquitinated species. In ‘no 
E3 assay’, reaction samples were treated with 2xbuffer containing 4 M Urea, 150 mM Tris pH 6.8, 5 mM 
ethylenediaminetetraacetic acid (EDTA), 2% SDS, 10% glycerol and bromophenol blue for analysis in non-reducing 
conditions. UblD is Ubiquitin-like domain, Ub is ubiquitin, UBR is UblD/Ub Binding Regions.’*’ indicates non-specific 
band. 
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The hydrophobic patch (Phe4, Ile44 and Val70) on UblD could represent an 
extended surface supporting intra-molecular interaction in Parkin and 
accordingly the Ile44Ala full-length Parkin mutant (I44A-Parkin) was active for 
auto-ubiquitination (Figure 43D). Furthermore, auto-ubiquitination was 
successfully observed in PD-linked K161N- and T240R-Parkin (UBR I and UBR 
III respectively) (Figure 37B) although T240R-Parkin activity was weaker of the 
two. Lys161Asn and Thr240Arg are drastic charge switching mutations and 
could possibly disrupt intra-molecular inhibition in a mechanism similar to the 
Lys48Ala mutation. True to its label, the ‘ligase-dead’ T415N mutation as well 
as the UblD+T415N Parkin tested alongside lacked auto-ubiquitination activity. 
At this stage, a correlation of the observed loss of activity observed with T415N-
Parkin and hydrophobic mutants of ubiquitin is tempting as the Thr415 lies in 
the UBR III on Parkin (Figure 40, a region that interacts with both UblD and 
ubiquitin.   
 
5.3 Novel requisite for ubiquitin ligase activity of Parkin  
 
The catalytic properties of RING E3s include activation of E2s and concomitant 
substrate ubiquitination (or auto-ubiquitination) (described earlier, Section 3.2). 
The auto-ubiquitination potential of Parkin was inhibited by a novel intra-
molecular interaction mediated by the UblD present on the N-terminus of 
Parkin. The above experiments reveal two contrasting mutations that inhibit 
Parkin’s auto-ubiquitination as well; the Ile44Ala on the hydrophobic patch of 
ubiquitin and Thr415Asn located on UBR III near the C-terminus of Parkin. 
Furthermore, both these mutations negatively regulate the E3 ligase activity of 
Parkin in a UblD background (Figure 43A and 43D) implying a distinct 
inhibitory mechanism.  
 
Subsequently, E2~ubiquitin thioester discharge assays that characterize E2 
activation properties of Parkin were carried out to examine the inhibitory 
mechanisms of the above mutations. These assays allow a comparison of E2 
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activation rates or rates at which ubiquitin is discharged from the E2~ubiquitin 
thioester conjugate and their setup is analogous to a pulse-chase experiment 
(Figure 44A). Conjugation of ubiquitin and E2 (by E1 and ATP/MgCl2) forms the 
pulse phase of the reaction. The reaction is then arrested by depletion of 
ATP/MgCl2 (Apyrase/ATPase action followed by buffer exchange) thereby 
preventing recharging of the E2 (via E1) in an event of a thioester discharge. 
The reaction is then chased by the RING E3, which enhances E2 activation or 
the discharge of ubiquitin from the thioester E2~ubiquitin conjugate (Petroski 
and Deshaies, 2005b).  In case of UBE2L3/UbcH7, which lacks intrinsic 
capability of ubiquitin chain synthesis, the RING mediated E2 activation event 
results in either the discharge of ubiquitin or discharge of ubiquitin followed by 
ligation onto a primary amine (lysine or N-terminus via isopeptide or peptide 
linkage). 
 
Thioester discharge assays were carried out using a combination of WT/mutant 
species of Parkin and ubiquitin to examine whether UBE2L3/UbcH7 charged 
with Ile44Ala mutant ubiquitin could be activated by constitutively active species 
of Parkin (UblD) (Figure 44C) and whether UBE2L3/UbcH7~ubiquitin could be 
activated by the UblD+T415N Parkin species (Figure 44E). In the absence of a 
RING E3, activation of UBE2L3 (illustrated by ratio of charged (E2~ubiquitin) 
versus uncharged/discharged E2) was muted (Figure 44B) however addition of 
UblD contributed to ubiquitin discharge (Figure 44C) rapidly accompanied by 
ubiquitination of the E2 and UblD auto-ubiquitination (confirmed by subjecting 
samples to reducing conditions, data not shown). E2 ubiquitination, could arise 
due to robust ligase activity of the UblD species contributing to reaction by-
products of in vitro assays or alternatively, E2s could act as pseudo-substrates 
for Parkin.  
 
A similar set-up with UblD and I44A-Ubiquitin led to rapid discharge of the 
ubiquitin conjugated UBE2L3, however no E2 ubiquitination was observed 
(Figure 44D). A double mutant (UblD+T415N) appeared to catalyse ubiquitin 
discharge quicker than the ‘no E3’ reaction however was comparatively slower 
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than other Parkin species tested alongside. The T415N mutation has been 
suggested to inactivate RING2 (Hampe et al., 2006, Matsuda et al., 2006), thus 
activation of the E2~ubiquitin thioester by the RING1 domain of Parkin cannot 
be excluded. Further analysis, using RING truncations or combinations of 
RING-E2 interaction abrogating mutants is required to understand ‘ligase-dead’ 
mechanisms of T415N-Parkin.  
Figure 44: E2~ubiquitin thioester discharge assays. A. Schematic describing the pulse-chase format of the E2~Ub 
thioester discharge assay with reaction times and temperatures for each stage indicated. All E2 and ubiquitin species 
are 6xHis- tagged to enabled detection by anti-His immunoblot. E2~ubiquitin/E3 species present in each chase reaction 
are listed alongside the corresponding immunoblots of chase samples. Chase reactions are; UBE2L3/UbcH7~ubiquitin 
only (in B), UBE2L3/UbcH7~ubiquitin with UblD (in C), UBE2L3/UbcH7~Ile44Ala ubiquitin with UblD (in D) and 
UBE2L3/UbcH7~ubiquitin with UblD+Thr415Asn Parkin (in E). Thioester discharge (hydrolysis of E2~ubiquitin 
conjugate) is muted in absence of E3 (B). However, rapid thioester discharge (D) and rapid thioester discharge followed 
by E2 ubiquitination (Ub-E2) (C) are observed in chase reactions containing UBE2L3/UbcH7~Ile44Ala ubiquitin with 
UblD and UBE2L3/UbcH7~ubiquitin with UblD, respectively. Discharge of UBE2L3/UbcH7~ubiquitin by 
UblD+Thr415Asn Parkin is quicker than no E3 reaction (E). Lanes in each immunoblot comprise of reaction samples 
collected at chase time points indicated. Chase reactions were conducted as single reaction mixtures (100 μl) and 
chase samples (10 μl) were collected at the indicate time points in 2x Non-Reducing (NR) sample buffer containing 4 M 
Urea, 150 mM Tris pH 6.8, 5 mM ethylenediaminetetraacetic acid (EDTA), 2% SDS, 10% glycerol and bromophenol 
blue. In addition, a zero time point reduced (0R) sample was collected with 2xNR buffer containing 200 μM -
mercaptoethanol. ATP is adenosine triphosphate, min is minutes and RT is room temperature.  
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Nevertheless, the concomitant absence of auto-ubiquitination when Ile44Ala 
Ubiquitin is used despite observed activation of the UBE2L3~I44AUb (Figure 
43D and 44E) provides experimental evidence of a novel requisite for Parkin’s 
ubiquitin ligase potential i.e. interaction with the hydrophobic patch of ubiquitin.  
 
5.4 Interactions between UblD/Ubiquitin and Parkin  
 
The above results propose cross-talk between the hydrophobic patch of 
ubiquitin and UBR III could perform crucial roles in events surrounding ligase 
activity of Parkin (auto- or substrate ubiquitination). While peptide array 
interaction assays revealed multiple UblD interactions along Parkin’s C-
terminus, interactions at protein/domain levels need to be examined to 
understand the cross-talk mechanisms and how they affect ligase activity.  
 
The molecular details of these interactions were addressed using NMR 
spectroscopy conducted in collaboration with Prof. Gary S. Shaw’s group at the 
University of Western Ontario, Canada. A N-terminal truncation of Parkin, 321C, 
containing IBR and RING2 domains as well as the UBR III was expressed and 
purified in the Walden lab and shipped to Canada for these studies. 
Interestingly, partial oligomerisation of this species is observed (see Methods 
2.2.1.5) however, the monomer fraction could be sufficiently isolated and was 
utilised for subsequent experiments. 15N-labelled UblD samples were prepared 
with Parkin truncations (UblD and 321C) at different ratios as part of standard 
[1H, 15N]-heteronuclear single quantum coherence (HSQC) experiments. In 
addition, 15N-labelled ubiquitin were prepared with 321C to compare the 
interaction surface of IBR-RING2. Dr. Kathryn R Barber prepared all 15N-
labelled reagents and spectroscopy experiments were carried out under the 
guidance of Prof. Shaw. A Bogue Research Fellowship awarded by University 
College London (UCL) supported the 7-week research visit. The results 
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discussed below are part of an on-going collaboration between the Walden and 
Shaw labs and should be considered as work-in-progress/preliminary data.  
 
Based on all preceding results that suggest an intra-molecular interaction within 
Parkin, a dramatic effect of 15N-UblD spectra was expected upon addition of 
unlabelled UblD, as observed in (Figure 45). The disappearance of the 
majority of the peaks in a 15N-UblD spectra is indicative of global changes in the 
chemical environment of UblD residues. A similar experiment with 15N-K48A 
UblD as the labelled species showed a less dramatic effect (data not shown). 
Multiple interactions between UblD and UblD (Parkin C-terminus), as 
suggested by peptide array experiments, and different titrants (UblD with 
pathogenic missense mutations and other Parkin truncations) could be used in 
tandem to enhance the output.  
 
Figure 45: Ubiquitin-like Domain (UblD) interactions with UblD. Overlay of 1H-15N HSQC spectra showing 
interactions of UblD with 15N labelled UblD. Spectra were collected using 150 μM UblD in 20 mM Tris pH 7.0, 150 mM 
NaCl, 1 mM Dithiothreitol (DTT) at 25˚C. Black contours indicate basal UblD spectra and green contours show effect of 
UblD (120 μM) addition. ppm - parts per million. 
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321C interaction experiments with 15N-UblD and 15N-Ub were more informative 
for identifying interacting residues and contrasting the binding regions. 
Reference peak lists for 15N-UblD and 15N-Ub (from the Shaw lab) were used 
for automatic peak assignment (with minor manual adjustments) in NMRView 
(Johnson and Blevins, 1994), with tolerance levels of 0.2 and 0.02 parts per 
million (ppm) along nitrogen and proton dimensions respectively. HSQC spectra 
were recorded and peak assignment carried out for each addition of the 321C. 
Slow and intermediate exchange rates of UblD peaks were predominantly 
observed upon 321C titration (Figure 46A), in contrast to the fast exchange 
rates of ubiquitin peak (linear peak movement) (Figure 47A). Saturation of 
ubiquitin - 321C interaction was not observed despite addition of 2x excess 
321C, however the UblD - 321C complex appeared closer to saturation as 
sample approached a ratio of 1:2. Combined changes in chemical shifts were 
calculated using the equation ((H)2 + (0.2*N)2 )1/2 and plotted as 
histograms. H and N represent change in proton and nitrogen chemical 
shifts (in ppm) for labelled UblD (0x versus 1.6x excess 321C) and labelled Ub 
(0.5x versus 2x excess 321C) (Figure 46B and 47B). Residues that were 
perturbed greater than set thresholds (Mean + 1 Standard Deviation (SD), 
0.024 ppm for UblD and 0.033 ppm for Ub) are indicated in the respective 
histograms.  
 
Chemical shifts greater than the threshold of 0.033 ppm (equivalent to the 
calculated Mean + 1 SD for Ub) were mapped on the respective structures 
(Figure 48 A and B) (PDB 1IYF and 1UBQ) (Vijay-Kumar et al., 1987, Sakata et 
al., 2003). Unexpectedly, analogous surfaces on the UblD and ubiquitin were 
significantly perturbed upon interaction with 321C. Residues Val5, His11, 
Phe13, Ile44, His68 and Ile69 along the -sheet of UblD show the largest 
changes while peaks corresponding to Gly12, Val67 and Val70 (indicated by 
asterisks in (Figure 46B) disappeared altogether or could not be assigned 
despite increasing the tolerance levels (0.5 and 0.05 ppm for 15N and 1H 
dimensions respectively). In addition, chemical shifts in Phe4, Asn8 and Ala46 
were greater than the internal threshold for UblD (Mean + 1 SD, (Figure 46B). 
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Figure 46: 
15
N-UblD interactions with 321C. A. 
1H-15N HSQC spectra of 15N labelled Ubiquitin-like domain/UblD (select 
region) overlaid with spectra of 321C interaction experiments (basal state in black contours and gradient of green 
coloured contours corresponding to increasing 321C concentrations (bottom right)). Assigned peaks are labelled and 
select residues are boxed (yellow/orange for sites of Parkinson Disease missense mutations, blue for residues mutated 
in Sections 4.2 and 5.2 of this study). Spectra were collected using 120 μM UblD in 20 mM Tris pH 8.0, 150 mM NaCl, 1 
mM Dithiothreitol (DTT) at 25˚C. B. Histograms show combined changes in chemical shifts [((H)2 + (0.2*N)2 )1/2] for 
the residues assigned (x axis). * indicate residues that disappear or could not be automatically assigned. Residues 
perturbed more than Mean + Standard Deviation  (SD = 0.024 parts per million (ppm); dashed line) are labelled. 
Threshold for comparison with shifts in Ub spectra (0.33 ppm) is also shown (dashed and dotted line). 
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Figure 47: 
15
N-Ub interactions with 321C. A. 
1H-15N HSQC spectra of 15N labelled ubiquitin/Ub (select region) overlaid 
with spectra of 321C interaction experiments (basal state in black contours and gradient of yellow coloured contours 
corresponding to increasing 321C concentrations (bottom right)). Assigned peaks are labelled and select residues are 
boxed (blue/pink for residues mutated in Section 5.2 of this study). Spectra were collected using 140 μM UblD in 20 mM 
Tris pH 7.0, 150 mM NaCl, 1 mM Dithiothreitol (DTT) at 25˚C. B. Histograms show combined changes in chemical shifts 
[((H)2 + (0.2*N)2 )1/2] for the residues assigned (x axis). Residues perturbed more than Mean + Standard Deviation 
(SD = 0.033 parts per million (ppm); dashed line) are labelled.  
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Residues Lys6, Ile44, Phe45, Gly47, Gln49, Leu67, His68, Leu69 and Val70 on 
ubiquitin correspond to a similar surface for 321C interaction (Figure 48B). In 
the context of the ligase activity of Parkin, residues Gly12, Ile44 and Ala46 on 
the UblD, Ile44 and Val70 on ubiquitin are noteworthy. Gly12 and Ala46 are 
sites of PD missense mutations (Gly12Arg and Ala46Pro). The latter along with 
the Ile44Ala mutation relieve UblD mediated auto-inhibition of Parkin. 
Conversely, auto-ubiquitination of UblD is abrogated by the Ile44Ala ubiquitin 
mutant and reduced in case of Val70Ala mutation (Figure 43A) 
 
The above experiments were initially executed as titration based experiments 
where 321C (at high concentrations) was added to the same NMR sample tube 
after every data collection. However, its was observed that 321C in the sample 
tube gradually began to precipitate over 2-3 rounds of data collection (verified 
by subjecting precipitant to SDS-PAGE analysis) where each run lasted for 
around 85 minutes at 25°C. Subsequently, multiple samples were prepared, 
each with increasing proportions of 321C with the labelled material kept as 
constant. This approach proved successful however, rapidly used up the 
Figure 48: 321C interaction surface on Ubiquitin-like Domain (UblD) and Ubiquitin. A. UblD and B. Ubiquitin 
Nuclear magnetic resonance (NMR) chemical shift perturbations upon 321C titrations were mapped on their respective 
structures (PDB 1IYF and 1UBQ). Residues that perturbed greater than the set threshold (0.033 ppm) were coloured 
olive on UblD, red on Ubiquitin and listed alongside. UblD residues that disappeared/could not be picked are coloured 
dark olive and underlined.   
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purified 321C samples that were shipped to the Shaw lab prior to the visit. After 
the initial data collections confirmed 321C interactions with both 15N-UblD and 
15N-Ub, a final set of experiments were planned to collect data at a range of 
321C concentrations (0 to 2.5 fold excess) with the labelled reagents. These 
experiments would also provide for a broader set of peak shifts required to 
determine values of binding affinities. Unexpectedly however, these 
experiments did not reproduce the chemical shifts observed during the initial 
runs and a complete data set could not achieved within the fellowship period. 
Nevertheless, the visit was partially successful in confirming UblD and ubiquitin 
interactions with C-terminus of Parkin. 
 
Given the UBR III is represented within 321C truncation of Parkin, a majority of 
the perturbations on both the spectra could be associated to interactions with 
this region. Interaction with the hydrophobic patch on ubiquitin was earlier 
shown to be a prerequisite for ubiquitin ligase activity of Parkin. Consequently, 
an intra-molecular interaction with the UblD could shield UBR III from ubiquitin 
thereby preventing auto-ubiquitination. Pathogenic mutations along the UblD - 
UBR III interface could disrupt this interaction resulting in constitutively active 
Parkin. Alternatively, as might be the case with T415N-Parkin, mutations that 
disrupt the Ub-UBR III interface result in ‘ligase-dead’ Parkin. Further analysis 
towards establishing binding affinities of the bivalent interactions observed with 
321C and characterising effects of pathogenic mutations are required to 
validate this hypothesis.  
 
5.5 ‘Mixed signals’ from Parkin 
 
Auto-ubiquitination of pure but tagged Parkin has been demonstrated as multi 
monoubiquitination in vitro (Matsuda et al., 2006, Hampe et al., 2006) and in 
vivo (Hampe et al., 2006). Both the reports conclude Parkin is an E3 ligase with 
monoubiquitination capacity and secondary factor like E4s (CHIP (Imai et al., 
2002, Imai et al., 2001)) or chain-specific E2s (UBE2N/UBE2V1 (Ubc13/UEV1) 
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heterodimer (Doss-Pepe et al., 2005, Olzmann et al., 2007)) are required to 
mediate substrate polyubiquitination. Furthermore, UblD directed substrate 
interaction of Parkin activated its monoubiquitination potential towards EPS15 
and endophilin-A (Fallon et al., 2006, Trempe et al., 2009). In both cases, 
Parkin auto-ubiquitination was observed, with multi-monoubiquitination 
confirmed in the former. Conversely, as introduced earlier, Parkin has been 
reported to catalyse K48-linked (Zhang et al., 2000, Corti et al., 2003) and K63-
linked (Chung et al., 2001, Olzmann et al., 2007) polyubiquitin chains on 
different substrates.   
 
The data presented here demonstrates inhibition of Parkin auto-ubiquitination 
by UblD domain. Thus, ubiquitin chain building capability of Parkin was 
investigated using full-length Parkin UblD mutations (pathogenic A42P-Parkin 
and directed by rationale; K48A-Parkin, I44A-Parkin) as well as the UblD 
truncation. Furthermore UBE2L3/UbcH7 was used the E2 of choice as it lacks 
intrinsic capability of ubiquitin chain synthesis. Auto-ubiquitination assays were 
conducted using wild-type ubiquitin and mutants bearing no lysines (K0Ub) and 
single lysine mutants K48Ub and K63Ub (Figure 49A). In addition, auto-
ubiquitination reactions with wild-type ubiquitin were subject to western blot 
analysis using antibodies that recognize mono and polyubiquitin (FK2) 
alongside those that exclusively recognise polyubiquitin species (FK1) (Figure 
49B).   
 
Auto-ubiquitination reactions with wild type and lysine mutants of ubiquitin show 
activity with all the Parkin species tested. Moderately lower levels of activity 
were observed with 6xHis-tagged K0Ub in all Parkin species (reactions 2 in 
(Figure 49A). As the mutant is incapable of chain formation, multi-
monoubiquitination was observed (at least three ubiquitins ligated) confirming 
the previous observations. A gradual trend of decreasing auto-ubiquitination, in 
the order of wild-type ubiquitin, K48Ub and K63Ub (reactions 1, 3 & 4 
respectively in (Figure 49A)), was observed in Parkin UblD mutants. The 
observations suggest multi-monoubiquitination is the underlying modification 
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with possibility of K48- and K63-linked polyubiquitin chains. This was confirmed 
by detection with FK2 antibodies however, signal levels were not comparable to 
detection by the anti-His antibody except in the case of UblD (Figure 49B). 
Unexpectedly, none of the UblD mutant species of Parkin showed 
polyubiquitination as observed with lack of high molecular weight species when 
probed with the polyubiquitin specific FK1 antibody. Absence of signal could be 
due technical factors and the possibility polyubiquitin chain synthesis by UblD 
mutants cannot be ruled out completely. Nevertheless, polyubiquitination of 
UblD was readily detected demonstrating, for the first time, that synthesis of 
polyubiquitin chains is an intrinsic property of Parkin.  
 
Unconfirmed observations suggest a similar pattern with the UBR I mutant 
K161N-Parkin and UBR II mutant T240R-Parkin, however polyubiquitination 
could not be confirmed with the latter (data not shown). Further experiments are 
required to establish the ubiquitination profile of various pathogenic mutations 
and more importantly, their effect on auto-inhibition. Mixed ubiquitin signals 
Figure 49: Analysis of ubiquitin chain synthesis. A. Auto-ubiquitination reactions with UblD (1 μM) and Parkin UblD 
mutants; Arg42Pro, Lys48Ala and Ile44Ala (0.77 μM each). UBE2L3/UbcH7 (1.1 μM) was the E2 used for all reactions, 
while 6xHis tagged Ubiquitin wild type K0, K48 and K63 were used in reactions 1, 2, 3 and 4 respectively. B. Reaction 
products of auto-ubiquitination with wild type ubiquitin (reactions 1 in A.) were analysed by antibodies that recognise 
mono and polyubiquitin species (FK2) and those exclusive for polyubiquitin chains (FK1). Immunoblots revealed 
polyubiquitination potential of UblD, while Parkin mutants were pre-dominantly mono-ubiquitinated. 
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generated by artificially activated Parkin species reveals another level in the 
ubiquitin ligase potential of Parkin with the UblD as the primary regulatory 
module of all the levels. UBRs III and I show ubiquitin interaction and the 
hydrophobic patch on ubiquitin was observed to be necessary for Parkin’s 
ubiquitin ligase. Thus, a trade-off between UblD/ubiquitin interactions and intra-
molecular co-operation between UBRs could play a crucial role in ubiquitin 
chain synthesis and specificity.   
 
In summary, the hydrophobic patch on ubiquitin was earlier shown as a novel 
requisite for enabling the ubiquitin ligase potential of Parkin.  Mechanisms of 
intra-molecular inhibition by the UblD are likely to involve the regulation of 
Parkin-Ubiquitin interaction, indirectly suggested by analogous surfaces on 
ubiquitin and UblD for interaction with 321C. UBR III, represented in 321C and 
earlier shown (section 4.5) to exhibit bivalent (UblD/Ub) interaction properties, is 
a probable candidate for such a surface. Finally, intrinsic polyubiquitination 
capacity of Parkin was demonstrated for the first time by the UblD species.  
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Chapter 6. Discussion 
 
6.1 Synopsis  
 
Parkin is a multifaceted RBR E3 ligase, observed to co-operate with several 
E2s, recognise a diverse group of substrates and catalyse distinct ubiquitination 
events including auto-ubiquitination. In addition, several mutations in the Parkin 
gene are causative of AR-JP and affect the E3 ligase properties of Parkin in 
different ways. Thus, the examination of Parkin’s E3 ligase properties will offer 
deeper insight into fundamental mechanisms of ubiquitin E3 ligases (substrate 
recognition and ubiquitin chain synthesis) and how they are 
regulated/deregulated.  
 
The work presented here introduces the regulation of the E3 ligase activity of 
Parkin as an inherent property, mediated by the UblD. Contrary to numerous 
reports over the last decade, wild type Parkin does not exhibit auto-
ubiquitination with any of its cognate E2s. The N-terminal UblD domain was 
demonstrated as an auto-inhibitory module that is disrupted by the presence of 
bulky N-terminal tags and UblD directed substrate interactions. Pathogenic 
mutations within the UblD that unfold the globular domain and domain deletion 
(UblD) disrupt the inhibition resulting in a constitutively active molecule. 
Accordingly, auto-inhibition can be restored in the UblD truncation upon N-
terminal re-ligation of the UblD.   
 
Auto-inhibition of Parkin or the intrinsic inhibition of ligase activity was observed 
to arise due to an intra-molecular interaction between the UblD and Parkin’s C-
terminus. A conserved residue (Lys48) in the UblD is crucial for the intra-
molecular interaction and essential RING-E2 interactions were not hindered by 
the ‘closed’ tertiary structure of Parkin. Interaction mapping experiments reveal 
at least two surfaces on the C-terminus of Parkin (UBRs II and III) that could 
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support the intra-molecular interface with the UblD. Furthermore, novel Parkin-
ubiquitin interaction surfaces were also revealed (UBRs I and III).  
 
Consequently, the hydrophobic patch on ubiquitin was demonstrated as a novel 
requisite enabling the ubiquitin ligase potential of Parkin. The C-terminal region 
of Parkin (321C which includes the IBR-RING2 domains) was shown to interact 
with analogous surfaces on ubiquitin and UblD. Auto-inhibition of Parkin is 
expected to involve UblD mediated preclusion of a Parkin-Ubiquitin interaction. 
Finally, the capacity to synthesise polyubiquitin chains was demonstrated as an 
intrinsic feature of Parkin and is likely to involve dynamic cross talk between 
UblD, the UBRs and ubiquitin.   
 
6.2 Structure-function characterisation of Parkin UBR III.  
 
The above studies introduce unique interaction surfaces that could prove critical 
in understanding the mechanisms of E3 ligase activity in Parkin and dysfunction 
in the disease context. A prerequisite for ubiquitin interaction in RING E3 ligase 
activity is a novel property described for Parkin and furthermore inherent 
regulation of this interaction, mediated by the UblD is proposed from the above 
observations. To understand the nature of the unique bivalent interactions 
observed with 321C, structural features of the UBR III were re-examined. 
PSIPRED, a secondary structure prediction software (http://bioinf.cs.ucl.ac.uk 
/psipred/) predicted residues Asp394 to Thr414 of the UBRIII to form a helical 
structure with high degree of confidence (Figure 50A). Unexpectedly, primary 
sequence analysis of the UBR III revealed an uncanny resemblance to UIM 
motifs. The eexxxxAe/zSzxe signature represents the canonical sequence for 
a UIM motif, where ‘e’ represents negatively charged,  for hydrophobic, z for 
bulky hydrophobic/polar and x represents any residue (Hirano et al., 2006, 
Hofmann and Falquet, 2001). These -helical UBDs pack against the 
hydrophobic patch of ubiquitin with the conserved Ala and Ser residues 
(underlined) making extensive contacts with the core hydrophobic residues 
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Ile44, Val70 and Leu8 ((Swanson et al., 2003) and reviewed in (Dikic et al., 
2009, Hurley et al., 2006). Multiple sequence alignments between UBR III and 
single-sided UIMs (1:1::UBD:ubiquitin interactions) revealed two stretches, 
Asp392 to Lys406 (UBR IIIa) and Glu399 to Lys413 (UBR IIIb), staggered by 
five residues, that resemble a UIM each (Figure 50B). However, neither of them 
follows the UIM canonical sequence, absence of the conserved Ser being the 
most notable exception (Ala403 and Thr410 in the respective stretches).  
 
Helical wheel projections (-helix) of the predicted UBR III helix shows 
polarized surfaces for the two putative UIMs (Figure 43C). However, alignments 
with double-sided UIMs (1:2::UBD:ubiquitin interactions), represented by the 
canonical sequence exexxAAzSzS/Ae (repeating UIMs with a +2 offset, 
refer (Hirano et al., 2006) for more details) showed even less agreement (data 
not shown). Pathogenic missense mutations punctuate more of UBR IIIa (Figure 
50C) in particular mutations Asp394Asn and Ala398Thr would disrupt 
supporting interactions in a ‘UIM’ - UblD/Ub complex. The Glu409X mutation 
would result in truncation of the predicted helix, more importantly in loss of 
RING2. However, Thr415, the site of the ‘ligase-dead’ Parkin mutation T415N, 
lies at the foot of UBRIIIb and two residues N-terminal of the first zinc 
coordinating cysteine in RING2. Given the analogous nature of the UblD/Ub - 
321C interaction surface, it is likely either UBRIIIa or UBRIIIb would behave as 
the sole UIM-like motif in UBR III.  
 
Interestingly, UblD residues shown to interact with EPS15 UIMs (Parkin 
substrate) are comparable to those perturbed in the presence of 321C ((Safadi 
and Shaw, 2010) and Figure 46 of this study, compiled in Figure 50D). Both 
RPN10 (Parkin interactor) and EPS15 have tandem UIMs with UIM II of EPS15 
is predicted to be a double-sided UIM (Hirano et al., 2006). UblD was observed 
to prefer UIM I for the S5A interaction while both the UIMs of EPS15 participate 
in the UblD interaction (Safadi and Shaw, 2010). Authentication of UBR III as a 
UIM-like motif and correlation with observed UblD interactions would be an 
attractive prospect for future work. 
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Figure 50: Structure-function analysis of UblD/Ub Binding Region (UBR) III. A. Secondary structure prediction of 
the UBR III by PSIPRED showing high probability of helical structure between Asp394 and Thr414. Overlap with RING2 
domain highlighted in brown and in bold is the zinc co-ordinating cysteine. B. Sequence alignments (ClustalW {Chenna, 
2003 #430} generated and manually adjusted) of putative Ubiquitin Interacting Motifs (UIM)-like motifs UBR IIIa and IIIb 
with UIM consensus sequence and known single-sided (Ss) UIM motifs. (x is any residue, z is bulky hydrophobic/polar, 
e is negatively charge,  is hydrophobic and e indicates position can be occupied by e/z). Residues conforming to 
consensus signature are coloured yellow and orange the latter specifies crucial residues. In bold is zinc co-ordinating 
cysteine of RING2. C. -Helical wheel projections of predicted UBR III helix (Asp394 to Thr414, renumbered 1-21 for 
clarity) showing polarised orientation of the putative UIMs, UBR IIIa (left) and UBR IIIb (right). Conforming and crucial 
residues are coloured yellow and orange respectively. Black and black with orange border indicate non-conforming 
resides, the latter denotes absence of crucial UIM residue. Location and nature of PD mutations within UBR IIIa and IIIb 
are indicated in the respective wheels. D. UblD residues that participate in interaction with RPN10 UIM I (purple dots) 
(Safadi and Shaw, 2010), EPS15 UIMs (blue dots) (Safadi and Shaw, 2010), and 321C (maroon dots; from Figure 48 in 
this study). UblD is ubiquitin like Domain, Ub is ubiquitin, RPN is Regulatory particle non-ATPase protein, RAP80 is 
Receptor associated Protein 80, and EPS 15 is Epidermal growth factor receptor substrate 15. 
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6.3 Implications for Parkinson’s disease 
 
In the context of the disease state, the data presented here demonstrates that 
ligase activity profile of Parkin most certainly is an indicator of 
function/dysfunction. At the basal level, the UblD inhibits auto-ubiquitination 
through an intra-molecular interaction where ligase activity is rendered latent. 
Substrate interactions mediated by the UblD activate the monoubiquitination 
potential of Parkin and its concomitant auto-ubiquitination. Auto-ubiquitination 
can also result from Parkin UblD mutants in particular those that unfold the N-
terminal domain. Substrate recognition by C-terminal domains of Parkin could 
result in a rearrangement of the intra-molecular inhibited state thereby releasing 
the polyubiquitination potential of Parkin. Preliminary observations with 
pathogenic mutations in the UBRs that exhibit auto-ubiquitination (Lys161Asn, 
data not shown) as well as UblD polyubiquitination support this theory.    
 
It has been previously suggested that Parkin may be physiologically 
processesed to release the UblD (Schlossmacher et al., 2002) and caspase 
cleavage upon induction of apoptosis (Kahns et al., 2003, Kahns et al., 2002). 
The translation of N-terminally truncated Parkin resulting in loss of the UblD was 
attributed to an alternative start site (codon 80) (Henn et al., 2005). The effect of 
ligase activity, however, was not addressed in the above reports. Given the 
data presented here, the above events are likely to activate auto-ubiquitination 
of Parkin.  
 
Conventionally, auto-ubiquitination has been used as a marker for ligase activity 
of Parkin. In addition, relative solubility levels of wild type and mutant Parkin 
reflect folded state and stability of the enzyme. Finally, comparative analyses of 
substrate ubiquitination levels determine function/dysfunction of the Parkin 
species. Deletion of the UblD had no effect on solubility and cellular localization 
of Parkin (Henn et al., 2005, Kyratzi et al., 2007). Other reports have 
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demonstrated that deletion of UblD resulted in the loss of substrate 
ubiquitination but not substrate binding/colocalization; AIMP2 (Corti et al., 2003) 
and Synaptotagmin-XI (Huynh et al., 2003) however the same deletion did not 
affect auto-ubiquitination (Finney et al., 2003). Conversely UblD mutants, in 
particular Arg42Pro, resulted in drastic destabilisation of Parkin and the 
formation of inclusion bodies (Henn et al., 2005, Kyratzi et al., 2007, Wang et 
al., 2005, Hampe et al., 2006) while auto-ubiquitination was observed in vitro 
(Matsuda et al., 2006) with ‘increased’ levels in vivo (Sriram et al., 2005). 
Furthermore, the same report observed enhanced non-degradative 
ubiquitination of Parkin substrates AIMP2 (despite reduced binding) and 
Synphilin-1 (increased binding), with accumulation of the former in inclusion 
bodies.  On the contrary, a higher rate of proteasomal turnover for Arg42Pro 
and other UblD mutants was observed elsewhere (Henn et al., 2005).  
  
Data presented here shows auto-ubiquitination of wild-type Parkin is inhibited 
thus changing the baseline for comparison of ligase activity and, more 
importantly shifting the focus toward substrate ubiquitination. In theory, 
‘activated’ Parkin (tagged/mutant/N-terminal truncated) could result in incessant 
auto-ubiquitination and indiscriminate substrate ubiquitination leading to 
redistribution to inclusion bodies/aggresomes (Cookson et al., 2003, Muqit et 
al., 2004). Alternatively, proteasomal turnover of auto-ubiquitinated Parkin could 
also occur (Choi et al., 2000, Zhang et al., 2000, Ardley et al., 2003, Junn et al., 
2002) contributing to loss of the required ubiquitin signal on Parkin substrates. 
Auto-ubiquitination of ‘activated’ Parkin could be also enhanced by E3 
independent monoubiquitination, a cis event arising from interaction between 
UBD element (Parkin UBRs) and ubiquitin moiety conjugated to an E2. 
Interestingly, auto-ubiquitination was observed in species with mutations in zinc 
co-ordinating residues Cys289Gly (RING1, in vitro (Matsuda et al., 2006)), 
Cys431Phe (RING2, in vivo (Sriram et al., 2005)). As these mutations are likely 
to unfold the catalytic RING domains rendering the ligase inactive, a UBD 
mediated ubiquitination could explain the ‘auto-ubiquitination’ events. 
Compounding these issues however, is the use of over-expressed tagged 
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Parkin to establish the mechanism of dysfunction. Loss-of-function is 
considered the pathogenic mechanism in AR-JP and majority of the mutations 
in the Parkin gene are heterozygous recessive. On the contrary, the above 
referenced reports portray a toxic gain of function for several of these mutations 
and furthermore over expression of Parkin, a common method used in the 
above studies could lead to non-physiological phenotypes (Kyratzi et al., 2007, 
Dawson and Dawson, 2010).  
 
The present study establishes the hydrophobic patch on Ubiquitin as a novel 
requisite of the ligase activity. UblD mediated auto-inhibition is likely to involve 
regulation of the Parkin-Ubiquitin cross-talk providing novel insights into 
regulation of Parkin ligase activity. Accordingly, some of the pathogenic 
missense mutations in the proposed ubiquitin interaction surfaces (14 mutations 
in UBRs I, II and minor hit E11-14) could disrupt the ubiquitin interaction 
resulting in ligase inactivation. Conversely, mixed ubiquitin signals generated by 
the UblD (and possibly other mutations) could also be interpreted as loss-of-
function. Deregulation of Parkin could render the ligase incapable of catalysing 
precise ubiquitin signals on substrates, thus contributing to loss of downstream 
functions. Further analysis into mechanisms of Parkin inactivation is required to 
understand true function of the E3 ligase and loss-of-function mechanism in 
AR-JP pathogenesis.  
 
6.4 Implications for the Ubiquitin pathway  
 
There are several proteins in the human proteome with integral ubiquitin like 
domains, primarily involved in various protein quality control systems as well as 
other cellular processes (reviewed in (Grabbe and Dikic, 2009, Welchman et al., 
2005)}. Intra-molecular inhibitory interactions were first reported within the UV 
excision repair protein RAD23 homolog B (hHR23B) (Ryu et al., 2003). The 
multi-domain protein includes an N-terminal Ubl domain (binds RPN10 subunit 
of 26S proteasome) and a xeroderma pigmentosum complementation group C 
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(XPC)-binding domain flanked by two UBA domains (UBA domains 1 and 2, the 
latter preferentially binds Lys48-linked polyubiquitin chains (Varadan et al., 
2005)). The protein has crucial functions in the nucleotide excision repair (NER) 
pathway in response to DNA damage as well as a ‘proteasomal shuttle’ 
(Schauber et al., 1998, Sugasawa et al., 1998). The latter function involves 
interactions between UBA domain 2 with Lys48-linked polyubiquitinated 
substrates and subsequent transfer to the 26S proteasome mediated by Ubl 
interactions with proteasomal subunits thereby regulating the turnover of 
polyubiquitinated substrates. Regulation of this function involves intramolecular 
interaction between Ubl and UBA domains thereby maintaining the protein in a 
‘closed’ or inactive conformation (Ryu et al., 2003).  
 
A similar closed/inactive state was revealed in this study for wild type Parkin, 
probably mediated by the UblD – UBR interactions. In addition, Parkin (UblD) 
interactions with RPN10 (UIM 1), proteasomal regulatory subunit have been 
observed (Sakata et al., 2003), and biophysically characterized (Safadi and 
Shaw, 2010). The UblD surface that supports interactions with RPN10 UIM I 
and the intra-molecular inhibitory interaction of Parkin are similar (Figure 50D), 
thus regulating Parkin-proteasome cross talk. However, a functional relevance 
of this binding is unclear and is likely to involve proteasomal degradation of 
auto-ubiquitinated/deregulated Parkin and/or its associated substrates 
(Upadhya and Hegde, 2003). A recent bioinformatics driven study in to multiple 
members of IAP family of RING E3 ligase uncovered a conserved UBA domain 
found to preferentially bind Lys63-linked polyubiquitin chains of potential 
significance in NF-kappaB signalling (Gyrd-Hansen et al., 2008). The presence 
of cryptic UblD/Ub binding regions in Parkin (UBR III and RING0) could help 
direct experiments that establish ‘novel ubiquitin receptor’ functions for the E3 
ligase. Alternatively, the presence of Parkin UBDs could be decisive in 
mechanisms of ubiquitin chain synthesis, a role previously proposed while 
describing acceptor lysine selection for ubiquitin chain type specificity by HECT 
E3 ligases (Wang and Pickart, 2005, Kim and Huibregtse, 2009) as well as for 
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promoting the formation of degradable ubiquitin chains by RING/U-box E3 
ligases under the influence of RPN10 UIMs (in trans) (Kim et al., 2009).  
  
This study proposes regulation of the E3 ligase activity as a novel role for Ubl 
domains. The mechanism of intra-molecular inhibition and/or a regulatory role 
for Ubls could be could be extended to other members of the E3 ligase family. 
Auto-inhibition of Smurf ligase activity has been observed and mediated by 
intra-molecular interaction through the C2 domain (Wiesner et al., 2007). 
Elongin-B, a subunit of the von-Hippel-Landu (VHL) E3 ubiquitin ligase complex 
also contains the Ubl domain, however has not been functional characterised. 
Interactions between the Ubl domains of Ubiquitin Specific Protease (USP) 7 
and the viral ring finger protein Herpes simplex virus type 1 immediate-early 
regulatory protein (ICP0) represses the auto-ubiquitination mediated destruction 
of the viral protein (Zhu et al., 2007, Canning et al., 2004).  
 
Regulation of ligase activity is critical to ensure ubiquitin signals are generated 
at the right place and right time. The heterodimeric LUBAC complex, consisting 
of HOIL-1L and HOIP is an interesting case of a RING E3 ligase complex 
capable of synthesising linear ubiquitin chains with a range of E2 enzymes 
(Kirisako et al., 2006) however, the mechanistic details of these events are 
awaited. Parkin shares the UblD/RING-IBR-RING domain arrangement with that 
of HOIL-1L however, the former bears two potential UBDs/UBRs located in 
RING0 (UBR I and minor hit E11-14) and UBRIII while the latter bears a 
ubiquitin binding Npl4 type Zinc Finger (NZF) domain for at a similar location as 
the first zinc finger of RING0. A recent report exploring the physiological state of 
Parkin in mouse brain, heart and skeletal muscle tissues observed the E3 
ligase to be part of a non-covalent ~110kDa heterogeneous complex (Van 
Humbeeck et al., 2008). Another report observed Parkin/DJ1/PINK1 operate as 
a complex when over-expressed in SH-SY5Y neuroblastoma cells, are 
predominantly localised in the cytoplasm and had E3 ligase properties (auto- 
and substrate ubiquitination (synphillin-1)) (Xiong et al., 2009). Furthermore, 
Parkin has been observed to function as the RING component of an SCF 
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complex in the degradation of cyclinE (Staropoli et al., 2003). Wild type Parkin, 
as observed in this study, needs to be activated (or relieved of the UblD 
mediated intramolecular inhibitory interaction) for the molecule to exhibit its E3 
ligase properties. Taken together, it is plausible that Parkin operates in different 
semi-CRL like complexes; each with a Parkin ‘effecter’ molecule that bears a 
UBD (or at least a Parkin UblD binding domain) thus, selectively activates the 
ligase when required. 
 
Activation of the dormant ligase allows additional control of E3 ligase enzymatic 
activity. Mechanisms of enhanced SCF ligase activity upon conjugation of the 
ubiquitin-like protein Nedd8 have been demonstrated (Duda et al., 2008, Saha 
and Deshaies, 2008, Yamoah et al., 2008). Differential regulation of the E2 
enzymatic properties upon sumoylation has also been observed; UBE2K/Ubc1 
(Pichler et al., 2005) and UBE2I/Ubc9 (Knipscheer et al., 2008). Degradative 
auto-ubiquitination of the RING E3 ligase cIAP1 induced by small-molecules 
presents a case for therapeutic strategies directed towards an E3 ligase (Sekine 
et al., 2008). Perhaps the strongest argument for activation of Parkin’s E3 
ligase potential comes from PINK1-Parkin interaction for mitochondria 
homeostasis. Recent reports have demonstrated that PINK1 selectively recruits 
Parkin to damaged mitochondria (Narendra et al., 2008) and activates its E3 
ligase potential (Matsuda et al., 2010, Narendra et al., 2010) while pathogenic 
mutations in Parkin disrupts clearance of damaged mitochondria (Geisler et al., 
2010, Lee et al., 2010). However, the mechanism of Parkin recruitment and 
activation is unclear and is likely to involve disruption of the UblD mediated 
auto-inhibition of Parkin.      
 
6.5 Future perspectives  
 
The data presented here establishes a novel E3 ligase inhibitory mechanism for 
Parkin’s UblD, likely to be its fundamental role. However, other functions of 
UblD have previously been demonstrated; substrate recognition (Fallon et al., 
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2006, Trempe et al., 2009) and interaction with proteasome (Sakata et al., 
2003). Given the prerequisite of ubiquitin’s hydrophobic patch for Parkin’s E3 
ligase activity, the presence of multiple UBRs and possible competition between 
UblD and ubiquitin for UBR interaction together predict a dynamic role for the 
UblD in ubiquitin chain synthesis. Recently, a similar requirement of ubiquitin 
interaction was reported for polyubiquitin chain synthesis by HECT E3 ligases 
Rsp5 (French et al., 2009) and Smurf (Ogunjimi et al., 2010).   
 
Authentication of UBR III as UIM(s) would be the first port of call and mutations 
predicted to disrupt UIM-ubiquitin interactions followed by auto-ubiquitination 
assays would present some clues. An interesting outcome would be if both IIIa 
and IIIb prove to be functional UIMs. In theory, UBR III could provide a 
molecular groove over which UblD could swivel, exposing/concealing adjacent 
UBRs and ubiquitin interactions thus regulating ubiquitin chain formation. 
Structural characterisation would also reveal deeper mechanistic insights of the 
interface. Validation of the RING0 region (contains UBR I and minor hit E11-14) 
as a possible zinc-finger based UBD needs to be addressed. Presence of two 
(or three) ‘UBDs’ on a single subunit RING E3 ligase could help direct specificity 
of the growing chain and possibly enhance processivity.   
 
In summary, this study shows the tertiary arrangement of Parkin domains 
influences its activity. A mechanistic insight into UblD mediated intra-molecular 
regulation of RING E3 ligase activity was presented along with the effect of 
certain pathogenic mutations to this regulation. Novel requirements for ligase 
activity were uncovered along with predictions of Parkin UBDs and ubiquitin 
interactions that could play a crucial role in diverse E3 ligase activities exhibited 
by Parkin.  
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